

Avelumab plus Axitinib versus Sunitinib for Advanced

New England Journal of Medicine

380, 1103-1115

DOI: [10.1056/nejmoa1816047](https://doi.org/10.1056/nejmoa1816047)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 1370-1385.	5.1	594
2	Treatment of advanced renal cell carcinoma patients with cabozantinib, an oral multityrosine kinase inhibitor of MET, AXL and VEGF receptors. <i>Future Oncology</i> , 2019, 15, 2337-2348.	1.1	15
3	Diagnostic role of kidney injury molecule-1 in renal cell carcinoma. <i>International Urology and Nephrology</i> , 2019, 51, 1893-1902.	0.6	6
4	Toward a genome-based treatment landscape for renal cell carcinoma. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 142, 141-152.	2.0	15
5	Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial. <i>Oncologist</i> , 2019, 24, 1497-1501.	1.9	22
6	Results from a meta-analysis of immune checkpoint inhibitors in first-line renal cancer patients: does PD-L1 matter?. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591986190.	1.4	31
7	Should we use combination therapy for all advanced renal cell carcinoma?. <i>Lancet Oncology</i> , The, 2019, 20, 1331-1332.	5.1	3
8	PTEN in Lung Cancer: Dealing with the Problem, Building on New Knowledge and Turning the Game Around. <i>Cancers</i> , 2019, 11, 1141.	1.7	71
11	Do biomarkers play a predictive role for response to novel immunotherapeutic agents in metastatic renal cell carcinoma?. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 1107-1110.	1.4	6
12	Enhanced efficacy of sitravatinib in metastatic models of antiangiogenic therapy resistance. <i>PLoS ONE</i> , 2019, 14, e0220101.	1.1	22
13	A Phase II, single-arm trial of neoadjuvant axitinib plus avelumab in patients with localized renal cell carcinoma who are at high risk of relapse after nephrectomy (NEOAVAX). <i>Future Oncology</i> , 2019, 15, 2203-2209.	1.1	19
14	Tumor Vasculatures: A New Target for Cancer Immunotherapy. <i>Trends in Pharmacological Sciences</i> , 2019, 40, 613-623.	4.0	79
15	Time on Therapy for at Least Three Months Correlates with Overall Survival in Metastatic Renal Cell Carcinoma. <i>Cancers</i> , 2019, 11, 1000.	1.7	17
16	Sunitinib for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis of Real-World and Clinical Trials Data. <i>Targeted Oncology</i> , 2019, 14, 405-416.	1.7	35
17	Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma. <i>European Urology</i> , 2019, 76, 151-156.	0.9	190
18	Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial. <i>Lancet Oncology</i> , The, 2019, 20, 1109-1123.	5.1	193
19	Validation of the IMDC Prognostic Model in Patients With Metastatic Renal-Cell Carcinoma Treated With First-Line Axitinib: A Multicenter Retrospective Study. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e1080-e1089.	0.9	10
20	Câ€reactive protein/albumin ratio is a predictive factor for prognosis in patients with metastatic renal cell carcinoma. <i>International Journal of Urology</i> , 2019, 26, 992-998.	0.5	16

#	ARTICLE	IF	CITATIONS
21	Phase I Trial of Targeted EGFR or ALK Therapy with Ipilimumab in Metastatic NSCLC with Long-Term Follow-Up. Targeted Oncology, 2019, 14, 417-421.	1.7	34
22	<p>Co-delivery of everolimus and vinorelbine via a tumor-targeted liposomal formulation inhibits tumor growth and metastasis in RCC</p>. International Journal of Nanomedicine, 2019, Volume 14, 5109-5123.	3.3	30
23	Inhibition of Tumor Growth and Sensitization to Sunitinib by RNA Interference Targeting Programmed Death-ligand 1 in Mouse Renal Cell Carcinoma RenCa Model. Anticancer Research, 2019, 39, 4737-4742.	0.5	8
24	Augmenting the randomized controlled trial with real-world data to aid clinical decision making in metastatic renal cell carcinoma: a systematic review and meta-analysis. Future Oncology, 2019, 15, 3987-4001.	1.1	6
25	Sunitinib First-line Treatment in Metastatic Renal Cell Carcinoma: Costs and Effects. Anticancer Research, 2019, 39, 5559-5564.	0.5	13
26	Management of Advanced Kidney Cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2019. Canadian Urological Association Journal, 2019, 13, 343-54.	0.3	10
27	Response of Primary Renal Cell Carcinoma to Systemic Therapy. European Urology, 2019, 76, 852-860.	0.9	9
28	Preclinical rationale and clinical efficacy of antiangiogenic therapy and immune checkpoint blockade combination therapy in urogenital tumors. Journal of Cancer Research and Clinical Oncology, 2019, 145, 3021-3036.	1.2	20
29	First-Line Systemic Therapy for Metastatic Clear-Cell Renal Cell Carcinoma: Critical Appraisal of Emerging Options. Targeted Oncology, 2019, 14, 639-645.	1.7	14
30	Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer. JAMA Oncology, 2019, 5, 1731.	3.4	150
31	Renal Cell Carcinoma: the Oncologist Asks, Can PSMA PET/CT Answer?. Current Urology Reports, 2019, 20, 68.	1.0	27
32	Inflammatory Biomarkers as Predictors of Response to Immunotherapy in Urological Tumors. Journal of Oncology, 2019, 2019, 1-11.	0.6	6
33	Avelumab monotherapy as first-line or second-line treatment in patients with metastatic renal cell carcinoma: phase Ib results from the JAVELIN Solid Tumor trial. , 2019, 7, 275.		48
34	Targeted Therapies Following First-Line Immune Checkpoint Inhibitor Combination in Metastatic Renal Cell Carcinoma: A Single Center Experience. Kidney Cancer, 2019, 3, 171-176.	0.2	3
36	Immunotherapy in renal cell carcinoma from poverty to the spoiled of choice. Immunotherapy, 2019, 11, 1507-1521.	1.0	17
37	Effect of third- and fourth-line systemic therapies for metastatic renal cell carcinoma. Scientific Reports, 2019, 9, 15451.	1.6	8
38	Adverse Events of Concurrent Immune Checkpoint Inhibitors and Antiangiogenic Agents: A Systematic Review. Frontiers in Pharmacology, 2019, 10, 1173.	1.6	35
39	Incidence of Immune Checkpoint Inhibitor-Associated Diabetes: A Meta-Analysis of Randomized Controlled Studies. Frontiers in Pharmacology, 2019, 10, 1453.	1.6	24

#	ARTICLE	IF	CITATIONS
41	Therapeutic Monoclonal Antibodies Targeting Immune Checkpoints for the Treatment of Solid Tumors. <i>Antibodies</i> , 2019, 8, 51.	1.2	32
42	Vascular endothelial growth factor and programmed death-1 pathway inhibitors in renal cell carcinoma. <i>Cancer</i> , 2019, 125, 4148-4157.	2.0	21
43	PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN. <i>Clinical Cancer Research</i> , 2019, 25, 6080-6088.	3.2	50
44	Cytoreductive nephrectomy in the current treatment algorithm. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591987902.	1.4	13
46	The Changing Therapeutic Landscape of Metastatic Renal Cancer. <i>Cancers</i> , 2019, 11, 1227.	1.7	49
47	Individualised axitinib regimen for patients with metastatic renal cell carcinoma after treatment with checkpoint inhibitors: a multicentre, single-arm, phase 2 study. <i>Lancet Oncology</i> , The, 2019, 20, 1386-1394.	5.1	69
48	Role of immune checkpoint inhibitor-based therapies for metastatic renal cell carcinoma in the first-line setting: A Bayesian network analysis. <i>EBioMedicine</i> , 2019, 47, 78-88.	2.7	24
49	First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic Renal-cell Carcinoma Database Consortium. <i>European Urology</i> , 2019, 76, 861-867.	0.9	71
51	The Evaluation of Response to Immunotherapy in Metastatic Renal Cell Carcinoma: Open Challenges in the Clinical Practice. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4263.	1.8	17
52	Immune checkpoint inhibitors of PD-L1 as cancer therapeutics. <i>Journal of Hematology and Oncology</i> , 2019, 12, 92.	6.9	485
53	Emerging therapeutic agents for genitourinary cancers. <i>Journal of Hematology and Oncology</i> , 2019, 12, 89.	6.9	33
54	Game of thrones: immunotherapy versus molecular targeted therapy in renal cell cancer scenarios. <i>International Urology and Nephrology</i> , 2019, 51, 2107-2117.	0.6	2
55	Management of metastatic renal cell carcinoma: The complexity of choice. <i>EBioMedicine</i> , 2019, 47, 2-3.	2.7	1
56	Next-generation computational tools for interrogating cancer immunity. <i>Nature Reviews Genetics</i> , 2019, 20, 724-746.	7.7	131
57	Current Advance of Therapeutic Agents in Clinical Trials Potentially Targeting Tumor Plasticity. <i>Frontiers in Oncology</i> , 2019, 9, 887.	1.3	19
58	Tumor Microenvironment Dynamics in Clear-Cell Renal Cell Carcinoma. <i>Cancer Discovery</i> , 2019, 9, 1349-1357.	7.7	226
59	Innovative Thinking on Endpoint Selection in Clinical Trials. <i>Journal of Biopharmaceutical Statistics</i> , 2019, 29, 941-951.	0.4	0
60	Investigational MET inhibitors to treat Renal cell carcinoma. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 851-860.	1.9	19

#	ARTICLE	IF	CITATIONS
61	First-line Treatment of Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis. <i>European Urology Oncology</i> , 2019, 2, 708-715.	2.6	64
62	Sorafenib Versus Observation Following Radical Metastasectomy for Clear-cell Renal Cell Carcinoma: Results from the Phase 2 Randomized Open-label RESORT Study. <i>European Urology Oncology</i> , 2019, 2, 699-707.	2.6	38
63	<p>Tivozanib for the treatment of renal cell carcinoma: patient selection and perspectives</p>. <i>International Journal of Nephrology and Renovascular Disease</i> , 2019, Volume 12, 137-141.	0.8	0
64	What Comes After Immuno-Oncology Therapy for Kidney Cancer?. <i>Kidney Cancer</i> , 2019, 3, 93-102.	0.2	4
65	Resistance to Systemic Agents in Renal Cell Carcinoma Predict and Overcome Genomic Strategies Adopted by Tumor. <i>Cancers</i> , 2019, 11, 830.	1.7	29
66	Uveal Melanoma, Angiogenesis and Immunotherapy, Is There Any Hope?. <i>Cancers</i> , 2019, 11, 834.	1.7	41
67	Safe Use of Immune Checkpoint Inhibitors in the Multidisciplinary Management of Urological Cancer: The European Association of Urology Position in 2019. <i>European Urology</i> , 2019, 76, 368-380.	0.9	48
68	Clear-cell Renal Cell Carcinoma: Molecular Characterization of IMDC Risk Groups and Sarcomatoid Tumors. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e981-e994.	0.9	34
69	Personalized approach to systemic therapy of renal cancer. <i>Expert Review of Precision Medicine and Drug Development</i> , 2019, 4, 179-188.	0.4	0
70	Immune Checkpoint Blockade plus Axitinib for Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2019, 380, 2581-2582.	13.9	8
71	Cancer immunotherapy: the art of targeting the tumor immune microenvironment. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 227-240.	1.1	50
72	Immunotherapy for renal cell carcinoma. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 897-905.	1.4	14
73	The role of metastasectomy in advanced renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 603-611.	1.1	7
74	Durable complete response in renal cell carcinoma clinical trials. <i>Lancet, The</i> , 2019, 393, 2362-2364.	6.3	7
75	Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors. <i>European Journal of Cancer</i> , 2019, 114, 67-75.	1.3	88
76	Reprogramming the Tumor Microenvironment to Improve Immunotherapy: Emerging Strategies and Combination Therapies. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 165-174.	1.8	123
77	Early Changes in CT Perfusion Parameters: Primary Renal Carcinoma Versus Metastases After Treatment with Targeted Therapy. <i>Cancers</i> , 2019, 11, 608.	1.7	5
78	Low-dose axitinib rechallenge with positive outcomes in a patient with metastatic renal cell carcinoma refractory to interferon β , sunitinib, axitinib, and nivolumab therapies: a case report. <i>Journal of Medical Case Reports</i> , 2019, 13, 98.	0.4	4

#	ARTICLE	IF	CITATIONS
79	Efficacy and safety of combination immunotherapy for malignant solid tumors: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 138, 178-189.	2.0	31
80	Targeting Tyrosine kinases in Renal Cell Carcinoma: "New Bullets against Old Guys" <i>International Journal of Molecular Sciences</i> , 2019, 20, 1901.	1.8	41
81	Perspectives on Geriatric Oncology Research presented at the 2019 American Society of Clinical Oncology Genitourinary Cancers Symposium. <i>Journal of Geriatric Oncology</i> , 2019, 10, 523-525.	0.5	0
82	Enhancing Antitumor Immunity with Antiangiogenic Therapy: A Clinical Model in Renal Cell Carcinoma?. <i>Oncologist</i> , 2019, 24, 725-727.	1.9	5
83	Towards individualized therapy for metastatic renal cell carcinoma. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 621-633.	12.5	148
84	Immune-based combination therapy for metastatic kidney cancer. <i>Nature Reviews Nephrology</i> , 2019, 15, 324-325.	4.1	3
85	Targeting the PD-1/PD-L1 Pathway in Renal Cell Carcinoma. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1692.	1.8	61
86	Re: Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. <i>European Urology</i> , 2019, 76, 126-127.	0.9	3
87	Axitinib "ICIs boost the RCC armamentarium. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 207-207.	12.5	0
88	Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy. <i>Journal of Hematology and Oncology</i> , 2019, 12, 27.	6.9	211
89	Prognostic Markers for Refined Stratification of IMDC Intermediate-Risk Metastatic Clear Cell Renal Cell Carcinoma Treated with First-Line Tyrosine Kinase Inhibitor Therapy. <i>Targeted Oncology</i> , 2019, 14, 179-186.	1.7	14
90	Novel Therapeutic Approaches and Targets Currently Under Evaluation for Renal Cell Carcinoma: Waiting for the Revolution. <i>Clinical Drug Investigation</i> , 2019, 39, 503-519.	1.1	26
91	The Intersection between Tumor Angiogenesis and Immune Suppression. <i>Clinical Cancer Research</i> , 2019, 25, 5449-5457.	3.2	300
92	Combination Therapy as First-Line Treatment in Metastatic Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2019, 380, 1176-1178.	13.9	54
93	Immunotherapy Is Changing First-Line Treatment of Metastatic Renal-Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e513-e521.	0.9	31
94	Immune Checkpoint Inhibition, the Key to Success in Renal Cell Carcinoma?. <i>Kidney Cancer</i> , 2019, 3, 199-211.	0.2	0
95	Individualization of Dose and Schedule Based On Toxicity for Oral VEGF Drugs in Kidney Cancer. <i>Kidney Cancer</i> , 2019, 3, 213-225.	0.2	3
97	Evolving Epidemiologic Trends of Renal Cell Cancer by Histologic Subtype: An Updated Analysis of the California Cancer Registry. <i>Kidney Cancer</i> , 2019, 3, 189-196.	0.2	0

#	ARTICLE	IF	CITATIONS
98	Real-World Results from One Year of Therapy with Tivozanib. <i>Kidney Cancer</i> , 2019, 3, 235-239.	0.2	2
99	Avelumab plus axitinib vs. sunitinib for advanced renal-cell carcinoma. <i>Translational Cancer Research</i> , 2019, 8, S585-S588.	0.4	1
100	Immunotherapy combinations transform the treatment paradigm for advanced renal cell carcinoma. <i>Annals of Translational Medicine</i> , 2019, 7, S385-S385.	0.7	2
101	Can immune biomarkers predict benefit from targeted agents in metastatic renal cell carcinoma?. <i>Annals of Translational Medicine</i> , 2019, 7, S275-S275.	0.7	0
102	Role of immunotherapy in metastatic renal cell cancer: past, present and future. <i>Annals of Translational Medicine</i> , 2019, 7, S349-S349.	0.7	5
104	First-line treatment of metastatic renal cell carcinoma: current standard of care. <i>Memo - Magazine of European Medical Oncology</i> , 2019, 12, 334-338.	0.3	1
105	The Role of Obesity in Renal Cell Carcinoma Patients: Clinical-Pathological Implications. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5683.	1.8	26
106	New immunotherapy in the treatment of advanced renal cancer. <i>Expert Opinion on Emerging Drugs</i> , 2019, 24, 233-237.	1.0	10
107	Cancer biomarkers for targeted therapy. <i>Biomarker Research</i> , 2019, 7, 25.	2.8	72
108	The Interplay between Inflammation, Anti-Angiogenic Agents, and Immune Checkpoint Inhibitors: Perspectives for Renal Cell Cancer Treatment. <i>Cancers</i> , 2019, 11, 1935.	1.7	21
109	Is cytoreductive nephrectomy relevant in the immunotherapy era?. <i>Current Opinion in Urology</i> , 2019, 29, 526-530.	0.9	12
110	The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC). , 2019, 7, 354.		182
111	Novel therapy for pediatric and adolescent kidney cancer. <i>Cancer and Metastasis Reviews</i> , 2019, 38, 643-655.	2.7	11
112	Second-line therapy in metastatic renal cell cancer—how do we treat after immuno-oncology drugs?. <i>Memo - Magazine of European Medical Oncology</i> , 2019, 12, 339-341.	0.3	1
113	Synchronous inhibition of mTOR and VEGF/NRP1 axis impedes tumor growth and metastasis in renal cancer. <i>Npj Precision Oncology</i> , 2019, 3, 31.	2.3	31
114	The pro-tumorigenic host response to cancer therapies. <i>Nature Reviews Cancer</i> , 2019, 19, 667-685.	12.8	135
115	Three case reports. <i>Medicine (United States)</i> , 2019, 98, e18098.	0.4	7
116	Patient selection for cytoreductive nephrectomy in combination with targeted therapies or immune checkpoint inhibitors. <i>Current Opinion in Urology</i> , 2019, 29, 513-520.	0.9	9

#	ARTICLE	IF	CITATIONS
117	The current role for adjuvant and neoadjuvant therapy in renal cell cancer. <i>Current Opinion in Urology</i> , 2019, 29, 636-642.	0.9	12
118	Cabozantinib in Combination with Immunotherapy for Advanced Renal Cell Carcinoma and Urothelial Carcinoma: Rationale and Clinical Evidence. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 2185-2193.	1.9	84
119	The Prognostic Value of Programmed Death-Ligand 1 in a Chinese Cohort With Clear Cell Renal Cell Carcinoma. <i>Frontiers in Oncology</i> , 2019, 9, 879.	1.3	6
120	Are targeted agents the key to unlock the code for immune checkpoint inhibitors in soft-tissue sarcomas?. <i>Future Oncology</i> , 2019, 15, 3185-3187.	1.1	1
121	Biomarkers of Prognosis and Efficacy of Anti-angiogenic Therapy in Metastatic Clear Cell Renal Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 1400.	1.3	39
122	Nicht metastasiertes Nierenzellkarzinom mit Tumorthrombus: Sunitinib und Sorafenib in der neoadjuvanten Therapie. <i>Karger Kompass Onkologie</i> , 2019, 6, 98-99.	0.0	0
123	Outcomes of combination therapy with tyrosine kinase inhibitors and immune checkpoint inhibitors in metastatic renal cell carcinoma – A retrospective study. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 556-563.	0.5	3
124	Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma: How to Apply New Evidence in Clinical Practice. <i>Oncology</i> , 2020, 98, 1-9.	0.9	10
125	C-reactive protein and the neutrophil-to-lymphocyte ratio are prognostic biomarkers in metastatic renal cell carcinoma patients treated with nivolumab. <i>International Journal of Clinical Oncology</i> , 2020, 25, 135-144.	1.0	38
126	Improving IMDC Prognostic Prediction Through Evaluation of Initial Site of Metastasis in Patients With Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e83-e90.	0.9	17
127	Complete response to combination therapy with nivolumab and ipilimumab for metastatic collecting duct carcinoma of the kidney. <i>International Cancer Conference Journal</i> , 2020, 9, 32-35.	0.2	22
128	Prognostic and predictive molecular biomarkers in metastatic renal cell carcinoma patients treated with immune checkpoint inhibitors: a systematic review. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 169-185.	1.5	21
129	Immune checkpoint inhibition for the treatment of renal cell carcinoma. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 83-94.	1.4	14
130	Patterns of treatment in metastatic renal cell carcinoma for older versus younger patients. <i>Journal of Geriatric Oncology</i> , 2020, 11, 724-726.	0.5	2
131	Long survival of patients with metastatic clear cell renal cell carcinoma. Results of real life study of 344 patients. <i>International Journal of Cancer</i> , 2020, 146, 1643-1651.	2.3	5
132	A Phase I Study of Alpha-1,3-Galactosyltransferase-Expressing Allogeneic Renal Cell Carcinoma Immunotherapy in Patients with Refractory Metastatic Renal Cell Carcinoma. <i>Oncologist</i> , 2020, 25, 121-e213.	1.9	28
133	Cardiovascular toxicity of immune checkpoint inhibitors in cancer patients: A review when cardiology meets immuno-oncology. <i>Journal of the Formosan Medical Association</i> , 2020, 119, 1461-1475.	0.8	57
134	Hyperprogressive Disease in Patients With Urothelial Carcinoma or Renal Cell Carcinoma Treated With PD-1/PD-L1 Inhibitors. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e122-e133.	0.9	32

#	ARTICLE	IF	CITATIONS
135	What Do International Guidelines Say About First-line Therapy for Clear-cell Metastatic Renal Cell Carcinoma?. <i>European Urology Focus</i> , 2020, 6, 48-52.	1.6	5
136	Impact of Patients' Gender on Efficacy of Immunotherapy in Patients With Metastatic Kidney Cancer: A Systematic Review and Meta-analysis. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 88-94.e2.	0.9	22
137	Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and/or Sarcomatoid Features. <i>Journal of Clinical Oncology</i> , 2020, 38, 63-70.	0.8	109
138	A review of checkpoint inhibitors in the management of renal cell carcinoma. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 445-458.	0.5	9
140	Current issues and perspectives in PD-1 blockade cancer immunotherapy. <i>International Journal of Clinical Oncology</i> , 2020, 25, 790-800.	1.0	120
141	Plasma Circulating Tumor DNA and Clonal Hematopoiesis in Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 322-331.e2.	0.9	30
142	Sarcomatoid Dedifferentiation in Renal Cell Carcinoma: From Novel Molecular Insights to New Clinical Opportunities. <i>Cancers</i> , 2020, 12, 99.	1.7	23
143	Progress and Opportunities to Advance Clinical Cancer Therapeutics Using Tumor Dynamic Models. <i>Clinical Cancer Research</i> , 2020, 26, 1787-1795.	3.2	51
144	Recent advancements in the treatment of metastatic clear cell renal cell carcinoma: A review of the evidence using second-generation p-values. <i>Cancer Treatment and Research Communications</i> , 2020, 23, 100166.	0.7	23
145	Novel immunotherapy combinations for genitourinary cancers. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 253-262.	1.4	11
146	Lenvatinib in Management of Solid Tumors. <i>Oncologist</i> , 2020, 25, e302-e310.	1.9	80
147	Comparable efficacy and safety between second-line and later-line nivolumab therapy for metastatic renal cell carcinoma. <i>International Journal of Clinical Oncology</i> , 2020, 25, 705-712.	1.0	3
148	Vessel co-option and resistance to anti-angiogenic therapy. <i>Angiogenesis</i> , 2020, 23, 55-74.	3.7	77
149	Understanding genetic determinants of resistance to immune checkpoint blockers. <i>Seminars in Cancer Biology</i> , 2020, 65, 123-139.	4.3	9
150	Predictive impact of an early change in serum C-reactive protein levels in nivolumab therapy for metastatic renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 526-532.	0.8	18
151	Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer. <i>JAMA Oncology</i> , 2020, 6, 375.	3.4	215
152	Real-world Clinical Outcomes of Pazopanib Immediately After Discontinuation of Immunotherapy for Advanced Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e37-e45.	0.9	14
153	Efficacy of Nivolumab plus Ipilimumab According to Number of IMDC Risk Factors in CheckMate 214. <i>European Urology</i> , 2020, 77, 449-453.	0.9	52

#	ARTICLE	IF	CITATIONS
154	Re: Brian I. Rini, Thomas Powles, Michael B. Atkins, et al. Atezolizumab plus Bevacizumab Versus Sunitinib in Patients with Previously Untreated Metastatic Renal Cell Carcinoma (IMmotion151): A Multicentre, Open-label, Phase 3, Randomised Controlled Trial. <i>Lancet</i> 2019;393:2404-15. <i>European Urology</i> , 2020, 77, e168-e169.	0.9	1
155	Concordance of PD-L1 and PD-L1 (B7-H1) in paired primary and metastatic clear cell renal cell carcinoma. <i>Cancer Medicine</i> , 2020, 9, 1152-1160.	1.3	17
156	Efficacy and Safety of Approved First-Line Tyrosine Kinase Inhibitor Treatments in Metastatic Renal Cell Carcinoma: A Network Meta-Analysis. <i>Advances in Therapy</i> , 2020, 37, 730-744.	1.3	16
157	Novel Risk Scoring System for Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors. <i>Oncologist</i> , 2020, 25, e484-e491.	1.9	29
158	The covalent CDK7 inhibitor THZ1 enhances temsirolimus-induced cytotoxicity via autophagy suppression in human renal cell carcinoma. <i>Cancer Letters</i> , 2020, 471, 27-37.	3.2	17
159	Combining Immune Checkpoint and VEGFR Inhibition in Favorable Risk and Elderly Patients With Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 179-184.e3.	0.9	6
160	Prognostic analysis of postoperative clinically nonmetastatic renal cell carcinoma. <i>Cancer Medicine</i> , 2020, 9, 959-970.	1.3	14
161	Clinical Outcomes of First-line Sunitinib Followed by Immuno-oncology Checkpoint Inhibitors in Patients With Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e350-e359.	0.9	3
162	Immune-Related Adverse Events in the Setting of PD-1/L1 Inhibitor Combination Therapy. <i>Oncologist</i> , 2020, 25, e398-e404.	1.9	10
163	Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer. <i>Cancer Discovery</i> , 2020, 10, 40-53.	7.7	219
164	Progress Toward Precision Medicine in Frontline Treatment of Metastatic Renal Cell Carcinoma. <i>JAMA Oncology</i> , 2020, 6, 25.	3.4	5
165	Important Considerations Regarding the Impact of Patients' Gender on Efficacy of Immunotherapy in Patients With Metastatic Kidney Cancer: A Systematic Review and Meta-analysis. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e293-e294.	0.9	0
166	Rational Approaches to Treatment Duration with Immunotherapy in Metastatic Renal Cell Carcinoma. <i>European Urology Focus</i> , 2020, 6, 31-33.	1.6	4
167	Comparative analysis of programmed cell death ligand 1 assays in renal cell carcinoma. <i>Histopathology</i> , 2020, 77, 67-78.	1.6	4
168	Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors. <i>Cancers</i> , 2020, 12, 84.	1.7	22
169	Editorial Comment to Efficacy and safety of first-line nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma: A multicenter retrospective study. <i>International Journal of Urology</i> , 2020, 27, 1100-1101.	0.5	0
170	RCC Immune Microenvironment Subsequent to Targeted Therapy: A Friend or a Foe?. <i>Frontiers in Oncology</i> , 2020, 10, 573690.	1.3	6
172	Smoking status-based efficacy difference in anti-PD-1/PD-L1 immunotherapy: a systematic review and meta-analysis. <i>Immunotherapy</i> , 2020, 12, 1313-1324.	1.0	5

#	ARTICLE	IF	CITATIONS
173	Targeted therapy for metastatic renal cell carcinoma. The Cochrane Library, 2020, 2020, CD012796.	1.5	23
175	Eligibility Criteria and Endpoints in Metastatic Renal Cell Carcinoma Trials. American Journal of Clinical Oncology: Cancer Clinical Trials, 2020, 43, 559-566.	0.6	3
176	Association between copy-number alteration of +20q, 14q and 18p and cross-sensitivity to tyrosine kinase inhibitors in clear-cell renal cell carcinoma. Cancer Cell International, 2020, 20, 482.	1.8	3
177	Potential Application of Chimeric Antigen Receptor (CAR)-T Cell Therapy in Renal Cell Tumors. Frontiers in Oncology, 2020, 10, 565857.	1.3	14
178	Consensus paper: current state of first- and second-line therapy in advanced clear-cell renal cell carcinoma. Future Oncology, 2020, 16, 2307-2328.	1.1	17
179	Treatment after progression in the era of immunotherapy. Lancet Oncology, The, 2020, 21, e463-e476.	5.1	115
181	No-cytoreductive nephrectomy should no longer be routinely performed. Current Opinion in Urology, 2020, Publish Ahead of Print, 743-745.	0.9	1
182	Prognostic and Predictive Factors in Metastatic Renal Cell Carcinoma. Cancer Journal (Sudbury, Mass) Tj ETQq1 1 0,784314 rgBT /Over	1.0	1
183	The von Hippel-Lindau Tumor Suppressor Gene. Cancer Journal (Sudbury, Mass), 2020, 26, 390-398.	1.0	123
184	Avelumab and axitinib combination therapy for the treatment of advanced renal cell carcinoma. Future Oncology, 2020, 16, 3021-3034.	1.1	3
185	Tumor Cellâ€‘Derived TGFÎ²1 Attenuates Antitumor Immune Activity of T Cells via Regulation of PD-1 mRNA. Cancer Immunology Research, 2020, 8, 1470-1484.	1.6	28
186	Cytoreductive Nephrectomy in Patients Presenting With Advanced Disease. Cancer Journal (Sudbury,) Tj ETQq1 1 0,784314 rgBT /Over	1.0	1
187	Biomarkers for immune checkpoint therapy targeting programmed death 1 and programmed death ligand 1. Biomedicine and Pharmacotherapy, 2020, 130, 110621.	2.5	8
188	The incidence risk of programmed cell death-1/programmed cell death ligand 1 inhibitor-related alopecia for cancer patients. Medicine (United States), 2020, 99, e22555.	0.4	2
189	Efficacy and safety of combination PDâ€‘1/PDâ€‘L1 checkpoint inhibitors for malignant solid tumours: A systematic review. Journal of Cellular and Molecular Medicine, 2020, 24, 13494-13506.	1.6	4
190	Designing novel immunocombinations in metastatic renal cell carcinoma. Immunotherapy, 2020, 12, 1257-1268.	1.0	6
191	Trends in Initial Systemic Therapy for Elderly Patients with Metastatic Clear Cell Renal Cell Carcinoma. Kidney Cancer, 2020, 4, 131-137.	0.2	2
192	Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. Lancet Oncology, The, 2020, 21, 1563-1573.	5.1	466

#	ARTICLE	IF	CITATIONS
193	The Reintroduction of Radiotherapy Into the Integrated Management of Kidney Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2020, 26, 448-459.	1.0	1
194	Severe fistulizing pancreatitis in a patient with Merkel cell carcinoma treated with avelumab. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 1266-1267.	0.8	5
195	The Role of Targeted Therapy in the Management of High-Risk Resected Kidney Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2020, 26, 376-381.	1.0	5
196	The Immunotherapy Revolution in Kidney Cancer Treatment. <i>Cancer Journal (Sudbury, Mass)</i> , 2020, 26, 419-431.	1.0	17
197	Sarcomatoid renal cell carcinoma: biology, natural history and management. <i>Nature Reviews Urology</i> , 2020, 17, 659-678.	1.9	76
198	Novel Therapeutic Approaches and the Evolution of Drug Development in Advanced Kidney Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2020, 26, 464-470.	1.0	18
199	The Immunotherapy Landscape in Renal Cell Carcinoma. <i>BioDrugs</i> , 2020, 34, 733-748.	2.2	27
200	Current Multimodality Treatments against Brain Metastases from Renal Cell Carcinoma. <i>Cancers</i> , 2020, 12, 2875.	1.7	14
201	Discontinuation of first-line molecular-targeted therapy and prognosis in patients with metastatic renal cell carcinoma: Impact of disease progression vs. adverse events. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 937.e19-937.e25.	0.8	2
202	Cultivation of Clear Cell Renal Cell Carcinoma Patient-Derived Organoids in an Air-Liquid Interface System as a Tool for Studying Individualized Therapy. <i>Frontiers in Oncology</i> , 2020, 10, 1775.	1.3	24
203	Kidney Cancer. <i>Urologic Clinics of North America</i> , 2020, 47, 419-431.	0.8	84
204	Immunotherapy for Metastatic Prostate Cancer: Current and Emerging Treatment Options. <i>Urologic Clinics of North America</i> , 2020, 47, 487-510.	0.8	10
205	Targeting the HIF2-VEGF axis in renal cell carcinoma. <i>Nature Medicine</i> , 2020, 26, 1519-1530.	15.2	248
206	Significance of tumor microenvironment in acquiring resistance to vascular endothelial growth factor-tyrosine kinase inhibitor and recent advance of systemic treatment of clear cell renal cell carcinoma. <i>Pathology International</i> , 2020, 70, 712-723.	0.6	5
207	Correlates of clinical benefit from immunotherapy and targeted therapy in metastatic renal cell carcinoma: comprehensive genomic and transcriptomic analysis. , 2020, 8, e000953.		32
208	Research progress of PD-1/PD-L1 immunotherapy in gastrointestinal tumors. <i>Biomedicine and Pharmacotherapy</i> , 2020, 129, 110504.	2.5	26
209	Baseline Frequency of Inflammatory Cxcl9-Expressing Tumor-Associated Macrophages Predicts Response to Avelumab Treatment. <i>Cell Reports</i> , 2020, 32, 107873.	2.9	42
210	Resistance to immune checkpoint inhibitors in non-small cell lung cancer: biomarkers and therapeutic strategies. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592093790.	1.4	49

#	ARTICLE	IF	CITATIONS
211	Characteristics and Outcome of Children with Renal Cell Carcinoma: A Narrative Review. <i>Cancers</i> , 2020, 12, 1776.	1.7	29
212	Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Analysis. <i>Targeted Oncology</i> , 2020, 15, 495-501.	1.7	28
213	Efficacy and safety of immune checkpoint inhibitors in patients with advanced non-â€‘small cell lung cancer (NSCLC): a systematic literature review. <i>Oncimmunology</i> , 2020, 9, 1774314.	2.1	34
214	Randomised Phase II study comparing alternating cycles of sunitinib and everolimus vs standard sequential administration in first-â€‘line metastatic renal carcinoma (SUNRISES study). <i>BJU International</i> , 2020, 126, 559-567.	1.3	5
215	Outcomes With First-Line PD-1/PD-L1 Inhibitor Monotherapy for Metastatic Renal Cell Carcinoma (mRCC): A Multi-Institutional Cohort. <i>Frontiers in Oncology</i> , 2020, 10, 581189.	1.3	11
216	Tyrosine Kinase Receptors in Oncology. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8529.	1.8	46
217	Pathological complete response after nivolumab therapy following angiogenesis inhibitors in a patient with metastatic renal cell carcinoma. <i>IJU Case Reports</i> , 2020, 3, 287-290.	0.1	6
218	First-line axitinib therapy is less effective in metastatic renal cell carcinoma with spindle histology. <i>Scientific Reports</i> , 2020, 10, 20089.	1.6	2
219	Construction of a Novel Multigene Panel Potently Predicting Poor Prognosis in Patients with Clear Cell Renal Cell Carcinoma. <i>Cancers</i> , 2020, 12, 3471.	1.7	8
220	Analysis of Response Data for Assessing Treatment Effects in Comparative Clinical Studies. <i>Annals of Internal Medicine</i> , 2020, 173, 368-374.	2.0	18
221	Prognostic significance and immune correlates of CD73 expression in renal cell carcinoma. , 2020, 8, e001467.		22
222	Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial. <i>Breast Cancer Research</i> , 2020, 22, 124.	2.2	21
223	Immune checkpoints and their inhibitors: Reappraisal of a novel diagnostic and therapeutic dimension in the urologic malignancies. <i>Seminars in Oncology</i> , 2020, 47, 367-379.	0.8	6
224	A Durable Response With the Combination of Nivolumab and Cabozantinib in a Patient With Metastatic Paraganglioma: A Case Report and Review of the Current Literature. <i>Frontiers in Endocrinology</i> , 2020, 11, 594264.	1.5	10
225	Immunotherapy for extensive stage small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2020, 12, 6212-6224.	0.6	3
226	Axitinib plus avelumab in the treatment of recurrent glioblastoma: a stratified, open-label, single-center phase 2 clinical trial (GliAvAx). , 2020, 8, e001146.		35
227	The Impact of Renal Impairment on Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma Treated With Tyrosine Kinase Inhibitors. <i>Cancer Control</i> , 2020, 27, 107327482097714.	0.7	2
228	The Immune Checkpoint PD-1 in Natural Killer Cells: Expression, Function and Targeting in Tumour Immunotherapy. <i>Cancers</i> , 2020, 12, 3285.	1.7	85

#	ARTICLE	IF	CITATIONS
229	Systematic Assessment of Risk of Fever in Solid Tumor Patients Treated With PD-1/PD-L1 Inhibitors: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 570080.	1.3	5
230	Therapy-Induced Modulation of the Tumor Microenvironment: New Opportunities for Cancer Therapies. <i>Frontiers in Oncology</i> , 2020, 10, 582884.	1.3	23
231	First-in-human, dose-escalation, phase 1 study of anti-angiopoietin-2 LY3127804 as monotherapy and in combination with ramucirumab in patients with advanced solid tumours. <i>British Journal of Cancer</i> , 2020, 123, 1235-1243.	2.9	12
232	LncRNA HOTAIR induces sunitinib resistance in renal cancer by acting as a competing endogenous RNA to regulate autophagy of renal cells. <i>Cancer Cell International</i> , 2020, 20, 338.	1.8	28
233	Genetic Alterations in Renal Cancers: Identification of The Mechanisms Underlying Cancer Initiation and Progression and of Therapeutic Targets. <i>Medicines (Basel, Switzerland)</i> , 2020, 7, 44.	0.7	13
234	Treating metastatic clear-cell renal cell carcinoma: beyond immunotherapy. <i>Medical Oncology</i> , 2020, 37, 81.	1.2	7
235	Complete response to immune checkpoint inhibitors-based therapy in advanced renal cell carcinoma patients. A meta-analysis of randomized clinical trials. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 798.e17-798.e24.	0.8	6
236	Comparative risk of serious and fatal treatment-related adverse events caused by 19 immune checkpoint inhibitors used in cancer treatment: a network meta-analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592094092.	1.4	11
237	Myeloid Cells as Clinical Biomarkers for Immune Checkpoint Blockade. <i>Frontiers in Immunology</i> , 2020, 11, 1590.	2.2	50
238	Good and sustained response to pembrolizumab and pazopanib in advanced undifferentiated pleomorphic sarcoma: a case report. <i>Clinical Sarcoma Research</i> , 2020, 10, 10.	2.3	11
239	Current Management and Progress in Radiotherapy for Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 1146.	1.3	24
240	Renal adverse effects following the use of different immune checkpoint inhibitor regimens: A real-world pharmacoepidemiology study of post-marketing surveillance data. <i>Cancer Medicine</i> , 2020, 9, 6576-6585.	1.3	21
241	Systemic Therapy of Common Tumours in Older Patients: Challenges and Opportunities. A Young International Society of Geriatric Oncology Review Paper. <i>Current Oncology Reports</i> , 2020, 22, 98.	1.8	3
242	Synergies of Antiangiogenic Therapy and Immune Checkpoint Blockade in Renal Cell Carcinoma: From Theoretical Background to Clinical Reality. <i>Frontiers in Oncology</i> , 2020, 10, 1321.	1.3	22
243	Resistance to Anti-angiogenic Therapies: A Mechanism Depending on the Time of Exposure to the Drugs. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 584.	1.8	40
244	The role of income disparities on survival in metastatic clear cell renal cell carcinoma in the targeted therapy era. <i>European Journal of Health Economics</i> , 2020, 21, 1223-1233.	1.4	4
245	Evolving Frontline Treatment Landscape for Advanced or Metastatic Renal Cell Carcinoma. <i>Kidney Cancer</i> , 2020, 4, 71-79.	0.2	2
246	Are we ready to accept intermediate outcome measures in clinical cancer trials?. <i>Annals of Oncology</i> , 2020, 31, 973-975.	0.6	1

#	ARTICLE	IF	CITATIONS
247	The immunology of renal cell carcinoma. <i>Nature Reviews Nephrology</i> , 2020, 16, 721-735.	4.1	229
248	Regulatory Considerations for Contribution of Effect of Drugs Used in Combination Regimens: Renal Cell Cancer Case Studies. <i>Clinical Cancer Research</i> , 2020, 26, 6406-6411.	3.2	5
249	Clinical and molecular characteristics associated with survival among cancer patients receiving first-line anti-PD-1/PD-L1-based therapies. <i>Biomarkers</i> , 2020, 25, 441-448.	0.9	1
250	The Value of PD-L1 Expression as Predictive Biomarker in Metastatic Renal Cell Carcinoma Patients: A Meta-Analysis of Randomized Clinical Trials. <i>Cancers</i> , 2020, 12, 1945.	1.7	49
251	Patients with sarcomatoid renal cell carcinoma “ re-defining the first-line of treatment: A meta-analysis of randomised clinical trials with immune checkpoint inhibitors. <i>European Journal of Cancer</i> , 2020, 136, 195-203.	1.3	47
252	Cost-effectiveness of pembrolizumab with axitinib as first-line treatment for advanced renal cell carcinoma. <i>Current Medical Research and Opinion</i> , 2020, 36, 1507-1517.	0.9	11
253	Targeting the immune milieu in gastrointestinal cancers. <i>Journal of Gastroenterology</i> , 2020, 55, 909-926.	2.3	7
254	Normalizing the Tumor Microenvironment for Radiosensitization. <i>Cancer Drug Discovery and Development</i> , 2020, , 301-338.	0.2	4
255	Cabozantinib in advanced renal cell carcinoma: A phase II, open-label, single-arm study of Japanese patients. <i>International Journal of Urology</i> , 2020, 27, 952-959.	0.5	17
256	Digital Pathology Analysis Quantifies Spatial Heterogeneity of CD3, CD4, CD8, CD20, and FoxP3 Immune Markers in Triple-Negative Breast Cancer. <i>Frontiers in Physiology</i> , 2020, 11, 583333.	1.3	42
257	BIONIKK: A phase 2 biomarker driven trial with nivolumab and ipilimumab or VEGFR tyrosine kinase inhibitor (TKI) in naïve metastatic kidney cancer. <i>Bulletin Du Cancer</i> , 2020, 107, eS22-eS27.	0.6	37
258	Advanced Non-Clear Cell Kidney Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2020, 26, 441-447.	1.0	1
259	Impact of COVID-19 pandemic on treatment patterns in metastatic clear cell renal cell carcinoma. <i>ESMO Open</i> , 2020, 5, e000852.	2.0	18
260	Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001-2020). <i>Journal of Hematology and Oncology</i> , 2020, 13, 143.	6.9	226
261	Optimized Management of Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma: A Response-Based Phase II Study (OMNIVORE). <i>Journal of Clinical Oncology</i> , 2020, 38, 4240-4248.	0.8	69
262	Old Player-New Tricks: Non Angiogenic Effects of the VEGF/VEGFR Pathway in Cancer. <i>Cancers</i> , 2020, 12, 3145.	1.7	42
263	Clinical Impact of Tumor-Infiltrating Lymphocytes and PD-L1-Positive Cells as Prognostic and Predictive Biomarkers in Urological Malignancies and Retroperitoneal Sarcoma. <i>Cancers</i> , 2020, 12, 3153.	1.7	15
264	Avelumab “cetuximab” radiotherapy versus standards of care in locally advanced squamous-cell carcinoma of the head and neck: The safety phase of a randomised phase III trial GORTEC 2017-01 (REACH). <i>European Journal of Cancer</i> , 2020, 141, 21-29.	1.3	48

#	ARTICLE	IF	CITATIONS
265	Ramucirumab in Combination with Pembrolizumab in Treatment-Naïve Advanced Gastric or GEJ Adenocarcinoma: Safety and Antitumor Activity from the Phase 1a/b JVDF Trial. <i>Cancers</i> , 2020, 12, 2985.	1.7	21
266	Pembrolizumab plus axitinib: another step ahead in advanced renal cell carcinoma. <i>Lancet Oncology</i> , 2020, 21, 1538-1539.	5.1	7
267	Combination therapy in metastatic renal cell carcinoma: Back to the future?. <i>Seminars in Oncology</i> , 2020, 47, 361-366.	0.8	11
268	Adjuvant therapy for high-risk renal cell carcinoma after nephrectomy how many trials are positive? Only one or more than one. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2020, 16, 12-17.	0.7	1
269	What is the optimum systemic treatment for advanced/metastatic renal cell carcinoma of favourable, intermediate and poor risk, respectively? A systematic review and network meta-analysis. <i>BMJ Open</i> , 2020, 10, e034626.	0.8	13
270	Interaction between Immunotherapy and Antiangiogenic Therapy for Cancer. <i>Molecules</i> , 2020, 25, 3900.	1.7	21
271	Pediatric and young adult renal cell carcinoma. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28675.	0.8	14
272	The clinical significance of routine risk categorization in metastatic renal cell carcinoma and its impact on treatment decision-making: a systematic review. <i>Future Oncology</i> , 2020, 16, 2879-2896.	1.1	3
273	<p>Pembrolizumab in Combination with Axitinib as First-Line Treatment for Patients with Renal Cell Carcinoma (RCC): Evidence to Date<p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 7321-7330.	0.9	24
274	First-line treatments for advanced renal-cell carcinoma with immune checkpoint inhibitors: systematic review, network meta-analysis and cost-effectiveness analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592095019.	1.4	21
275	Predicting Response to Immunotherapy in Metastatic Renal Cell Carcinoma. <i>Cancers</i> , 2020, 12, 2662.	1.7	31
277	MASCC 2020 recommendations for the management of immune-related adverse events of patients undergoing treatment with immune checkpoint inhibitors. <i>Supportive Care in Cancer</i> , 2020, 28, 6107-6110.	1.0	16
278	Immune Related Adverse Events. <i>Cancer Journal (Sudbury, Mass)</i> , 2020, 26, 432-440.	1.0	4
279	Integrated Genomic Characterization of the Human Immunome in Cancer. <i>Cancer Research</i> , 2020, 80, 4854-4867.	0.4	11
280	Treatment sequencing strategies in metastatic renal cell carcinoma: A critical interpretation of available data. <i>Journal of Onco-Nephrology</i> , 2020, 4, 153-164.	0.3	0
281	Camrelizumab plus apatinib successfully treated a patient with advanced esophageal squamous cell carcinoma. <i>Immunotherapy</i> , 2020, 12, 1161-1166.	1.0	7
283	Prospective Translational Study Investigating Molecular PrEdictors of Resistance to First-Line Pazopanib in Metastatic reNal CELL Carcinoma (PIPELINE Study). <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020, 43, 621-627.	0.6	4
285	Patient selection and risk factors in the changing treatment landscape of metastatic renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 831-840.	1.1	3

#	ARTICLE	IF	CITATIONS
286	Treatment patterns, outcomes and clinical characteristics in advanced renal cell carcinoma: a real-world US study. <i>Future Oncology</i> , 2020, 16, 3045-3060.	1.1	7
287	Phage Display Derived Monoclonal Antibodies: From Bench to Bedside. <i>Frontiers in Immunology</i> , 2020, 11, 1986.	2.2	146
288	Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial. <i>Nature Medicine</i> , 2020, 26, 1733-1741.	15.2	282
289	Predictive Biomarkers of Response to Immunotherapy in Metastatic Renal Cell Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 1644.	1.3	48
290	Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors. <i>Journal of Clinical Oncology</i> , 2020, 38, 3672-3684.	0.8	78
291	<p>Research Status and Outlook of PD-1/PD-L1 Inhibitors for Cancer Therapy<p>. <i>Drug Design, Development and Therapy</i> , 2020, Volume 14, 3625-3649.	2.0	80
292	Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity. <i>Experimental and Molecular Medicine</i> , 2020, 52, 1475-1485.	3.2	306
294	Safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma: a systematic review and meta-analysis. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 1329-1338.	1.0	64
296	Angiogenic and Immune-Related Biomarkers and Outcomes Following Axitinib/Pembrolizumab Treatment in Patients with Advanced Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 5598-5608.	3.2	13
297	Uncommon Subtypes of Malignant Melanomas: A Review Based on Clinical and Molecular Perspectives. <i>Cancers</i> , 2020, 12, 2362.	1.7	22
298	Treatment of Advanced Renal Cell Carcinoma: Immunotherapies Have Demonstrated Overall Survival Benefits While Targeted Therapies Have Not. <i>European Urology Open Science</i> , 2020, 22, 61-73.	0.2	11
299	Immune-Related Neurological Toxicities of PD-1/PD-L1 Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis. <i>Frontiers in Immunology</i> , 2020, 11, 595655.	2.2	8
300	Individualizing Systemic Therapies in First Line Treatment and beyond for Advanced Renal Cell Carcinoma. <i>Cancers</i> , 2020, 12, 3750.	1.7	10
301	Complete Pathologic Responses With Immunotherapy in Metastatic Renal Cell Carcinoma: Case Reports. <i>Frontiers in Oncology</i> , 2020, 10, 609235.	1.3	9
302	Downstream neighbor of SON (DONSON) is associated with unfavorable survival across diverse cancers with oncogenic properties in clear cell renal cell carcinoma. <i>Translational Oncology</i> , 2020, 13, 100844.	1.7	8
303	Immunotherapy in sarcomatoid renal cell carcinoma: A case for optimism. <i>Cancer Treatment and Research Communications</i> , 2020, 25, 100257.	0.7	0
304	Soluble forms of PD-L1 and PD-1 as prognostic and predictive markers of sunitinib efficacy in patients with metastatic clear cell renal cell carcinoma. <i>Oncolmmunology</i> , 2020, 9, 1846901.	2.1	27
305	Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade. <i>Cancer Cell</i> , 2020, 38, 803-817.e4.	7.7	262

#	ARTICLE	IF	CITATIONS
306	Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities. <i>Frontiers in Immunology</i> , 2020, 11, 598877.	2.2	133
307	TFE3&PD&L1 axis is pivotal for sunitinib resistance in clear cell renal cell carcinoma. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 14441-14452.	1.6	7
308	Acute interstitial nephritis, a potential predictor of response to immune checkpoint inhibitors in renal cell carcinoma. , 2020, 8, e001198.		24
309	Biomarkers Towards New Era of Therapeutics for Metastatic Renal Cell Carcinoma. <i>Kidney Cancer</i> , 2020, 4, 61-69.	0.2	1
310	First-Line Immune Checkpoint Inhibitor-Based Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review. <i>Kidney Cancer</i> , 2020, 4, 81-92.	0.2	1
311	Validation of the Correlation Between Single Nucleotide Polymorphism rs307826 in VEGFR3 and Outcome in Metastatic Clear-Cell Renal Cell Carcinoma Patients Treated with Sunitinib. <i>Kidney Cancer</i> , 2020, 4, 139-149.	0.2	0
313	Cost-effectiveness of Pembrolizumab Plus Axitinib Vs Nivolumab Plus Ipilimumab as First-Line Treatment of Advanced Renal Cell Carcinoma in the US. <i>JAMA Network Open</i> , 2020, 3, e2016144.	2.8	24
314	Cancer Immunotherapy Dosing: A Pharmacokinetic/Pharmacodynamic Perspective. <i>Vaccines</i> , 2020, 8, 632.	2.1	23
315	Current State of Combination of Locoregional Therapies with Immune Checkpoint Inhibition. <i>Journal of Vascular and Interventional Radiology</i> , 2020, 31, 1740-1744.e9.	0.2	5
316	Response to nivolumab combining radiotherapy and nimotuzumab in metastatic oral squamous cell carcinoma patient with strong PD-L1 expression: a case report. <i>Annals of Translational Medicine</i> , 2020, 8, 402-402.	0.7	8
317	Small molecules"Giant leaps for immuno-oncology. <i>Progress in Medicinal Chemistry</i> , 2020, 59, 1-62.	4.1	2
318	The preliminary outcome of the combination of immunotherapy and targeted therapy after recurrence and metastasis for hereditary leiomyomatosis and renal cell cancer"a case report. <i>Translational Andrology and Urology</i> , 2020, 9, 789-793.	0.6	6
319	Combination treatments with immunotherapy in brain metastases patients. <i>Future Oncology</i> , 2020, 16, 1691-1705.	1.1	2
320	Eighteenth International Kidney Cancer Symposium, November 15-16, 2019, Trump National Doral Miami Hotel, Miami, Florida. <i>Kidney Cancer</i> , 2020, 4, SI-S56.	0.2	3
321	A guide to cancer immunotherapy: from T cell basic science to clinical practice. <i>Nature Reviews Immunology</i> , 2020, 20, 651-668.	10.6	2,160
322	Advancing the Science and Management of Renal Cell Carcinoma: Bridging the Divide between Academic and Community Practices. <i>Journal of Clinical Medicine</i> , 2020, 9, 1508.	1.0	3
323	Angiogenic and immunomodulatory biomarkers in axitinib-treated patients with advanced renal cell carcinoma. <i>Future Oncology</i> , 2020, 16, 1199-1210.	1.1	4
324	Immune-related adverse events of checkpoint inhibitors. <i>Nature Reviews Disease Primers</i> , 2020, 6, 38.	18.1	684

#	ARTICLE	IF	CITATIONS
325	Efficacy and safety of nivolumab for renal cell carcinoma in patients over 75 years old from multiple Japanese institutes. <i>International Journal of Clinical Oncology</i> , 2020, 25, 1543-1550.	1.0	10
326	Renal Cell and Urothelial Carcinoma: Biomarkers for New Treatments. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, e197-e206.	1.8	10
327	Immune Checkpoint Blockade for Prostate Cancer: Niche Role or Next Breakthrough?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, e89-e106.	1.8	17
328	The Prognostic Value of Systemic Inflammatory Markers in Advanced Renal Cell Carcinoma Patients Treated With Molecular Targeted Therapies. <i>Anticancer Research</i> , 2020, 40, 1739-1745.	0.5	11
329	Therapeutic Targeting of Autophagy for Renal Cell Carcinoma Therapy. <i>Cancers</i> , 2020, 12, 1185.	1.7	31
330	Mechanistic Learning for Combinatorial Strategies With Immuno-oncology Drugs: Can Model-Informed Designs Help Investigators?. <i>JCO Precision Oncology</i> , 2020, 4, 486-491.	1.5	9
332	Elective Cytoreductive Nephrectomy After Checkpoint Inhibitor Immunotherapy in Patients With Initially Unresectable Metastatic Clear Cell Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 361-366.	0.9	13
333	Contemporary Cytoreductive Nephrectomy Provides Survival Benefit in Clear-cell Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e730-e738.	0.9	9
334	PD-1/PD-L1 Based Combinational Cancer Therapy: Icing on the Cake. <i>Frontiers in Pharmacology</i> , 2020, 11, 722.	1.6	65
335	Management of oligometastatic and oligoprogressive renal cell carcinoma: state of the art and future directions. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 491-501.	1.1	14
336	Immune checkpoint inhibition in muscle-invasive and locally advanced bladder cancer. <i>Current Opinion in Urology</i> , 2020, 30, 547-556.	0.9	12
337	Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma. <i>Annals of Oncology</i> , 2020, 31, 1030-1039.	0.6	316
338	Gender-Related Approach to Kidney Cancer Management: Moving Forward. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3378.	1.8	27
339	Advanced renal cell carcinoma (RCC) management: an expert panel recommendation from the Latin American Cooperative Oncology Group (LACOG) and the Latin American Renal Cancer Group (LARCG). <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 1829-1845.	1.2	3
340	Gut Bacteria Composition Drives Primary Resistance to Cancer Immunotherapy in Renal Cell Carcinoma Patients. <i>European Urology</i> , 2020, 78, 195-206.	0.9	192
341	Tumor Endothelial Cellâ€”A Biological Tool for Translational Cancer Research. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3238.	1.8	22
342	An evaluation of avelumab for the treatment of genitourinary tumors. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 971-979.	1.4	4
343	The hypoxic tumour microenvironment: A safe haven for immunosuppressive cells and a therapeutic barrier to overcome. <i>Cancer Letters</i> , 2020, 487, 34-44.	3.2	32

#	ARTICLE	IF	CITATIONS
344	Real-world use of tamsirolimus in Japanese patients with unresectable or metastatic renal cell carcinoma: recent consideration based on the results of a post-marketing, all-case surveillance study. Japanese Journal of Clinical Oncology, 2020, 50, 940-947.	0.6	3
345	Novel therapies for advanced urologic cancers. Current Opinion in Urology, 2020, 30, 594-601.	0.9	2
346	Safety and efficacy of CDX-014, an antibody-drug conjugate directed against T cell immunoglobulin mucin-1 in advanced renal cell carcinoma. Investigational New Drugs, 2020, 38, 1807-1814.	1.2	14
347	A Systematic Review of Systemic Treatment Options for Advanced Non-Clear Cell Renal Cell Carcinoma. Kidney Cancer, 2020, 4, 15-27.	0.2	5
348	The future of cancer immunotherapy: microenvironment-targeting combinations. Cell Research, 2020, 30, 507-519.	5.7	480
349	Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. Nature Medicine, 2020, 26, 909-918.	15.2	488
350	PD1/PD-L1 therapy in metastatic renal cell carcinoma. Current Opinion in Urology, 2020, 30, 534-541.	0.9	8
351	The Pan-Omics Landscape of Renal Cell Carcinoma and Its Implication on Future Clinical Practice. Kidney Cancer, 2020, 4, 121-129.	0.2	2
352	Anlotinib for Patients With Metastatic Renal Cell Carcinoma Previously Treated With One Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor: A Phase 2 Trial. Frontiers in Oncology, 2020, 10, 664.	1.3	19
353	A Cost-Effectiveness Analysis: First-Line Avelumab Plus Axitinib Versus Sunitinib for Advanced Renal-Cell Carcinoma. Frontiers in Pharmacology, 2020, 11, 619.	1.6	16
354	Anti-angiogenesis and Immunotherapy: Novel Paradigms to Envision Tailored Approaches in Renal Cell-Carcinoma. Journal of Clinical Medicine, 2020, 9, 1594.	1.0	49
355	Immune Checkpoint Inhibitors in Genitourinary Malignancies. Current Oncology, 2020, 27, 69-77.	0.9	13
356	Proliferative potential and response to nivolumab in clear cell renal cell carcinoma patients. OncoImmunology, 2020, 9, 1773200.	2.1	10
357	The landscape of contemporary clinical trials for untreated metastatic clear cell renal cell carcinoma. Cancer Treatment and Research Communications, 2020, 24, 100183.	0.7	8
358	Cytoreductive Nephrectomy in the Era of Tyrosine Kinase and Immuno-Oncology Checkpoint Inhibitors. Urologic Clinics of North America, 2020, 47, 359-370.	0.8	10
359	Epidemiology, Risk Assessment, and Biomarkers for Patients with Advanced Renal Cell Carcinoma. Urologic Clinics of North America, 2020, 47, 293-303.	0.8	25
360	Pazopanib as a possible option for the treatment of metastatic non-clear cell renal carcinoma patients: a systematic review. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592091530.	1.4	10
361	Salvage Ipilimumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma After Prior Immune Checkpoint Inhibitors. Journal of Clinical Oncology, 2020, 38, 3088-3094.	0.8	61

#	ARTICLE	IF	CITATIONS
362	Cabozantinib in combination with atezolizumab versus sorafenib in treatment-naive advanced hepatocellular carcinoma: COSMIC-312 Phase III study design. <i>Future Oncology</i> , 2020, 16, 1525-1536.	1.1	50
363	Clinical outcomes of second-line treatment following prior targeted therapy in patients with metastatic renal cell carcinoma: a comparison of axitinib and nivolumab. <i>International Journal of Clinical Oncology</i> , 2020, 25, 1678-1686.	1.0	9
364	Co-Regulation of Immune Checkpoint PD-L1 with Interferon-Gamma Signaling is Associated with a Survival Benefit in Renal Cell Cancer. <i>Targeted Oncology</i> , 2020, 15, 377-390.	1.7	15
365	Cytoreductive Nephrectomy in Metastatic Patients with Signs or Symptoms: Implications for Renal Cell Carcinoma Guidelines. <i>European Urology</i> , 2020, 78, 321-326.	0.9	25
366	Systemic therapy in metastatic renal cell carcinoma: Emerging challenges in therapeutic choice. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 152, 102971.	2.0	7
368	<p>Optimal Management of First-Line Advanced Renal Cell Carcinoma: Focus on Pembrolizumab</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 4021-4034.	1.0	5
369	A Randomized Phase IIa Trial with Temsirolimus versus Sunitinib in Advanced Non-Clear Cell Renal Cell Carcinoma: An Intergroup Study of the CESAR Central European Society for Anticancer Drug Research-EWIV and the Interdisciplinary Working Group on Renal Cell Cancer (IAGN) of the German Cancer Society. <i>Oncology Research and Treatment</i> , 2020, 43, 333-339.	0.8	20
370	Sequencing Therapies for Metastatic Renal Cell Carcinoma. <i>Urologic Clinics of North America</i> , 2020, 47, 305-318.	0.8	14
371	Neoadjuvant Therapy for Locally Advanced Renal Cell Carcinoma. <i>Urologic Clinics of North America</i> , 2020, 47, 329-343.	0.8	10
372	The Evolving Role of Metastasectomy for Patients with Metastatic Renal Cell Carcinoma. <i>Urologic Clinics of North America</i> , 2020, 47, 379-388.	0.8	12
373	Impact of the systemic immune-inflammation index for the prediction of prognosis and modification of the risk model in patients with metastatic renal cell carcinoma treated with first-line tyrosine kinase inhibitors. <i>Canadian Urological Association Journal</i> , 2020, 14, E582-E587.	0.3	11
374	Optimizing patient selection for cytoreductive nephrectomy based on outcomes in the contemporary era of systemic therapy. <i>Cancer</i> , 2020, 126, 3950-3960.	2.0	34
375	Neoadjuvant Cabozantinib in Renal-Cell Carcinoma: A Brief Review. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e688-e691.	0.9	11
376	Exploring Biological Predictive Factors of Progression After Surgery in High-Risk Renal Cell Carcinoma: Results From the French Cohort of the Randomized S-TRAC Trial Patients. <i>Frontiers in Surgery</i> , 2020, 7, 26.	0.6	2
377	Targeting glycolysis with 2-deoxy-d-glucose sensitizes primary cell cultures of renal cell carcinoma to tyrosine kinase inhibitors. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 2255-2265.	1.2	10
378	Spectrum and Clinical Activity of PD-1/PD-L1 Inhibitors: Regulatory Approval and Under Development. <i>Current Oncology Reports</i> , 2020, 22, 70.	1.8	11
379	Genomic profiling in renal cell carcinoma. <i>Nature Reviews Nephrology</i> , 2020, 16, 435-451.	4.1	99
380	Redefining the Role of Surgical Management of Metastatic Renal Cell Carcinoma. <i>Current Oncology Reports</i> , 2020, 22, 35.	1.8	3

#	ARTICLE	IF	CITATIONS
381	Visible-light induced decarboxylative coupling of redox-active esters with disulfides to construct C–S bonds. <i>Chemical Communications</i> , 2020, 56, 4164-4167.	2.2	37
382	Multicentric Analytical and Inter-observer Comparability of Four Clinically Developed Programmed Death-ligand 1 Immunohistochemistry Assays in Advanced Clear-cell Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e629-e642.	0.9	8
383	Harnessing cell-free DNA: plasma circulating tumour DNA for liquid biopsy in genitourinary cancers. <i>Nature Reviews Urology</i> , 2020, 17, 271-291.	1.9	32
385	Lactate dehydrogenase: a marker of diminished antitumor immunity. <i>Oncolmunology</i> , 2020, 9, 1731942.	2.1	107
386	Combining Immune Checkpoint Inhibitors with Anti-Angiogenic Agents. <i>Journal of Clinical Medicine</i> , 2020, 9, 675.	1.0	57
387	Real-world Experience With Sunitinib Treatment in Patients With Metastatic Renal Cell Carcinoma: Clinical Outcome According to Risk Score. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e588-e597.	0.9	11
388	Axitinib in first-line for patients with metastatic papillary renal cell carcinoma: Results of the multicentre, open-label, single-arm, phase II AXIPAP trial. <i>European Journal of Cancer</i> , 2020, 129, 107-116.	1.3	35
389	Single-Cell Approaches to Profile the Response to Immune Checkpoint Inhibitors. <i>Frontiers in Immunology</i> , 2020, 11, 490.	2.2	38
390	Upregulated immuno-modulator PD-L1 in malignant peripheral nerve sheath tumors provides a potential biomarker and a therapeutic target. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 1307-1313.	2.0	6
391	Frequency of discordance in programmed death-ligand 1 (PD-L1) expression between primary tumors and paired distant metastases in advanced cancers: a systematic review and meta-analysis. <i>Acta Oncologica</i> , 2020, 59, 696-704.	0.8	6
392	The Story of Angiogenesis Inhibitors in Non-small-cell Lung Cancer: The Past, Present, and Future. <i>Clinical Lung Cancer</i> , 2020, 21, 308-313.	1.1	26
394	New prognostic model for synchronous metastatic renal cell carcinoma. <i>International Journal of Urology</i> , 2020, 27, 448-456.	0.5	4
395	Tyrosine kinase inhibitors and immunotherapy combinations in renal cell carcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592090750.	1.4	94
396	Outcomes According to MSKCC Risk Score with Focus on the Intermediate-Risk Group in Metastatic Renal Cell Carcinoma Patients Treated with First-Line Sunitinib: A Retrospective Analysis of 2390 Patients. <i>Cancers</i> , 2020, 12, 808.	1.7	10
397	The Therapeutic Landscape of Renal Cell Carcinoma: From the Dark Age to the Golden Age. <i>Seminars in Nephrology</i> , 2020, 40, 28-41.	0.6	42
398	Immune Checkpoint Inhibitors in the Treatment of Renal Cell Carcinoma. <i>Seminars in Nephrology</i> , 2020, 40, 76-85.	0.6	18
399	First-line Treatment of Metastatic Renal Cell Carcinoma in the Immuno-oncology Era: Systematic Review and Network Meta-analysis. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 244-251.e4.	0.9	16
401	Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma. <i>European Journal of Cancer</i> , 2020, 135, 203-210.	1.3	50

#	ARTICLE	IF	CITATIONS
402	Immunomodulatory Roles of VEGF Pathway Inhibitors in Renal Cell Carcinoma. <i>Drugs</i> , 2020, 80, 1169-1181.	4.9	53
403	Immune Checkpoint Inhibitors in the Treatment of Renal Cancer: Current State and Future Perspective. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4691.	1.8	40
404	Adjuvant Therapy for Localized High-Risk Renal Cell Carcinoma. <i>Urologic Clinics of North America</i> , 2020, 47, 345-358.	0.8	5
405	Combination Therapy for Metastatic Renal Cell Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020, 43, 477-483.	0.6	3
406	The immunotherapy revolution in genitourinary malignancies. <i>Immunotherapy</i> , 2020, 12, 819-831.	1.0	10
407	A comprehensive review of the role of immune checkpoint inhibitors in elderly patients affected by renal cell carcinoma. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 153, 103036.	2.0	5
408	Development of canine PD-1/PD-L1 specific monoclonal antibodies and amplification of canine T cell function. <i>PLoS ONE</i> , 2020, 15, e0235518.	1.1	26
409	Immune Checkpoint Inhibition—Does It Cause Rheumatic Diseases? Mechanisms of Cancer-Associated Loss of Tolerance and Pathogenesis of Autoimmunity. <i>Rheumatic Disease Clinics of North America</i> , 2020, 46, 587-603.	0.8	3
410	Comparative Efficacy of First-Line Immune-Based Combination Therapies in Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-Analysis. <i>Cancers</i> , 2020, 12, 1673.	1.7	13
411	The impact of cytoreductive nephrectomy on survival outcomes in patients treated with tyrosine kinase inhibitors for metastatic renal cell carcinoma in a real-world cohort. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 739.e9-739.e15.	0.8	11
412	Combination of Ipilimumab and Nivolumab in Cancers: From Clinical Practice to Ongoing Clinical Trials. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4427.	1.8	67
413	Evolving Role of Urologists in the Management of Advanced Renal Cell Carcinoma. <i>Urologic Clinics of North America</i> , 2020, 47, 271-280.	0.8	2
414	Axitinib plus immune checkpoint inhibitor: evidence- and expert-based consensus recommendation for treatment optimisation and management of related adverse events. <i>British Journal of Cancer</i> , 2020, 123, 898-904.	2.9	36
415	Hyperprogressive disease in patients with advanced renal cell carcinoma: a new pattern of post-treatment cancer behavior. <i>Immunologic Research</i> , 2020, 68, 204-212.	1.3	5
416	Efficacy and safety of neoadjuvant immunotherapy in resectable nonsmall cell lung cancer: A meta-analysis. <i>Lung Cancer</i> , 2020, 147, 143-153.	0.9	66
417	Systemic therapy for advanced clear cell renal cell carcinoma after discontinuation of immune-oncology and VEGF targeted therapy combinations. <i>BMC Urology</i> , 2020, 20, 84.	0.6	12
418	Immunotherapy combinations for the treatment of patients with solid tumors. <i>Future Oncology</i> , 2020, 16, 1715-1736.	1.1	6
419	Immune checkpoint inhibitors: Key trials and an emerging role in breast cancer. <i>Seminars in Cancer Biology</i> , 2022, 79, 44-57.	4.3	104

#	ARTICLE	IF	CITATIONS
420	Association between PD-L1 Expression and the Prognosis and Clinicopathologic Features of Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. <i>Urologia Internationalis</i> , 2020, 104, 533-541.	0.6	23
421	Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 251-266.	12.5	408
422	Targeting cancer stem cell pathways for cancer therapy. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 8.	7.1	998
423	Avelumab plus axitinib vs sunitinib for advanced renal cell carcinoma: Japanese subgroup analysis from JAVELIN Renal 101. <i>Cancer Science</i> , 2020, 111, 907-923.	1.7	33
424	Clinical efficacy and safety of anti-PD-1/PD-L1 inhibitors for the treatment of advanced or metastatic cancer: a systematic review and meta-analysis. <i>Scientific Reports</i> , 2020, 10, 2083.	1.6	124
425	A Case Report with Severe Thrombocytopenia Induced by Axitinib. <i>Case Reports in Hematology</i> , 2020, 2020, 1-4.	0.3	2
426	Phase Ib/II Clinical Trial of Pembrolizumab With Bevacizumab for Metastatic Renal Cell Carcinoma: BTCRC-GU14-003. <i>Journal of Clinical Oncology</i> , 2020, 38, 1138-1145.	0.8	32
427	New First Line Treatment Options of Clear Cell Renal Cell Cancer Patients with PD-1 or PD-L1 Immune-Checkpoint Inhibitor-Based Combination Therapies. <i>Journal of Clinical Medicine</i> , 2020, 9, 565.	1.0	35
428	Modeling clear cell renal cell carcinoma and therapeutic implications. <i>Oncogene</i> , 2020, 39, 3413-3426.	2.6	86
429	Restricted mean survival time as a summary measure of time-to-event outcome. <i>Pharmaceutical Statistics</i> , 2020, 19, 436-453.	0.7	21
430	Fatal Adverse Events Associated With Programmed Cell Death Ligand 1 Inhibitors: A Systematic Review and Meta-Analysis. <i>Frontiers in Pharmacology</i> , 2020, 11, 5.	1.6	12
431	Dual targeting of TGF- β 2 and PD-L1 via a bifunctional anti-PD-L1/TGF- β 2RII agent: status of preclinical and clinical advances. , 2020, 8, e000433.		166
432	Flawed trials for cancer. <i>Annals of Oncology</i> , 2020, 31, 331-333.	0.6	5
433	Synchronous Versus Metachronous Metastatic Disease: Impact of Time to Metastasis on Patient Outcome—Results from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>European Urology Oncology</i> , 2020, 3, 530-539.	2.6	29
434	Outcomes Associated with First-Line anti-PD-1/ PD-L1 agents vs. Sunitinib in Patients with Sarcomatoid Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2020, 12, 408.	1.7	32
435	Current State of Systemic Therapies for Advanced Renal Cell Carcinoma. <i>Current Oncology Reports</i> , 2020, 22, 26.	1.8	38
436	A new scenario in metastatic renal cell carcinoma: a SOG-GU consensus. <i>Clinical and Translational Oncology</i> , 2020, 22, 1565-1579.	1.2	1
437	Real-World Assessment of Clinical Outcomes Among First-Line Sunitinib Patients with Clear Cell Metastatic Renal Cell Carcinoma (mRCC) by the International mRCC Database Consortium Risk Group. <i>Oncologist</i> , 2020, 25, 422-430.	1.9	12

#	ARTICLE	IF	CITATIONS
438	Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2020, 72, 307-319.	1.8	310
439	Overcoming immunotherapeutic resistance by targeting the cancer inflammation cycle. <i>Seminars in Cancer Biology</i> , 2020, 65, 38-50.	4.3	34
440	Immunotherapy-based combinations versus standard first-line treatment for metastatic clear cell renal cell carcinoma: a systematic review and meta-analysis. <i>Clinical and Translational Oncology</i> , 2020, 22, 1657-1663.	1.2	5
441	Ex-Vivo Treatment of Tumor Tissue Slices as a Predictive Preclinical Method to Evaluate Targeted Therapies for Patients with Renal Carcinoma. <i>Cancers</i> , 2020, 12, 232.	1.7	40
442	New rising entities in cancer of unknown primary: Is there a real therapeutic benefit?. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 147, 102882.	2.0	42
443	A historical turning point for the treatment of advanced renal cell carcinoma: inhibition of immune checkpoint. <i>Current Medical Research and Opinion</i> , 2020, 36, 625-635.	0.9	4
444	The Future of Immunotherapy-Based Combination Therapy in Metastatic Renal Cell Carcinoma. <i>Cancers</i> , 2020, 12, 143.	1.7	36
445	Clinical importance of the expression of CD4+CD8+ T cells in renal cell carcinoma. <i>International Immunology</i> , 2020, 32, 347-357.	1.8	10
446	SEOM clinical guideline for treatment of kidney cancer (2019). <i>Clinical and Translational Oncology</i> , 2020, 22, 256-269.	1.2	18
447	Beyond the concept of cold and hot tumors for the development of novel predictive biomarkers and the rational design of immunotherapy combination. <i>International Journal of Cancer</i> , 2020, 147, 1509-1518.	2.3	44
448	Optimising first-line treatment for metastatic renal cell carcinoma. <i>Lancet, The</i> , 2020, 395, e6.	6.3	1
449	Optimizing treatment of renal cell carcinoma with VEGFR-TKIs: a comparison of clinical pharmacology and drug-drug interactions of anti-angiogenic drugs. <i>Cancer Treatment Reviews</i> , 2020, 84, 101966.	3.4	44
450	Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors. <i>Journal of Clinical Oncology</i> , 2020, 38, 1154-1163.	0.8	276
451	Evolution in upfront treatment strategies for metastatic RCC. <i>Nature Reviews Urology</i> , 2020, 17, 73-74.	1.9	9
452	Treatment Choices for Front-line Metastatic Clear Cell Renal Cancer. <i>European Urology</i> , 2020, 77, 454-456.	0.9	6
453	Combining microenvironment normalization strategies to improve cancer immunotherapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 3728-3737.	3.3	163
454	Clinical and economic outcomes of treatment sequences for intermediate- to poor-risk advanced renal cell carcinoma. <i>Immunotherapy</i> , 2020, 12, 37-51.	1.0	10
456	Phase 1 trial of vorolanib (CM082) in combination with everolimus in patients with advanced clear-cell renal cell carcinoma. <i>EBioMedicine</i> , 2020, 55, 102755.	2.7	12

#	ARTICLE	IF	CITATIONS
457	Deferred Cytoreductive Nephrectomy in Patients with Newly Diagnosed Metastatic Renal Cell Carcinoma. <i>European Urology</i> , 2020, 78, 615-623.	0.9	44
458	Patient-Reported Outcomes from the Phase III Randomized IMmotion151 Trial: Atezolizumab + Bevacizumab versus Sunitinib in Treatment-Naïve Metastatic Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 2506-2514.	3.2	20
459	IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation. <i>Future Oncology</i> , 2020, 16, 975-989.	1.1	136
460	Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence. <i>Cancers</i> , 2020, 12, 738.	1.7	826
461	Immunotherapy in Renal Cell Carcinoma: The Future Is Now. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2532.	1.8	126
463	Acquired Resistance to Immune Checkpoint Inhibitors. <i>Cancer Cell</i> , 2020, 37, 443-455.	7.7	444
464	PD-L1 Assay Concordance in Metastatic Renal Cell Carcinoma and Metastatic Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 509-513.	0.9	1
465	Clinicopathological implications of the expression of vascular endothelial growth factor and programmed death ligand 1 in clear-cell renal cell carcinoma. <i>Human Pathology</i> , 2020, 99, 88-97.	1.1	2
466	Improved survival after cytoreductive nephrectomy for metastatic renal cell carcinoma in the contemporary immunotherapy era: An analysis of the National Cancer Database. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 604.e9-604.e17.	0.8	77
467	Tumour grade significantly correlates with total dysfunction of tumour tissue-infiltrating lymphocytes in renal cell carcinoma. <i>Scientific Reports</i> , 2020, 10, 6220.	1.6	25
468	Atezolizumab for the treatment of renal cell carcinoma. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 679-686.	1.4	0
469	Mammalian SWI/SNF Complex Genomic Alterations and Immune Checkpoint Blockade in Solid Tumors. <i>Cancer Immunology Research</i> , 2020, 8, 1075-1084.	1.6	47
470	Combination Strategies for Immune-Checkpoint Blockade and Response Prediction by Artificial Intelligence. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2856.	1.8	31
471	The genetic landscapes of urological cancers and their clinical implications in the era of high-throughput genome analysis. <i>BJU International</i> , 2020, 126, 26-54.	1.3	5
472	Current Approaches to the Treatment of Advanced or Metastatic Renal Cell Carcinoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, 187-196.	1.8	26
473	On the Shoulders of Giants: The Evolution of Renal Cell Carcinoma Treatmentâ€”Cytokines, Targeted Therapy, and Immunotherapy. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, 418-435.	1.8	16
474	Anti-angiogenesis therapy overcomes the innate resistance to PD-1/PD-L1 blockade in VEGFA-overexpressed mouse tumor models. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 1781-1799.	2.0	56
475	Survival Benefits of Second-line Axitinib Versus Everolimus After First Line Sunitinib Treatment in Metastatic Renal Cell Carcinoma. <i>Pathology and Oncology Research</i> , 2020, 26, 2201-2207.	0.9	4

#	ARTICLE	IF	CITATIONS
476	Avelumab and axitinib in the treatment of renal cell carcinoma: safety and efficacy. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 343-354.	1.1	0
477	Liver metastases and the efficacy of the PD-1 or PD-L1 inhibitors in cancer: a meta-analysis of randomized controlled trials. <i>OncImmunity</i> , 2020, 9, 1746113.	2.1	15
478	Immune Checkpoint Inhibitors for Brain Metastases: A Primer for Neurosurgeons. <i>Neurosurgery</i> , 2020, 87, E281-E288.	0.6	22
479	Challenges and opportunities in the management of metastatic renal cell carcinoma: combination therapy and the role of cytoreductive surgery. <i>Current Opinion in Oncology</i> , 2020, 32, 240-249.	1.1	15
480	Mechanism-based treatment of cancer with immune checkpoint inhibitor therapies. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1690-1702.	1.1	26
481	Patient-reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinoma. <i>BJU International</i> , 2020, 126, 73-82.	1.3	19
482	Safety and efficacy of restarting immune checkpoint inhibitors after clinically significant immune-related adverse events in metastatic renal cell carcinoma. , 2020, 8, e000144.		56
483	Pazopanib after Nivolumab-Induced Tumor Lysis Syndrome in a Patient with Metastatic Clear-Cell Renal Cell Carcinoma. <i>Case Reports in Oncology</i> , 2020, 13, 249-254.	0.3	3
484	RUNX1 Is a Driver of Renal Cell Carcinoma Correlating with Clinical Outcome. <i>Cancer Research</i> , 2020, 80, 2325-2339.	0.4	21
485	Targeting PD-1 or PD-L1 in Metastatic Kidney Cancer: Combination Therapy in the First-Line Setting. <i>Clinical Cancer Research</i> , 2020, 26, 2087-2095.	3.2	35
486	Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy. <i>Journal of Hematology and Oncology</i> , 2020, 13, 29.	6.9	146
487	Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations. <i>Frontiers in Immunology</i> , 2020, 11, 373.	2.2	27
488	Landscape and Future Perspectives of Immunotherapy in Neuroendocrine Neoplasia. <i>Cancers</i> , 2020, 12, 832.	1.7	27
489	High level of EZH2 expression is linked to high density of CD8-positive T-lymphocytes and an aggressive phenotype in renal cell carcinoma. <i>World Journal of Urology</i> , 2021, 39, 481-490.	1.2	11
491	Patients'™ Perspective on Digital Technologies in Advanced Genitourinary Cancers. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 76-82.e6.	0.9	12
492	Blocking IL1 Beta Promotes Tumor Regression and Remodeling of the Myeloid Compartment in a Renal Cell Carcinoma Model: Multidimensional Analyses. <i>Clinical Cancer Research</i> , 2021, 27, 608-621.	3.2	73
493	Systemic therapy for metastatic renal cell carcinoma in the first-line setting: a systematic review and network meta-analysis. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 265-273.	2.0	44
494	Immune Checkpoint Inhibitor Cardiotoxicity: Understanding Basic Mechanisms and Clinical Characteristics and Finding a Cure. <i>Annual Review of Pharmacology and Toxicology</i> , 2021, 61, 113-134.	4.2	40

#	ARTICLE	IF	CITATIONS
495	Complete response of hereditary leiomyomatosis and renal cell cancer (HLRCC)-associated renal cell carcinoma to nivolumab and ipilimumab combination immunotherapy by: a case report. <i>Familial Cancer</i> , 2021, 20, 75-80.	0.9	17
496	From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm. <i>Trends in Cancer</i> , 2021, 7, 15-28.	3.8	61
497	TiNivo: safety and efficacy of tivozanib-nivolumab combination therapy in patients with metastatic renal cell carcinoma. <i>Annals of Oncology</i> , 2021, 32, 97-102.	0.6	42
498	Multicenter Phase II Trial of Axitinib Monotherapy for Gemcitabine-Based Chemotherapy Refractory Advanced Biliary Tract Cancer (AX-BC Study). <i>Oncologist</i> , 2021, 26, 97-e201.	1.9	2
499	Comparison of nivolumab plus ipilimumab with tyrosine kinase inhibitors as first-line therapies for metastatic renal-cell carcinoma: a multicenter retrospective study. <i>International Journal of Clinical Oncology</i> , 2021, 26, 154-162.	1.0	11
500	Pembrolizumab plus axitinib combination and the paradigm change in the treatment of advanced renal cell carcinoma. <i>Future Oncology</i> , 2021, 17, 241-254.	1.1	4
501	Phase II Study of Avelumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib. <i>Clinical Cancer Research</i> , 2021, 27, 713-718.	3.2	27
502	Synergism between anti-angiogenic and immune checkpoint inhibitor drugs: A hypothesis. <i>Medical Hypotheses</i> , 2021, 146, 110399.	0.8	5
503	Modest efficacy of nivolumab plus ipilimumab in patients with papillary renal cell carcinoma. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 646-653.	0.6	22
504	KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1. <i>Cancer Immunology Research</i> , 2021, 9, 156-169.	1.6	56
505	An Illustrative Case of Combination Cabozantinib/Nivolumab for Progressive Metastatic Renal Cell Carcinoma (mRCC). <i>Oncologist</i> , 2021, 26, e508-e511.	1.9	4
506	Exploring the knowledge gap of immune checkpoint inhibitors in chronic renal failure: A systematic review of the literature. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103169.	2.0	14
507	Enhancing anti-tumour efficacy with immunotherapy combinations. <i>Lancet, The</i> , 2021, 397, 1010-1022.	6.3	196
508	Creation of a primary tumor tissue expression biomarker-augmented prognostic model for patients with metastatic renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 135.e1-135.e8.	0.8	2
509	Multicenter Phase I/II Study of Nivolumab Combined with Paclitaxel Plus Ramucirumab as Second-line Treatment in Patients with Advanced Gastric Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 1029-1036.	3.2	46
510	Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma. <i>Clinical Cancer Research</i> , 2021, 27, 1048-1057.	3.2	129
511	A novel prognostic model based on immunogenomics for clear cell renal cell carcinoma. <i>International Immunopharmacology</i> , 2021, 90, 107119.	1.7	2
512	Predictive role of $\hat{\gamma}^3$ -glutamyltransferase in patients receiving nivolumab therapy for metastatic renal cell carcinoma. <i>International Journal of Clinical Oncology</i> , 2021, 26, 552-561.	1.0	7

#	ARTICLE	IF	CITATIONS
513	Molecular Profiling of Exceptional Responders to Cancer Therapy. <i>Oncologist</i> , 2021, 26, 186-195.	1.9	15
514	Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies. <i>Cancer</i> , 2021, 127, 840-849.	2.0	51
515	The Predictive Value of Programmed Death Ligand 1 in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-checkpoint Inhibitors: A Systematic Review and Meta-analysis. <i>European Urology</i> , 2021, 79, 783-792.	0.9	46
516	Combination of Immunotherapy and Antiangiogenic Therapy in Cancer—a Rational Approach. <i>Journal of Thoracic Oncology</i> , 2021, 16, 178-182.	0.5	8
517	The need for new algorithms of treatment sequencing in clear-cell metastatic renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 401-412.	1.1	8
518	Current status of PD-1/PD-L1 blockade immunotherapy in breast cancer. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 321-332.	0.6	22
519	Efficacy and Biomarker Analysis of Camrelizumab in Combination with Apatinib in Patients with Advanced Nonsquamous NSCLC Previously Treated with Chemotherapy. <i>Clinical Cancer Research</i> , 2021, 27, 1296-1304.	3.2	79
520	A network meta-analysis of efficacy and safety of first-line and second-line therapies for the management of metastatic renal cell carcinoma. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2021, 46, 35-49.	0.7	18
521	Absorption of the orally active multikinase inhibitor axitinib as a therapeutic index to guide dose titration in metastatic renal cell carcinoma. <i>Investigational New Drugs</i> , 2021, 39, 595-604.	1.2	6
522	Everolimus after failure of one prior VEGF -targeted therapy in metastatic renal cell carcinoma: Final results of the MARC -2 trial. <i>International Journal of Cancer</i> , 2021, 148, 1685-1694.	2.3	7
523	TIM3 expression on tumor cells predicts response to anti-PD-1 therapy for renal cancer. <i>Translational Oncology</i> , 2021, 14, 100918.	1.7	11
524	Cost-Effectiveness of Pembrolizumab plus Axitinib Versus Sunitinib as First-Line Therapy in Advanced Renal Cell Carcinoma in the U.S.. <i>Oncologist</i> , 2021, 26, e290-e297.	1.9	15
525	Immune evasion in renal cell carcinoma: biology, clinical translation, future directions. <i>Kidney International</i> , 2021, 99, 75-85.	2.6	22
526	6-Gingerol suppresses tumor cell metastasis by increasing YAP ^{ser127} phosphorylation in renal cell carcinoma. <i>Journal of Biochemical and Molecular Toxicology</i> , 2021, 35, e22609.	1.4	13
527	Avelumab: search for combinations of immune checkpoint inhibition with chemotherapy. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 311-322.	1.4	10
528	Cytotoxic CD8+ T cells in cancer and cancer immunotherapy. <i>British Journal of Cancer</i> , 2021, 124, 359-367.	2.9	590
529	Pazopanib as Second-line Antiangiogenic Treatment in Metastatic Renal Cell Carcinoma After Tyrosine Kinase Inhibitor (TKI) Failure: A Phase 2 Trial Exploring Immune-related Biomarkers for Testing in the Post-immunotherapy/TKI Era. <i>European Urology Oncology</i> , 2021, 4, 502-505.	2.6	5
530	Aberrant Epidermal Growth Factor Receptor RNA Splice Products Are Among the Most Frequent Somatic Alterations in Clear Cell Renal Cell Carcinoma and Are Associated with a Poor Response to Immunotherapy. <i>European Urology Focus</i> , 2021, 7, 373-380.	1.6	4

#	ARTICLE	IF	CITATIONS
531	Metastatic Renal Cell Carcinoma Rapidly Progressive to Sunitinib: What to Do Next?. European Urology Oncology, 2021, 4, 274-281.	2.6	7
532	Outcomes of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy After Immuno-oncology Checkpoint Inhibitors. European Urology Oncology, 2021, 4, 102-111.	2.6	26
533	Avelumab internalization by human circulating immune cells is mediated by both Fc gamma receptor and PD-L1 binding. Oncoimmunology, 2021, 10, 1958590.	2.1	16
534	Genetic analysis of primary renal cell carcinoma to determine treatment approaches. Expert Review of Precision Medicine and Drug Development, 2021, 6, 107-115.	0.4	1
535	Update on First-Line Combination Treatment Approaches in Metastatic Clear-Cell Renal Cell Carcinoma. Current Treatment Options in Oncology, 2021, 22, 15.	1.3	13
536	Neuropilin 1 and Neuropilin 2 gene invalidation or pharmacological inhibition reveals their relevance for the treatment of metastatic renal cell carcinoma. Journal of Experimental and Clinical Cancer Research, 2021, 40, 33.	3.5	11
537	Cancer Immunology. , 2021, , .		0
538	Response to systemic therapy in locally advanced and metastatic renal cell carcinoma: can it be predicted?. Expert Review of Anticancer Therapy, 2021, 21, 629-639.	1.1	0
539	Factors Modifying the Associations of Single or Combination Programmed Cell Death 1 and Programmed Cell Death Ligand 1 Inhibitor Therapies With Survival Outcomes in Patients With Metastatic Clear Cell Renal Cell Carcinoma. JAMA Network Open, 2021, 4, e2034201.	2.8	4
540	Therapeutic Effect of an Anti-Human Programmed Death-Ligand 1 (PD-L1) Nanobody on Polymicrobial Sepsis in Humanized Mice. Medical Science Monitor, 2021, 27, e926820.	0.5	7
541	The implementation of lenvatinib/everolimus or lenvatinib/pembrolizumab combinations in the treatment of metastatic renal cell carcinoma. Expert Review of Anticancer Therapy, 2021, 21, 365-372.	1.1	5
542	Cancer Immunotherapy: Overview of Immune Checkpoint Inhibitors. , 2021, , 31-47.		0
543	Increased expression of adenosine 2A receptors in metastatic renal cell carcinoma is associated with poorer response to anti-vascular endothelial growth factor agents and anti-PD-1/Anti-CTLA4 antibodies and shorter survival. Cancer Immunology, Immunotherapy, 2021, 70, 2009-2021.	2.0	27
544	ACE2 abrogates tumor resistance to VEGFR inhibitors suggesting angiotensin-(1-7) as a therapy for clear cell renal cell carcinoma. Science Translational Medicine, 2021, 13, .	5.8	29
545	New approaches to first-line treatment of advanced renal cell carcinoma. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110347.	1.4	25
546	Update on the most promising biomarkers of response to immune checkpoint inhibitors in clear cell renal cell carcinoma. World Journal of Urology, 2021, 39, 1377-1385.	1.2	15
547	Unleashing the power of immunotherapy and targeted therapy combinations: Advancing cancer care or discovering unknown toxicities?. Journal of Oncology Pharmacy Practice, 2021, 27, 930-938.	0.5	6
548	External validation of the albumin, C-reactive protein and lactate dehydrogenase model in patients with metastatic renal cell carcinoma receiving second-line axitinib therapy in a Japanese multi-center cohort. Japanese Journal of Clinical Oncology, 2021, 51, 810-818.	0.6	0

#	ARTICLE	IF	CITATIONS
549	Tumor flare of brain metastases upon dose interruption of sunitinib in a patient with metastatic renal cell carcinoma. <i>Cancer Treatment and Research Communications</i> , 2021, 27, 100367.	0.7	2
550	Phase II Trial Investigating Definitive Radiation Therapy in Lieu of Systemic Therapy for Oligometastatic Renal Cell Carcinoma. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
551	A phase 1b trial of the CXCR4 inhibitor mavorixafor and nivolumab in advanced renal cell carcinoma patients with no prior response to nivolumab monotherapy. <i>Investigational New Drugs</i> , 2021, 39, 1019-1027.	1.2	22
552	Pembrolizumab plus axitinib and nivolumab plus ipilimumab as first-line treatments of advanced intermediate- or poor-risk renal-cell carcinoma: a number needed to treat analysis from the Brazilian private perspective. <i>Journal of Medical Economics</i> , 2021, 24, 291-298.	1.0	4
553	Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy. , 2021, 9, e001642.		28
554	Tumor Microenvironment Features as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors (ICI) in Metastatic Clear Cell Renal Cell Carcinoma (mccRCC). <i>Cancers</i> , 2021, 13, 231.	1.7	42
555	Regorafenib-Avelumab Combination in Patients with Microsatellite Stable Colorectal Cancer (REGOMUNE): A Single-arm, Open-label, Phase II Trial. <i>Clinical Cancer Research</i> , 2021, 27, 2139-2147.	3.2	77
556	Efficacy and safety of anti-PD-1/PD-L1 combinations versus standard of care in cancer: a systematic review and meta-analysis.. <i>Oncolmmunology</i> , 2021, 10, 1878599.	2.1	11
557	Mapping the immune environment in clear cell renal carcinoma by single-cell genomics. <i>Communications Biology</i> , 2021, 4, 122.	2.0	139
558	Mitochondrial stress induced by continuous stimulation under hypoxia rapidly drives T cell exhaustion. <i>Nature Immunology</i> , 2021, 22, 205-215.	7.0	358
559	Development of a novel gene signature to predict prognosis and response to PD-1 blockade in clear cell renal cell carcinoma. <i>Oncolmmunology</i> , 2021, 10, 1933332.	2.1	26
560	Comorbidity and frailty assessment in renal cell carcinoma patients. <i>World Journal of Urology</i> , 2021, 39, 2831-2841.	1.2	7
561	Real Impact of Novel Immunotherapy Drugs in Cancer. The Experience of 10 Last Years. <i>Toxins</i> , 2021, 13, 149.	1.5	6
562	Progress Update in Pediatric Renal Tumors. <i>Current Oncology Reports</i> , 2021, 23, 33.	1.8	14
563	First-line treatment of metastatic clear cell renal cell carcinoma: a decision-making analysis among experts. <i>ESMO Open</i> , 2021, 6, 100030.	2.0	35
564	Natural history of untreated kidney cancer. <i>World Journal of Urology</i> , 2021, 39, 2825-2829.	1.2	5
565	Characteristics and outcome of pediatric renal cell carcinoma patients registered in the International Society of Pediatric Oncology (<scp>SIOP</scp>) 93â€1, 2001 and <scp>UKâ€IMPORT</scp> database: A report of the <scp>SIOPâ€Renal</scp> Tumor Study Group. <i>International Journal of Cancer</i> , 2021, 148, 2724-2735.	2.3	26
566	Dissecting Outcomes: Should Cytoreductive Nephrectomy Be Performed for Patients With Metastatic Renal Cell Carcinoma With Sarcomatoid Dedifferentiation?. <i>Frontiers in Oncology</i> , 2020, 10, 627025.	1.3	6

#	ARTICLE	IF	CITATIONS
567	Survival After Combining Stereotactic Body Radiation Therapy and Tyrosine Kinase Inhibitors in Patients With Metastatic Renal Cell Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 607595.	1.3	5
568	Efficacy and safety of subsequent molecular targeted therapy after immuno-checkpoint therapy, retrospective study of Japanese patients with metastatic renal cell carcinoma (AFTER I-O study). <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 966-975.	0.6	12
569	Plk1, upregulated by HIF-2, mediates metastasis and drug resistance of clear cell renal cell carcinoma. <i>Communications Biology</i> , 2021, 4, 166.	2.0	19
570	A challenging frontier – the genomics and therapeutics of nonclear cell renal cell carcinoma. <i>Current Opinion in Oncology</i> , 2021, 33, 212-220.	1.1	6
571	Immune Infiltration Landscape in Clear Cell Renal Cell Carcinoma Implications. <i>Frontiers in Oncology</i> , 2020, 10, 491621.	1.3	15
572	Sunitinib Exerts In Vitro Immunomodulatory Activity on Sarcomas via Dendritic Cells and Synergizes With PD-1 Blockade. <i>Frontiers in Immunology</i> , 2021, 12, 577766.	2.2	16
573	PD-L1 as a biomarker of response to immune-checkpoint inhibitors. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 345-362.	12.5	646
574	Association between Immune Related Adverse Events and Outcome in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors. <i>Cancers</i> , 2021, 13, 860.	1.7	37
575	Prognostic significance of pathologic nodal positivity in non-metastatic patients with renal cell carcinoma who underwent radical or partial nephrectomy. <i>Scientific Reports</i> , 2021, 11, 3079.	1.6	1
577	Combination of immune checkpoint inhibitors and tyrosine kinase inhibitors for the treatment of renal cell carcinoma. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 1215-1226.	1.4	10
579	PD-L1 as a Potential Target in Cancer Therapy (Review). <i>Drug Development and Registration</i> , 2021, 10, 31-36.	0.2	3
580	Clear-cell renal cell carcinoma - A comprehensive review of agents used in the contemporary management of advanced/metastatic disease. <i>Oncology Reviews</i> , 2021, 15, 530.	0.8	9
581	Immune checkpoint blockade in renal cell carcinoma. <i>Journal of Surgical Oncology</i> , 2021, 123, 739-750.	0.8	13
582	Clinical utility of head computed tomography scan during systemic therapy for metastatic renal cell carcinoma. <i>International Journal of Urology</i> , 2021, 28, 450-456.	0.5	4
583	Sex-specific hormone changes during immunotherapy and its influence on survival in metastatic renal cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 2805-2817.	2.0	13
584	IGLL5 is correlated with tumor-infiltrating immune cells in clear cell renal cell carcinoma. <i>FEBS Open Bio</i> , 2021, 11, 898-910.	1.0	11
585	Chemotherapeutic and targeted agents can modulate the tumor microenvironment and increase the efficacy of immune checkpoint blockades. <i>Molecular Cancer</i> , 2021, 20, 27.	7.9	54
586	Adjuvant therapy in renal cell carcinoma: is it the right strategy to inhibit VEGF?. <i>Translational Andrology and Urology</i> , 2021, 10, 1581-1587.	0.6	3

#	ARTICLE	IF	CITATIONS
588	Current Advance of Immune Evasion Mechanisms and Emerging Immunotherapies in Renal Cell Carcinoma. <i>Frontiers in Immunology</i> , 2021, 12, 639636.	2.2	33
589	Perioperative therapy in renal cancer in the era of immune checkpoint inhibitor therapy. <i>Current Opinion in Urology</i> , 2021, 31, 262-269.	0.9	16
590	Phase IB study of sorafenib and evofosfamide in patients with advanced hepatocellular and renal cell carcinomas (NCCTG N1135, Alliance). <i>Investigational New Drugs</i> , 2021, 39, 1072-1080.	1.2	4
591	Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2021, 384, 829-841.	13.9	961
592	A case of multiple metastatic sarcomatoid renal cell carcinoma with complete response to nivolumab. <i>Cancer Reports</i> , 2021, 4, e1356.	0.6	2
593	Impact of albumin to globulin ratio on survival outcomes of patients with metastatic renal cell carcinoma. <i>Turkish Journal of Urology</i> , 2021, 47, 113-119.	1.3	5
594	What is next in second- and later-line treatment of metastatic renal cell carcinoma? review of the recent literature. <i>Current Opinion in Urology</i> , 2021, 31, 276-284.	0.9	7
595	Renal Cell Carcinoma and Kidney Transplantation: A Narrative Review. <i>Transplantation</i> , 2022, 106, e52-e63.	0.5	25
597	Finding predictive factors for immunotherapy in metastatic renal-cell carcinoma: What are we looking for?. <i>Cancer Treatment Reviews</i> , 2021, 94, 102157.	3.4	16
598	Targeting the Tumor Microenvironment for Improving Therapeutic Effectiveness in Cancer Immunotherapy: Focusing on Immune Checkpoint Inhibitors and Combination Therapies. <i>Cancers</i> , 2021, 13, 1188.	1.7	27
599	Direct and Indirect Modulation of T Cells by VEGF-A Counteracted by Anti-Angiogenic Treatment. <i>Frontiers in Immunology</i> , 2021, 12, 616837.	2.2	72
600	Combination of cabozantinib and immune checkpoint inhibitors in advanced renal cell carcinoma: update from the European Society for Medical Oncology 2020. <i>Future Oncology</i> , 2021, 17, 991-992.	1.1	0
601	Clinical Features and Multiplatform Molecular Analysis Assist in Understanding Patient Response to Anti-PD-1/PD-L1 in Renal Cell Carcinoma. <i>Cancers</i> , 2021, 13, 1475.	1.7	10
602	The Evolving Immunotherapy Landscape and the Epidemiology, Diagnosis, and Management of Cardiotoxicity. <i>JACC: CardioOncology</i> , 2021, 3, 35-47.	1.7	80
603	Biomarker-Oriented Therapy in Bladder and Renal Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2832.	1.8	18
604	Lenvatinib Plus Pembrolizumab Improves Outcomes in Previously Untreated Advanced Clear Cell Renal Cell Carcinoma. , 2021, 28, .		1
605	Management of advanced kidney cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2021. <i>Canadian Urological Association Journal</i> , 2020, 15, 84-97.	0.3	11
606	Active surveillance of metastatic renal cell carcinoma: Results from a prospective observational study (MaRCC). <i>Cancer</i> , 2021, 127, 2204-2212.	2.0	32

#	ARTICLE	IF	CITATIONS
607	Efficacy of Anti-PD-1/PD-L1 Monotherapy or Combinational Therapy in Patients Aged 75 Years or Older: A Study-Level Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 538174.	1.3	11
608	Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naïve Metastatic Clear-Cell Renal Cell Carcinoma. <i>European Urology</i> , 2021, 79, 339-342.	0.9	98
609	Drug-Related Pneumonitis in Cancer Treatment during the COVID-19 Era. <i>Cancers</i> , 2021, 13, 1052.	1.7	5
610	Renal toxicity of targeted therapies for renal cell carcinoma in patients with normal and impaired kidney function. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 87, 723-742.	1.1	13
611	Clinical Potential of Kinase Inhibitors in Combination with Immune Checkpoint Inhibitors for the Treatment of Solid Tumors. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2608.	1.8	13
612	Paradigms on Immunotherapy Combinations with Chemotherapy. <i>Cancer Discovery</i> , 2021, 11, 1353-1367.	7.7	197
613	Real-World Experience of Cabozantinib in Metastatic Renal Cell Carcinoma (mRCC): Results from the Canadian Kidney Cancer information system (CKCis). <i>Kidney Cancer</i> , 2021, 5, 21-29.	0.2	3
615	PD-L1 Expression and Treatment Implications in Metastatic Clear Cell Renal Cell Carcinoma: A Systematic Review. <i>Kidney Cancer</i> , 2021, 5, 31-46.	0.2	2
616	Individualizing renal cell carcinoma treatment through biomarkers discovery in the era of immune checkpoint inhibitors: where do we stand?. <i>Current Opinion in Urology</i> , 2021, 31, 236-241.	0.9	4
617	Combination antiangiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes. <i>Cancer Medicine</i> , 2021, 10, 2341-2349.	1.3	15
618	Roles of the Dynamic Tumor Immune Microenvironment in the Individualized Treatment of Advanced Clear Cell Renal Cell Carcinoma. <i>Frontiers in Immunology</i> , 2021, 12, 653358.	2.2	19
619	Outcomes of patients with intermediate-risk or poor-risk metastatic renal cell carcinoma who received their first cycle of nivolumab and ipilimumab in the hospital because of symptomatic disease: The MD Anderson Cancer Center experience. <i>International Journal of Cancer</i> , 2021, 149, 387-393.	2.3	6
620	Control of renal cell carcinoma brain metastases with cabozantinib following progression on immune checkpoint inhibitor therapy. <i>Current Problems in Cancer Case Reports</i> , 2021, 3, 100060.	0.1	0
621	Comparative efficacy and safety of immunotherapy in the first-line treatment of metastatic renal cell carcinoma: a systematic review and network meta-analysis. <i>Annals of Palliative Medicine</i> , 2021, 10, 2805-2814.	0.5	5
622	Current status of antigen-specific T-cell immunotherapy for advanced renal-cell carcinoma. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 1882-1896.	1.4	10
623	Renal cell carcinoma pathology in 2021: a new need for renal cancer immune profiling™. <i>Current Opinion in Urology</i> , 2021, 31, 228-235.	0.9	5
624	Dual immune check point blockade or immune check point-tyrosine kinase inhibitor combination: as a first-line treatment in metastatic renal cell carcinoma?. <i>Current Opinion in Urology</i> , 2021, 31, 270-275.	0.9	5
625	Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 1020-1028.	0.8	83

#	ARTICLE	IF	CITATIONS
626	Balancing efficacy and quality of life measurements among metastatic renal cell carcinoma (RCC) studies. <i>Oncoscience</i> , 2021, 8, 40-45.	0.9	1
627	Comprehensive Molecular Characterization and Response to Therapy in Fumarate Hydratase-Deficient Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 2910-2919.	3.2	45
628	First-line Immunotherapy-based Combinations for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis. <i>European Urology Oncology</i> , 2021, 4, 755-765.	2.6	100
630	Pembrolizumab plus axitinib for the treatment of advanced renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 693-703.	1.1	3
631	Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. <i>New England Journal of Medicine</i> , 2021, 384, 1289-1300.	13.9	956
632	Clinical efficacy of immune checkpoint inhibitors in patients with brain metastases. <i>Immunotherapy</i> , 2021, 13, 419-432.	1.0	9
633	Axitinib Induces and Aggravates Hypertension Regardless of Prior Treatment With Tyrosine Kinase Inhibitors. <i>Circulation Reports</i> , 2021, 3, 234-240.	0.4	5
634	Efficacy and Safety of Checkpoint Inhibitor Treatment in Patients with Advanced Renal or Urothelial Cell Carcinoma and Concomitant Chronic Kidney Disease: A Retrospective Cohort Study. <i>Cancers</i> , 2021, 13, 1623.	1.7	4
635	The Role of Epigenetics in the Progression of Clear Cell Renal Cell Carcinoma and the Basis for Future Epigenetic Treatments. <i>Cancers</i> , 2021, 13, 2071.	1.7	25
636	Anti-angiogenic agents "overcoming tumour endothelial cell energy and improving immunotherapy outcomes. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 527-540.	12.5	162
637	Development of Immunotherapy Combination Strategies in Cancer. <i>Cancer Discovery</i> , 2021, 11, 1368-1397.	7.7	130
638	Immunology and Immunotherapeutic Approaches for Advanced Renal Cell Carcinoma: A Comprehensive Review. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4452.	1.8	13
639	Avelumab in Combination with Axitinib as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma: Results from the Phase 1b VEGF Liver 100 Trial. <i>Liver Cancer</i> , 2021, 10, 249-259.	4.2	49
640	Do we need skin toxicity? Association of immune checkpoint inhibitor and tyrosine kinase inhibitor-related cutaneous adverse events with outcomes in metastatic renal cell carcinoma. <i>International Journal of Dermatology</i> , 2021, 60, 1242-1247.	0.5	2
641	Systemic therapy and COVID19: Immunotherapy and chemotherapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 213-220.	0.8	5
642	Therapeutic Application of Monoclonal Antibodies in Pancreatic Cancer: Advances, Challenges and Future Opportunities. <i>Cancers</i> , 2021, 13, 1781.	1.7	17
643	Paraneoplastic Neurological Syndromes and Beyond Emerging With the Introduction of Immune Checkpoint Inhibitor Cancer Immunotherapy. <i>Frontiers in Neurology</i> , 2021, 12, 642800.	1.1	26
644	A Step Ahead in Metastatic Renal Cell Carcinoma. <i>New England Journal of Medicine</i> , 2021, 384, 1360-1361.	13.9	5

#	ARTICLE	IF	CITATIONS
645	Metastatic Renal Cell Carcinoma Management: From Molecular Mechanism to Clinical Practice. <i>Frontiers in Oncology</i> , 2021, 11, 657639.	1.3	18
646	The Next Decade of Immune Checkpoint Therapy. <i>Cancer Discovery</i> , 2021, 11, 838-857.	7.7	363
647	Anti-Angiogenic Therapy: Current Challenges and Future Perspectives. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3765.	1.8	136
648	Nephrotoxicity of Anti-Angiogenic Therapies. <i>Diagnostics</i> , 2021, 11, 640.	1.3	16
649	Considerations on the mechanics and sample sizes for early trials of targeted agents and immunotherapy in oncology. <i>Expert Review of Precision Medicine and Drug Development</i> , 2021, 6, 271-280.	0.4	0
650	Registration trials in countries without access to US standards of care – pitfalls of interpretation. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 395-396.	12.5	1
651	Angiogenesis as a hallmark of solid tumors - clinical perspectives. <i>Cellular Oncology (Dordrecht)</i> , 2021, 44, 715-737.	2.1	109
652	Tumor mutational burden and immune infiltrates in renal cell carcinoma and matched brain metastases. <i>ESMO Open</i> , 2021, 6, 100057.	2.0	13
653	Therapeutic Targeting of the Tumor Microenvironment. <i>Cancer Discovery</i> , 2021, 11, 933-959.	7.7	646
654	Development of a highly pulmonary metastatic orthotopic renal cell carcinoma murine model. <i>Biology Open</i> , 2021, 10, .	0.6	6
655	Real-World Outcomes Among US Veterans Health Administration Patients Newly Diagnosed with Metastatic Renal Cell Carcinoma and Treated with First-Line Monotherapy. <i>Advances in Therapy</i> , 2021, 38, 2644-2661.	1.3	1
656	Development and validation of the prognostic value of the immune-related genes in clear cell renal cell carcinoma. <i>Translational Andrology and Urology</i> , 2021, 10, 1607-1619.	0.6	10
657	Cytoreductive nephrectomy in the era of targeted- And immuno- therapy for metastatic renal cell carcinoma: An elusive issue? A systematic review of the literature. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 160, 103293.	2.0	7
658	Addressing resistance to immune checkpoint inhibitor therapy: An urgent unmet need. <i>Future Oncology</i> , 2021, 17, 1401-1439.	1.1	17
659	A Living, Interactive Systematic Review and Network Meta-analysis of First-line Treatment of Metastatic Renal Cell Carcinoma. <i>European Urology</i> , 2021, 80, 712-723.	0.9	43
660	The DEAD/DEAH Box Helicase, DDX11, Is Essential for the Survival of Advanced Clear Cell Renal Cell Carcinoma and Is a Determinant of PARP Inhibitor Sensitivity. <i>Cancers</i> , 2021, 13, 2574.	1.7	7
661	Adverse events of systemic immune-based combination therapies in the first-line treatment of patients with metastatic renal cell carcinoma: systematic review and network meta-analysis. <i>Current Opinion in Urology</i> , 2021, 31, 332-339.	0.9	9
662	Real-World Survival Outcomes Associated With First-Line Immunotherapy, Targeted Therapy, and Combination Therapy for Metastatic Clear Cell Renal Cell Carcinoma. <i>JAMA Network Open</i> , 2021, 4, e2111329.	2.8	21

#	ARTICLE	IF	CITATIONS
663	Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma. <i>Cancer Cell</i> , 2021, 39, 649-661.e5.	7.7	263
664	Pazopanib together with 6-8 cycles of sintilimab followed by single use of pazopanib in the second-line treatment of advanced renal cell carcinoma. <i>Translational Andrology and Urology</i> , 2021, 10, 2078-2083.	0.6	3
665	Targeting the Proteasome in Advanced Renal Cell Carcinoma: Complexity and Limitations of Patient-Individualized Preclinical Drug Discovery. <i>Biomedicines</i> , 2021, 9, 627.	1.4	5
666	Cytoreductive Nephrectomy Following Immunotherapy-Based Treatment in Metastatic Renal Cell Carcinoma: A Case Series and Review of Current Literature. <i>Current Oncology</i> , 2021, 28, 1921-1926.	0.9	6
667	CD137 as an Attractive T Cell Co-Stimulatory Target in the TNFRSF for Immuno-Oncology Drug Development. <i>Cancers</i> , 2021, 13, 2288.	1.7	32
668	Reversing T-cell exhaustion in immunotherapy: a review on current approaches and limitations. <i>Expert Opinion on Therapeutic Targets</i> , 2021, 25, 347-363.	1.5	25
669	High Response Rate and Durability Driven by HLA Genetic Diversity in Patients with Kidney Cancer Treated with Lenvatinib and Pembrolizumab. <i>Molecular Cancer Research</i> , 2021, 19, 1510-1521.	1.5	20
670	Sarcomatoid Renal Cell Carcinoma: An Immune Checkpoint-responsive Subset?. <i>European Urology</i> , 2021, 79, 663-664.	0.9	0
671	Expanding the Role of Checkpoint Inhibitors in Immune Cold Tumors. <i>Advances in Oncology</i> , 2021, 1, 85-95.	0.1	0
672	Assessment of the Clinical Trials Safety Profile of PD-1/PD-L1 Inhibitors Among Patients With Cancer: An Updated Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 662392.	1.3	3
673	Anti-Vascular Endothelial Growth Factor C Antibodies Efficiently Inhibit the Growth of Experimental Clear Cell Renal Cell Carcinomas. <i>Cells</i> , 2021, 10, 1222.	1.8	10
674	The Immunotherapy Landscape in Adrenocortical Cancer. <i>Cancers</i> , 2021, 13, 2660.	1.7	8
675	Treatment of advanced urogenital cancers with immune checkpoint inhibitors. <i>Journal of the Korean Medical Association</i> , 2021, 64, 349-357.	0.1	0
676	Adoption of multiple primary endpoints in phase III trials of systemic treatments in patients with advanced solid tumours. A systematic review. <i>European Journal of Cancer</i> , 2021, 149, 49-60.	1.3	1
677	Single-cell sequencing links multiregional immune landscapes and tissue-resident T cells in ccRCC to tumor topology and therapy efficacy. <i>Cancer Cell</i> , 2021, 39, 662-677.e6.	7.7	179
678	PD-1/PD-L1 in Cancer: Pathophysiological, Diagnostic and Therapeutic Aspects. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5123.	1.8	61
679	Gene Expression Signature Correlates with Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with Everolimus Alone or with a Vascular Disrupting Agent. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 1454-1461.	1.9	6
680	Surgery for renal cell carcinoma extending to the right atrium in Japanese institutions: Focusing on cardiopulmonary bypass with or without deep hypothermic circulatory arrest. <i>International Journal of Urology</i> , 2021, 28, 1001-1007.	0.5	0

#	ARTICLE	IF	CITATIONS
681	Practical Considerations and Recommendations for Master Protocol Framework: Basket, Umbrella and Platform Trials. <i>Therapeutic Innovation and Regulatory Science</i> , 2021, 55, 1145-1154.	0.8	31
682	Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial. <i>ESMO Open</i> , 2021, 6, 100101.	2.0	25
684	Real-world symptoms, disease burden, resource use and quality of life in US patients with advanced renal cell cancer. <i>Future Oncology</i> , 2021, 17, 2169-2182.	1.1	3
685	Determinants of resistance to VEGF-TKI and immune checkpoint inhibitors in metastatic renal cell carcinoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 186.	3.5	77
686	Combining VEGF receptor inhibitors and angiotensin-(1 α) ⁷ to target renal cell carcinoma. <i>Molecular and Cellular Oncology</i> , 2021, 8, 1918529.	0.3	2
687	PBRM1 Mutations as a Predictive Biomarker for Immunotherapy in Metastatic Renal Cell Carcinoma: A Systematic Review. <i>Kidney Cancer</i> , 2021, 5, 79-92.	0.2	2
688	Comparative effectiveness of first-line immune checkpoint inhibitors plus tyrosine kinase inhibitors according to IMDC ¹ risk groups in metastatic renal cell carcinoma: a meta-analysis. <i>Immunotherapy</i> , 2021, 13, 783-793.	1.0	3
689	Canonical NF- κ B signaling maintains corneal epithelial integrity and prevents corneal aging via retinoic acid. <i>ELife</i> , 2021, 10, .	2.8	7
690	Ang2 inhibitors and Tie2 activators: potential therapeutics in perioperative treatment of early stage cancer. <i>EMBO Molecular Medicine</i> , 2021, 13, e08253.	3.3	18
691	The Efficacy of Surgical Metastasectomy for Solitary Metastasis of Renal Cell Carcinoma. <i>Urologia Internationalis</i> , 2022, 106, 397-403.	0.6	3
692	The Tumor Microenvironment Factors That Promote Resistance to Immune Checkpoint Blockade Therapy. <i>Frontiers in Oncology</i> , 2021, 11, 641428.	1.3	32
693	Biomarkers in renal cell carcinoma: Are we there yet?. <i>Asian Journal of Urology</i> , 2021, 8, 362-375.	0.5	15
694	Determinants of treatment for first-line immune-based combinations in metastatic renal cell carcinoma: a critical overview of recent evidence. <i>Immunotherapy</i> , 2021, 13, 685-692.	1.0	7
695	Sex-related differences in the efficacy of immune checkpoint inhibitors in malignancy: a systematic review and meta-analysis. <i>Aging</i> , 2021, 13, 15413-15432.	1.4	9
696	In the Age of Immunotherapy, How Can We Translate the CARMENA Results into Practice?. <i>European Urology Oncology</i> , 2021, 4, 515-516.	2.6	0
697	Real-world outcomes in patients with metastatic renal cell carcinoma according to risk factors: the STAR-TOR registry. <i>Future Oncology</i> , 2021, 17, 2325-2338.	1.1	3
698	Two cases of delayed onset of immune-related adverse events after discontinuation of nivolumab in patients with metastatic renal cell cancer. <i>IJU Case Reports</i> , 2021, 4, 326-329.	0.1	2
699	Making Patient-Specific Treatment Decisions Using Prognostic Variables and Utilities of Clinical Outcomes. <i>Cancers</i> , 2021, 13, 2741.	1.7	23

#	ARTICLE	IF	CITATIONS
701	Cancer Vaccines for Genitourinary Tumors: Recent Progresses and Future Possibilities. <i>Vaccines</i> , 2021, 9, 623.	2.1	17
702	Biomarkers of therapeutic response with immune checkpoint inhibitors. <i>Annals of Translational Medicine</i> , 2021, 9, 1040-1040.	0.7	3
703	Breaking Barriers: Addressing Issues of Inequality in Trial Enrollment and Clinical Outcomes for Patients With Kidney and Bladder Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2021, 41, e174-e181.	1.8	4
704	Immunotherapy in the treatment of lymphoma. <i>World Journal of Stem Cells</i> , 2021, 13, 503-520.	1.3	3
705	Detection of von Hippel-Lindau gene mutation in circulating cell-free DNA for clear cell renal cell carcinoma. <i>Cancer Science</i> , 2021, 112, 3363-3374.	1.7	10
706	Multidiscipline Immunotherapy-Based Rational Combinations for Robust and Durable Efficacy in Brain Metastases from Renal Cell Carcinoma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6290.	1.8	4
709	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. , 2021, 9, e002435.		298
710	Pembrolizumab for the treatment of renal cell carcinoma. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 1157-1164.	1.4	2
711	Efficacy of immune-checkpoint inhibitors (ICI) in the treatment of older adults with metastatic renal cell carcinoma (mRCC) – an International mRCC Database Consortium (IMDC) analysis. <i>Journal of Geriatric Oncology</i> , 2021, 12, 820-826.	0.5	10
712	Circulating Levels of the Interferon- γ -Regulated Chemokines CXCL10/CXCL11, IL-6 and HGF Predict Outcome in Metastatic Renal Cell Carcinoma Patients Treated with Antiangiogenic Therapy. <i>Cancers</i> , 2021, 13, 2849.	1.7	10
713	T-cell responses and combined immunotherapy against human carbonic anhydrase 9-expressing mouse renal cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 339-352.	2.0	2
714	Sunitinib and Axitinib increase secretion and glycolytic activity of small extracellular vesicles in renal cell carcinoma. <i>Cancer Gene Therapy</i> , 2022, 29, 683-696.	2.2	4
715	Prognosis of Japanese metastatic renal cell carcinoma patients in the targeted therapy era. <i>International Journal of Clinical Oncology</i> , 2021, 26, 1947-1954.	1.0	4
716	Lenvatinib plus pembrolizumab: the next frontier for the treatment of hepatocellular carcinoma?. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 371-378.	1.9	65
717	Quality of life assessment in renal cell carcinoma – Phase II and III clinical trials published between 2010 and 2020: a systematic review. <i>Future Oncology</i> , 2021, 17, 2671-2681.	1.1	17
718	Clinical and immunologic implications of COVID-19 in patients with melanoma and renal cell carcinoma receiving immune checkpoint inhibitors. , 2021, 9, e002835.		11
719	Changes in prescribing habits for the treatment of metastatic renal clear cell carcinoma (<sc>mRCC</sc>) in Australia. <i>Internal Medicine Journal</i> , 2021, 51, 1173-1177.	0.5	0
720	Cardiovascular toxicity of angiogenesis inhibitors and immune checkpoint inhibitors: synergistic anti-tumour effects at the cost of increased cardiovascular risk?. <i>Clinical Science</i> , 2021, 135, 1649-1668.	1.8	10

#	ARTICLE	IF	CITATIONS
721	Lenvatinib plus pembrolizumab in patients with either treatment-naïve or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study. <i>Lancet Oncology</i> , The, 2021, 22, 946-958.	5.1	100
722	Characteristics and Treatment Challenges of Non-Clear Cell Renal Cell Carcinoma. <i>Cancers</i> , 2021, 13, 3807.	1.7	17
723	A Prospective Multicenter Evaluation of Initial Treatment Choice in Metastatic Renal Cell Carcinoma Prior to the Immunotherapy Era: The MaRCC Registry Experience. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 1-10.	0.9	4
724	Von Hippel-Lindau tumor suppressor pathways & corresponding therapeutics in kidney cancer. <i>Journal of Genetics and Genomics</i> , 2021, 48, 552-559.	1.7	8
725	Cutaneous adverse events associated with immune checkpoint blockade: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 163, 103376.	2.0	9
726	Systematic review of combinations of targeted or immunotherapy in advanced solid tumors. , 2021, 9, e002459.		41
727	Multiplexed single-cell pathology reveals the association of CD8 T-cell heterogeneity with prognostic outcomes in renal cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 3001-3013.	2.0	17
728	Immunotherapy in Older Adults With Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 2115-2127.	0.8	33
729	Differential Dermatologic Adverse Events Associated With Checkpoint Inhibitor Monotherapy and Combination Therapy: A Meta-Analysis of Randomized Control Trials. <i>Frontiers in Pharmacology</i> , 2021, 12, 640099.	1.6	3
730	Role of Radioembolization in the Management of Liver-Dominant Metastatic Renal Cell Carcinoma: A Single-Center, Retrospective Study. <i>CardioVascular and Interventional Radiology</i> , 2021, 44, 1755-1762.	0.9	4
731	Prognostic value of DCE-CT-derived blood volume and flow compared to core biopsy microvessel density in patients with metastatic renal cell carcinoma. <i>European Radiology Experimental</i> , 2021, 5, 32.	1.7	2
732	Outcomes of axitinib versus sunitinib as first-line therapy to patients with metastatic renal cell carcinoma in the immune-oncology era. <i>Cancer Medicine</i> , 2021, 10, 5839-5846.	1.3	10
733	Tumor Growth Rate Decline despite Progressive Disease May Predict Improved Nivolumab Treatment Outcome in mRCC: When RECIST Is Not Enough. <i>Cancers</i> , 2021, 13, 3492.	1.7	3
734	Recent Advances in Glioma Therapy: Combining Vascular Normalization and Immune Checkpoint Blockade. <i>Cancers</i> , 2021, 13, 3686.	1.7	16
735	Comparisons of Underlying Mechanisms, Clinical Efficacy and Safety Between Anti-PD-1 and Anti-PD-L1 Immunotherapy: The State-of-the-Art Review and Future Perspectives. <i>Frontiers in Pharmacology</i> , 2021, 12, 714483.	1.6	9
736	Characterization and Management of Treatment-emergent Hepatic Toxicity in Patients with Advanced Renal Cell Carcinoma Receiving First-line Pembrolizumab plus Axitinib. Results from the KEYNOTE-426 Trial. <i>European Urology Oncology</i> , 2022, 5, 225-234.	2.6	17
737	Modified Glasgow Prognostic Score associated with survival in metastatic renal cell carcinoma treated with immune checkpoint inhibitors. , 2021, 9, e002851.		12
738	The Risk of Immune-Related Thyroid Dysfunction Induced by PD-1/PD-L1 Inhibitors in Cancer Patients: An Updated Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 667650.	1.3	8

#	ARTICLE	IF	CITATIONS
739	Current Imaging Evaluation of Tumor Response to Advanced Medical Treatment in Metastatic Renal-Cell Carcinoma: Clinical Implications. <i>Applied Sciences (Switzerland)</i> , 2021, 11, 6930.	1.3	4
740	Outcomes of patients with solid tumour malignancies treated with first-line immuno-oncology agents who do not meet eligibility criteria for clinical trials. <i>European Journal of Cancer</i> , 2021, 151, 115-125.	1.3	22
741	SNP-mediated lncRNA-ENTPD3-AS1 upregulation suppresses renal cell carcinoma via miR-155/HIF-1 β signaling. <i>Cell Death and Disease</i> , 2021, 12, 672.	2.7	29
742	Precision Bayesian phase I dose-finding based on utilities tailored to prognostic subgroups. <i>Statistics in Medicine</i> , 2021, 40, 5199-5217.	0.8	15
743	Inhibitors of immune checkpoints—PD-1, PD-L1, CTLA-4—new opportunities for cancer patients and a new challenge for internists and general practitioners. <i>Cancer and Metastasis Reviews</i> , 2021, 40, 949-982.	2.7	72
744	Systematic Review of PD-1/PD-L1 Inhibitors in Oncology: From Personalized Medicine to Public Health. <i>Oncologist</i> , 2021, 26, e1786-e1799.	1.9	52
746	Tislelizumab combined with apatinib in the treatment of advanced renal clear cell carcinoma: a case report. <i>Anti-Cancer Drugs</i> , 2022, 33, e834-e839.	0.7	2
747	Re: Nivolumab plus Cabozantinib Versus Sunitinib for Advanced Renal-cell Carcinoma. <i>European Urology</i> , 2021, 80, 256-257.	0.9	0
748	Integrated Analysis Of Immunotherapy Treated Clear Cell Renal Cell Carcinomas: An Exploratory Study. <i>Journal of Immunotherapy</i> , 2022, 45, 35-42.	1.2	3
749	Trends in the Research Into Immune Checkpoint Blockade by Anti-PD1/PDL1 Antibodies in Cancer Immunotherapy: A Bibliometric Study. <i>Frontiers in Pharmacology</i> , 2021, 12, 670900.	1.6	9
750	What is the role of real-world data in metastatic renal cell cancer?. <i>Future Oncology</i> , 2021, 17, 3905-3909.	1.1	1
751	Outcome of immune checkpoint inhibitors in metastatic renal cell carcinoma across different treatment lines. <i>ESMO Open</i> , 2021, 6, 100122.	2.0	6
752	A Contemporary Review of Immune Checkpoint Inhibitors in Advanced Clear Cell Renal Cell Carcinoma. <i>Vaccines</i> , 2021, 9, 919.	2.1	9
753	Evaluation of Technology-Enabled Monitoring of Patient-Reported Outcomes to Detect and Treat Toxic Effects Linked to Immune Checkpoint Inhibitors. <i>JAMA Network Open</i> , 2021, 4, e2122998.	2.8	13
754	Myocarditis occurrence with cancer immunotherapy across indications in clinical trial and post-marketing data. <i>Scientific Reports</i> , 2021, 11, 17324.	1.6	24
755	First-line immune checkpoint inhibitor-based combinations in unresectable hepatocellular carcinoma: current management and future challenges. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 1245-1251.	1.4	75
756	Efficacy of PD-1/PD-L1 inhibitors in ovarian cancer: a single-arm meta-analysis. <i>Journal of Ovarian Research</i> , 2021, 14, 112.	1.3	24
757	Nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer: a phase II and biomarker study. <i>Npj Breast Cancer</i> , 2021, 7, 110.	2.3	20

#	ARTICLE	IF	CITATIONS
758	Clinical outcomes of second-line treatment following first-line VEGFR-TKI failure in patients with metastatic renal cell carcinoma: a comparison of axitinib alone and axitinib plus anti-PD-L1 antibody. <i>Cancer Communications</i> , 2021, 41, 1071-1074.	3.7	4
759	Pathology and systemic therapy of non-clear cell renal cell carcinoma: an overview. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 1273-1286.	1.1	7
760	Clinical Effectiveness of Second-line Sunitinib Following Immuno-oncology Therapy in Patients with Metastatic Renal Cell Carcinoma: A Real-world Study. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 354-361.	0.9	5
761	Prognostic Impact of Trial-Eligibility Criteria in Patients with Metastatic Renal Cell Carcinoma. <i>Urologia Internationalis</i> , 2022, 106, 368-375.	0.6	6
762	Association of AXL and PD-L1 Expression with Clinical Outcomes in Patients with Advanced Renal Cell Carcinoma Treated with PD-1 Blockade. <i>Clinical Cancer Research</i> , 2021, 27, 6749-6760.	3.2	39
763	First-Line Immuno-Oncology Combinations for Metastatic Clear Cell Renal Cell Carcinoma (mRCC): A Systematic Review of Phase III Clinical Trials. <i>Kidney Cancer</i> , 2021, 5, 207-217.	0.2	3
764	PD-L1/PD-L1 inhibitors-based treatment for advanced renal cell carcinoma: Mechanisms affecting efficacy and combination therapies. <i>Cancer Medicine</i> , 2021, 10, 6384-6401.	1.3	10
765	A case of clear cell renal cell carcinoma with vena cava thrombus responding to presurgical avelumab, and axitinib. <i>IJU Case Reports</i> , 2021, 4, 412-416.	0.1	8
766	A Systematic Review and Meta-analysis of Dual Therapy in Patients With Advanced Renal Cell Carcinoma of Favourable Risk. <i>Urology</i> , 2021, 157, 8-14.	0.5	3
767	Predictive radiomics signature for treatment response to nivolumab in patients with advanced renal cell carcinoma. <i>Canadian Urological Association Journal</i> , 2021, 16, .	0.3	2
768	CTLA4 promoter hypomethylation is a negative prognostic biomarker at initial diagnosis but predicts response and favorable outcome to anti-PD-1 based immunotherapy in clear cell renal cell carcinoma. , 2021, 9, e002949.		22
769	Camrelizumab plus Famitinib in Patients with Advanced or Metastatic Renal Cell Carcinoma: Data from an Open-label, Multicenter Phase II Basket Study. <i>Clinical Cancer Research</i> , 2021, 27, 5838-5846.	3.2	14
770	Integrated mRNA and miRNA Transcriptomic Analyses Reveals Divergent Mechanisms of Sunitinib Resistance in Clear Cell Renal Cell Carcinoma (ccRCC). <i>Cancers</i> , 2021, 13, 4401.	1.7	8
771	Immune Checkpoint Inhibitor in First-Line Treatment of Metastatic Renal Cell Carcinoma: A Review of Current Evidence and Future Directions. <i>Frontiers in Oncology</i> , 2021, 11, 707214.	1.3	26
772	Cabozantinib in Pretreated Patients with Metastatic Renal Cell Carcinoma with Sarcomatoid Differentiation: A Real-World Study. <i>Targeted Oncology</i> , 2021, 16, 625-632.	1.7	6
773	Cabozantinib and nivolumab as first-line treatment in advanced renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 1183-1192.	1.1	0
774	Current status and future perspectives of immunotherapy against urothelial and kidney cancer. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 1481-1492.	0.6	7
775	First-Line Immunotherapy Combinations in Advanced Renal Cell Carcinoma: A Rapid Review and Meta-Analysis. <i>Kidney Cancer</i> , 2021, 5, 153-163.	0.2	1

#	ARTICLE	IF	CITATIONS
776	A Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab Versus Pembrolizumab Plus Axitinib and Versus Avelumab Plus Axitinib in First-Line Treatment of Advanced Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 370-370.e7.	0.9	8
777	Median time to progression with TKI-based therapy after failure of immuno-oncology therapy in metastatic kidney cancer: A systematic review and meta-analysis. <i>European Journal of Cancer</i> , 2021, 155, 245-255.	1.3	2
778	Primary Renal Tumour Response in Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma: Results from the GETUG-AFU 26 NIVOREN Trial. <i>European Urology</i> , 2021, 80, 325-329.	0.9	16
779	Profiling the inhibitory receptors LAG-3, TIM-3, and TIGIT in renal cell carcinoma reveals malignancy. <i>Nature Communications</i> , 2021, 12, 5547.	5.8	31
780	Immune checkpoint inhibitors and cardiotoxicity: possible mechanisms, manifestations, diagnosis and management. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 1211-1228.	1.1	1
781	Use of Second-line Immunotherapy in Control Arms of Randomized Clinical Trials in Kidney Cancer. <i>JAMA Network Open</i> , 2021, 4, e2124728.	2.8	4
782	Atezolizumab: an investigational agent for the treatment of biliary tract cancer. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 1007-1015.	1.9	2
783	First-line chemotherapy or in combination with programmed cell death protein-1 antibody in patients with metastatic or recurrent biliary tract cancer. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, , .	1.4	2
784	2021 ASCO genitourinary cancers symposium: a focus on renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 1203-1206.	1.1	2
786	Complete response and renal cell carcinoma in the immunotherapy era: The paradox of good news. <i>Cancer Treatment Reviews</i> , 2021, 99, 102239.	3.4	13
787	Clinical Review on the Management of Metastatic Renal Cell Carcinoma. <i>JCO Oncology Practice</i> , 2022, 18, 187-196.	1.4	62
788	From Anti-PD-1/PD-L1 to CTLA-4 and to MUC1: Is the Better Response to Treatment in Smokers of Cancer Patients Drug Specific?. <i>Journal of Personalized Medicine</i> , 2021, 11, 914.	1.1	2
789	Sex and Gender Differences in Kidney Cancer: Clinical and Experimental Evidence. <i>Cancers</i> , 2021, 13, 4588.	1.7	24
790	Prospective observational study on Pazopanib in patients treated for advanced or metastatic renal cell carcinoma in countries in Asia Pacific, North Africa, and Middle East regions: PARACHUTE study. <i>BMC Cancer</i> , 2021, 21, 1021.	1.1	7
791	Combine and conquer: manganese synergizing anti-TGF- β 2/PD-L1 bispecific antibody YM101 to overcome immunotherapy resistance in non-inflamed cancers. <i>Journal of Hematology and Oncology</i> , 2021, 14, 146.	6.9	68
792	Cost-Effectiveness of Frontline Treatment for Advanced Renal Cell Carcinoma in the Era of Immunotherapies. <i>Frontiers in Pharmacology</i> , 2021, 12, 718014.	1.6	8
793	Tumor-infiltrating CD8+ T cells recognize a heterogeneously expressed functional neoantigen in clear cell renal cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 905-918.	2.0	8
794	RAMPART: A model for a regulatory-ready academic-led phase III trial in the adjuvant renal cell carcinoma setting. <i>Contemporary Clinical Trials</i> , 2021, 108, 106481.	0.8	2

#	ARTICLE	IF	CITATIONS
795	Loss of Von Hippel-Lindau (VHL) Tumor Suppressor Gene Function: VHL-HIF Pathway and Advances in Treatments for Metastatic Renal Cell Carcinoma (RCC). <i>International Journal of Molecular Sciences</i> , 2021, 22, 9795.	1.8	32
796	A 25 year perspective on the evolution and advances in an understanding of the biology, evaluation and treatment of kidney cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 548-560.	0.8	13
797	Development of an Interferon Gamma Response-Related Signature for Prediction of Survival in Clear Cell Renal Cell Carcinoma. <i>Journal of Inflammation Research</i> , 2021, Volume 14, 4969-4985.	1.6	7
798	Reply to Xiaoshuai Gao, Guo Chen, and Xin Wei's Letter to the Editor re: Keiichiro Mori, Mohammad Abufaraj, Hadi Mostafaei, et al. The Predictive Value of Programmed Death Ligand 1 in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-checkpoint Inhibitors: A Systematic Review and Meta-analysis. <i>Eur Urol</i> 2021;79:783-92. <i>European Urology</i> , 2021, 80, e145-e146.	0.9	0
799	Re: Keiichiro Mori, Mohammad Abufaraj, Hadi Mostafaei, et al. The Predictive Value of Programmed Death Ligand 1 in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-checkpoint Inhibitors: A Systematic Review and Meta-analysis. <i>Eur Urol</i> 2021;79:783-92. <i>European Urology</i> , 2021, 80, e143-e144.	0.9	0
800	Activity of Systemic Treatments After Cabozantinib Failure in Advanced Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 80-87.	0.9	7
801	Clinical outcomes in patients with metastatic renal cell carcinoma and brain metastasis treated with ipilimumab and nivolumab. , 2021, 9, e003281.		9
802	Nivolumab Reduces PD1 Expression and Alters Density and Proliferation of Tumor Infiltrating Immune Cells in a Tissue Slice Culture Model of Renal Cell Carcinoma. <i>Cancers</i> , 2021, 13, 4511.	1.7	5
803	Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 3725-3736.	0.8	69
804	RAMPART: A phase III multi-arm multi-stage trial of adjuvant checkpoint inhibitors in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse. <i>Contemporary Clinical Trials</i> , 2021, 108, 106482.	0.8	33
805	Differences in oncological and toxicity outcomes between programmed cell death-1 and programmed cell death ligand-1 inhibitors in metastatic renal cell carcinoma: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2021, 99, 102242.	3.4	13
806	Combination strategies to maximize the benefits of cancer immunotherapy. <i>Journal of Hematology and Oncology</i> , 2021, 14, 156.	6.9	202
807	Renal Mass Biopsy. <i>Techniques in Vascular and Interventional Radiology</i> , 2021, 24, 100774.	0.4	2
808	PD-L1 Expression and Clinicopathological Factors in Renal Cell Carcinoma: A Comparison of Antibody Clone 73-10 With Clone 28-8. <i>Anticancer Research</i> , 2021, 41, 4577-4586.	0.5	4
809	Prediction of early progression of metastatic renal cell carcinoma treated with first-line tyrosine kinase inhibitor. <i>Current Urology</i> , 2021, 15, 187-192.	0.4	3
810	Development of patient-derived tumor organoids and a drug testing model for renal cell carcinoma. <i>Oncology Reports</i> , 2021, 46, .	1.2	14
811	Efficacy and safety profile of avelumab monotherapy. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 166, 103464.	2.0	2
812	A Phase I/II Study to Assess the Safety and Efficacy of Pazopanib and Pembrolizumab Combination Therapy in Patients with Advanced Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 434-446.	0.9	16

#	ARTICLE	IF	CITATIONS
814	Time to Resolution of Axitinib-Related Adverse Events After Treatment Interruption in Patients With Advanced Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2021, 19, e306-e312.	0.9	12
815	Immunotherapy for metastatic renal cell carcinoma: A brief history, current trends, and future directions. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 664-677.	0.8	7
816	Prognostic impact of immune-related adverse events in metastatic renal cell carcinoma treated with nivolumab plus ipilimumab. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 735.e9-735.e16.	0.8	15
817	The 2021 Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibitor-based Combination Therapies for Treatment-naïve Metastatic Clear-cell Renal Cell Carcinoma Are Standard of Care. <i>European Urology</i> , 2021, 80, 393-397.	0.9	103
818	Immune checkpoint inhibitor cardiotoxicity: Breaking barriers in the cardiovascular immune landscape. <i>Journal of Molecular and Cellular Cardiology</i> , 2021, 160, 121-127.	0.9	6
819	Avelumab plus axitinib therapy for renal cell carcinoma in a patient with pulmonary alveolar proteinosis: A case report. <i>Urology Case Reports</i> , 2021, 39, 101843.	0.1	0
820	Ocular side effects of checkpoint inhibitors. <i>Survey of Ophthalmology</i> , 2021, 66, 951-959.	1.7	16
821	Combinatorial therapy in tumor microenvironment: Where do we stand?. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1876, 188585.	3.3	48
822	The role of immunotherapy in advanced renal cell carcinoma. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2021, 47, 1228-1242.	0.7	10
823	The effects of anticancer therapies on bone metastases in breast cancer. , 2022, , 987-1002.		0
824	Current and future perspectives on functional molecular imaging in nephro-urology: theranostics on the horizon. <i>Theranostics</i> , 2021, 11, 6105-6119.	4.6	13
825	Cabozantinib real-world effectiveness in the first-through fourth-line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>Cancer Medicine</i> , 2021, 10, 1212-1221.	1.3	22
826	Efficacy and safety of immunological checkpoint inhibitors combined with anti-angiogenic drugs in first-line treatment of metastatic renal cell carcinoma: a systematic review and meta-analysis. <i>Translational Andrology and Urology</i> , 2021, 10, 300-309.	0.6	4
827	Antiangiogenic tyrosine kinase inhibitors and immunotherapy as first-line treatment for metastatic renal cell carcinoma: is there an increased risk of hypothyroidism?. <i>Therapeutic Advances in Urology</i> , 2021, 13, 175628722110297.	0.9	2
828	Testosterone for Managing Treatment-related Fatigue in Patients With Metastatic Renal Cell Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2021, 44, 137-142.	0.6	3
829	IMbrave 151: a randomized phase II trial of atezolizumab combined with bevacizumab and chemotherapy in patients with advanced biliary tract cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110365.	1.4	24
830	Beyond conventional immune-checkpoint inhibition – novel immunotherapies for renal cell carcinoma. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 199-214.	12.5	179
831	Body Mass Index in Patients Treated with Cabozantinib for Advanced Renal Cell Carcinoma: A New Prognostic Factor?. <i>Diagnostics</i> , 2021, 11, 138.	1.3	13

#	ARTICLE	IF	CITATIONS
832	Clinical Outcomes of Metastatic Renal Carcinoma Following Disease Progression to Programmed Death (PD)-1 or PD-L1 Inhibitors (IO). American Journal of Clinical Oncology: Cancer Clinical Trials, 2021, 44, 121-125.	0.6	12
833	Current Landscape of Immunotherapy in Genitourinary Malignancies. Advances in Experimental Medicine and Biology, 2020, 1244, 107-147.	0.8	3
834	Checkpoint inhibitor immunotherapy in kidney cancer. Nature Reviews Urology, 2020, 17, 137-150.	1.9	162
838	Supplementation of L-arginine boosts the therapeutic efficacy of anticancer chemoimmunotherapy. Cancer Science, 2020, 111, 2248-2258.	1.7	31
839	A Novel GUCY2C-CD3 T-Cell Engaging Bispecific Construct (PF-07062119) for the Treatment of Gastrointestinal Cancers. Clinical Cancer Research, 2020, 26, 2188-2202.	3.2	31
840	Multiorgan Signaling Mobilizes Tumor-Associated Erythroid Cells Expressing Immune Checkpoint Molecules. Molecular Cancer Research, 2021, 19, 507-515.	1.5	16
841	Tivozanib in renal cell carcinoma: a new approach to previously treated disease. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592092381.	1.4	10
842	Clinical Cancer Advances 2020: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. Journal of Clinical Oncology, 2020, 38, 1081.	0.8	101
843	Toxicity Management of Front-Line Pembrolizumab Combined With Axitinib in Clear Cell Metastatic Renal Cell Carcinoma: A Case Study Approach. JCO Oncology Practice, 2020, 16, 15s-19s.	1.4	8
844	Characteristics of clear cell renal cell carcinoma metastases to the thyroid gland: A systematic review. World Journal of Clinical Cases, 2019, 7, 3474-3485.	0.3	16
845	Evolving Paradigms in the Management and Outcomes of Sarcomatoid Renal Cell Carcinoma in the Era of Immune Checkpoint Inhibitors. World Journal of Oncology, 2020, 11, 183-187.	0.6	4
846	Antiangiogenic therapies for pheochromocytoma and paraganglioma. Endocrine-Related Cancer, 2020, 27, R239-R254.	1.6	23
847	Using genetics to inform the pharmacological targeting of neuroendocrine neoplasms. Endocrine-Related Cancer, 2020, 27, R293-R305.	1.6	1
848	Renal cell carcinoma: what's new in 2019. Onkourologiya, 2020, 15, 120-125.	0.1	3
849	To Be or Not to Be: Nodal Disease and the Role of Lymphadenectomy in the Treatment of Renal Cell Carcinoma. Medical Research Archives, 2020, 8, .	0.1	4
850	Identification of international metastatic renal cell carcinoma database consortium (IMDC) intermediate-risk subgroups in patients with metastatic clear-cell renal cell carcinoma. Oncotarget, 2020, 11, 4582-4592.	0.8	14
851	Drug resistance in cancer immunotherapy: new strategies to improve checkpoint inhibitor therapies. , 2019, 2, 980-993.		9
852	A review of mechanisms of resistance to immune checkpoint inhibitors and potential strategies for therapy. , 2020, 3, 252-275.		18

#	ARTICLE	IF	CITATIONS
853	https://cdrjournal.com/article/view/3531 . , 2020, 3, 454-471.		4
854	Systemic therapy for metastatic renal cell carcinoma—“is timing everything?”. <i>Annals of Translational Medicine</i> , 2019, 7, S185-S185.	0.7	2
855	Anaplastic lymphoma kinase (ALK) rearrangement in adult renal cell carcinoma with lung metastasis: a case report and literature review. <i>Translational Andrology and Urology</i> , 2020, 9, 2855-2861.	0.6	5
856	Cytoreductive nephrectomy for metastatic renal cell carcinoma, the ultimate urologic “Choosing Wisely” campaign: a narrative review. <i>Translational Cancer Research</i> , 2020, 9, 7337-7349.	0.4	13
857	Immunotherapy and Radiation Therapy in Renal Cell Carcinoma. <i>Current Drug Targets</i> , 2020, 21, 1463-1475.	1.0	10
858	PD1 and PD-L1 Inhibitors for the Treatment of Kidney Cancer: The Role of PD-L1 Assay. <i>Current Drug Targets</i> , 2020, 21, 1664-1671.	1.0	12
859	PD-L1 Inhibitors for the Treatment of Prostate Cancer. <i>Current Drug Targets</i> , 2020, 21, 1558-1565.	1.0	4
860	Combinations using checkpoint blockade to overcome resistance. <i>Ecancermedicalsecience</i> , 2020, 14, 1148.	0.6	11
861	Novel Nuclear Medicine Imaging Applications in Immuno-Oncology. <i>Cancers</i> , 2020, 12, 1303.	1.7	6
862	Immune Checkpoint Inhibitors in Uro-Oncology: Urgent Call for Biomarkers. <i>Cancers</i> , 2020, 12, 2768.	1.7	2
863	New Treatments in Renal Cancer: The AhR Ligands. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3551.	1.8	14
864	ABL001, a Bispecific Antibody Targeting VEGF and DLL4, with Chemotherapy, Synergistically Inhibits Tumor Progression in Xenograft Models. <i>International Journal of Molecular Sciences</i> , 2021, 22, 241.	1.8	26
865	Immunotherapy and Targeted Therapy for Hepatocellular Carcinoma: A Literature Review and Treatment Perspectives. <i>Pharmaceuticals</i> , 2021, 14, 28.	1.7	17
866	Different immunological effects of the molecular targeted agents sunitinib, everolimus and temsirolimus in patients with renal cell carcinoma. <i>International Journal of Oncology</i> , 2020, 56, 999-1013.	1.4	5
867	Programmed death-ligand 1 expression and its correlation with clinicopathological parameters in gallbladder cancer. <i>Journal of Pathology and Translational Medicine</i> , 2020, 54, 154-164.	0.4	15
868	Immune checkpoint inhibitor-induced diarrhea/colitis: Endoscopic and pathologic findings. <i>World Journal of Gastrointestinal Pathophysiology</i> , 2019, 10, 17-28.	0.5	26
869	Combination drug regimens for metastatic clear cell renal cell carcinoma. <i>World Journal of Clinical Oncology</i> , 2020, 11, 541-562.	0.9	19
870	NCCN Guidelines Insights: Kidney Cancer, Version 2.2020. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 1278-1285.	2.3	185

#	ARTICLE	IF	CITATIONS
871	NCCN Guidelines Updates: Management of Metastatic Kidney Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 587-589.	2.3	22
872	Prognosis of Incidental Brain Metastases in Patients With Advanced Renal Cell Carcinoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 432-438.	2.3	19
873	ISPRF: a machine learning model to predict the immune subtype of kidney cancer samples by four genes. Translational Andrology and Urology, 2021, 10, 3773-3786.	0.6	6
874	Radioimmunotherapy for solid tumors: spotlight on Glypican-1 as a radioimmunotherapy target. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110229.	1.4	3
875	Renal Cancer. UNIPA Springer Series, 2021, , 755-774.	0.1	1
876	Evolving Patterns of Metastasis in Renal Cell Carcinoma. Journal of Kidney Cancer and VHL, 2021, 8, 13-19.	0.2	1
877	Cytoreductive Nephrectomy in the Management of Metastatic Renal Cell Carcinoma: Is There Still a Debate?. Current Urology Reports, 2021, 22, 54.	1.0	6
878	Immunotherapies in Genitourinary Oncology: Where Are We Now? Where Are We Going?. Cancers, 2021, 13, 5065.	1.7	13
879	N6-Methyladenosine-Related Long Non-coding RNA Signature Associated With Prognosis and Immunotherapeutic Efficacy of Clear-Cell Renal Cell Carcinoma. Frontiers in Genetics, 2021, 12, 726369.	1.1	9
880	Association between prior nephrectomy and efficacy of immune checkpoint inhibitor therapy in metastatic renal cell carcinoma - A systematic review and meta-analysis. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 64.e17-64.e24.	0.8	3
881	Targeted Anti-CTLA-4 Tumor Immunotherapy Using Tumor Infiltrating Cells. Advanced Science, 2021, 8, e2101672.	5.6	36
882	Landscape of prognostic signatures and immunogenomics of the AXL/GAS6 axis in renal cell carcinoma. British Journal of Cancer, 2021, 125, 1533-1543.	2.9	13
883	Balancing the Risk-Benefit Ratio of Immune Checkpoint Inhibitor and Anti-VEGF Combination Therapy in Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. Frontiers in Oncology, 2021, 11, 739263.	1.3	8
884	Complete Response of Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC)-Associated Renal Cell Carcinoma to Pembrolizumab Immunotherapy: A Case Report. Frontiers in Oncology, 2021, 11, 735077.	1.3	5
885	Predictive impact of early changes in serum C-reactive protein levels in nivolumab plus ipilimumab therapy for metastatic renal cell carcinoma. Clinical Genitourinary Cancer, 2021, , .	0.9	6
886	Endoscopic Ultrasound-Guided Radiofrequency Ablation as an Future Alternative to Pancreatectomy for Pancreatic Metastases from Renal Cell Carcinoma: A Prospective Study. Cancers, 2021, 13, 5267.	1.7	10
887	The Association of Clinical Outcomes with Posttreatment Changes in the Relative Eosinophil Counts and Neutrophil-to-Eosinophil Ratio in Patients with Advanced Urothelial Carcinoma Treated with Pembrolizumab. Cancer Management and Research, 2021, Volume 13, 8049-8056.	0.9	11
888	Efficacy of nivolumab plus ipilimumab as first-line therapy for primary tumors in patients with renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 13.e19-13.e27.	0.8	4

#	ARTICLE	IF	CITATIONS
889	Experimental and computational modeling for signature and biomarker discovery of renal cell carcinoma progression. <i>Molecular Cancer</i> , 2021, 20, 136.	7.9	17
890	Axitinib Reverses Resistance to Anti-Programmed Cell Death-1 Therapy in a Patient With Renal Cell Carcinoma. <i>Frontiers in Immunology</i> , 2021, 12, 728750.	2.2	4
891	Clinical factors associated with long-term benefit in patients with metastatic renal cell carcinoma treated with axitinib: Real-world AXILONG study. <i>Clinical Genitourinary Cancer</i> , 2021, , .	0.9	2
892	Metastasectomy in kidney cancer: current indications and treatment approaches. <i>Current Opinion in Supportive and Palliative Care</i> , 2021, 15, 266-275.	0.5	4
893	The impact of hypoxia on immune state in cancer. <i>Life Sciences</i> , 2021, 286, 120057.	2.0	46
895	Uroonkologie beim Älteren Patienten. <i>Springer Reference Medizin</i> , 2019, , 1-10.	0.0	0
896	Real-world clinical outcomes of pazopanib immediately following immunotherapy discontinuation for the treatment of advanced renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, 573-573.	0.8	1
897	Critical appraisal of clinical trials in oncology " part I. <i>Oncology in Clinical Practice</i> , 2019, 15, 89-103.	0.1	1
898	Revisiting the role of lymph node dissection in renal cell carcinoma. <i>Annals of Translational Medicine</i> , 2019, 7, S91-S91.	0.7	0
899	Role of stereotactic body radiation therapy for the management of renal cell carcinoma: tailoring treatment in the era of the "embarrassment of riches". <i>Annals of Translational Medicine</i> , 2019, 7, S106-S106.	0.7	0
900	Biomarkers in metastatic renal cell carcinoma in the era of immune checkpoint inhibitors. <i>Annals of Translational Medicine</i> , 2019, 7, S203-S203.	0.7	1
901	The way towards tailored treatment for metastatic renal cancer patients in the omics era: are we getting a "transcriptomic compass"? <i>Annals of Translational Medicine</i> , 2019, 7, S190-S190.	0.7	1
902	Pembrolizumab plus axitinib: a new treatment option for patients with metastatic renal cell carcinoma. <i>Chinese Clinical Oncology</i> , 2019, 8, S21-S21.	0.4	9
903	Which Way Should be Chosen for Treatment of Metastatic Renal Cell Carcinoma?. <i>Novel Approaches in Cancer Study</i> , 2019, 3, .	0.2	0
904	Characteristics of clear cell renal cell carcinoma metastases to the thyroid gland: A systematic review. <i>World Journal of Clinical Cases</i> , 2019, 7, 3457-3468.	0.3	0
905	The role of immunotherapy in the management of patients with renal cell carcinoma and brain metastases. <i>Annals of Translational Medicine</i> , 2019, 7, S313-S313.	0.7	3
906	The tango of immunotherapy and targeted therapy in metastatic renal cell carcinoma. <i>Translational Cancer Research</i> , 2019, 8, E1-E6.	0.4	3
908	Klassifikation und medikamentöse Therapie des Nierenzellkarzinoms. , 2020, , 163-187.		0

#	ARTICLE	IF	CITATIONS
909	Tumors: Urologic Cancer. , 2020, , 1-11.		0
911	Precision medicine in medical oncology: hope, disappointment and reality. <i>Clinical Chemistry and Laboratory Medicine</i> , 2020, 58, 1427-1431.	1.4	4
912	Resistance to Pembrolizumab and Axitinib in Renal Cell Carcinoma: Clinical and Genomic Evaluation. <i>Journal of Kidney Cancer and VHL</i> , 2020, 7, 7-11.	0.2	4
913	The Recent Advances of Anti-PD-1/PD-L1 Immunotherapy. , 2020, , .		0
914	Clinical efficacy, predictive biomarkers and response patterns of immunotherapy combinations for patients with cancer. <i>Future Oncology</i> , 2020, 16, 1659-1664.	1.1	2
917	What morphology can teach us about renal cell carcinoma clonal evolution. <i>Kidney Cancer Journal: Official Journal of the Kidney Cancer Association</i> , 2020, 18, 68-76.	0.1	12
918	A Dual PI3K/HDAC Inhibitor Induces Immunogenic Ferroptosis to Potentiate Cancer Immune Checkpoint Therapy. <i>Cancer Research</i> , 2021, 81, 6233-6245.	0.4	77
919	Uveitis associated with cancer immunotherapy: long-term outcomes. <i>Immunotherapy</i> , 2021, 13, 1465-1481.	1.0	3
920	Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma. <i>Cancer Cell</i> , 2021, 39, 1497-1518.e11.	7.7	126
921	Overall survival improvement in patients with metastatic clear-cell renal cell carcinoma between 2000 and 2020: a retrospective cohort study. <i>Acta Oncol</i> , 2022, 61, 22-29.	0.8	17
922	Sarcomatoid Renal Cell Carcinoma: The Present and Future of Treatment Paradigms. <i>Kidney Cancer</i> , 2021, 5, 167-179.	0.2	1
923	Immune Checkpoint Inhibitors for Genitourinary Cancers: Treatment Indications, Investigational Approaches and Biomarkers. <i>Cancers</i> , 2021, 13, 5415.	1.7	13
924	Immunotherapy-based combinations in the first-line treatment of metastatic renal cell carcinoma with sarcomatoid features: a systematic review and network meta-analysis. <i>Current Opinion in Urology</i> , 2022, 32, 61-68.	0.9	7
925	Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma: a single-arm, single-centre, feasibility, phase 2 trial. <i>Lancet Oncology</i> , The, 2021, 22, 1732-1739.	5.1	84
926	ESMO guidelines on Renal Cell Carcinoma: the paradox of the fine line that separates scientific robustness from cost-efficiency analysis. <i>Annals of Oncology</i> , 2021, 32, 1466-1467.	0.6	1
927	Immune checkpoint inhibition for the treatment of cancers: An update and critical review of ongoing clinical trials. <i>Clinical Immunology</i> , 2021, 232, 108873.	1.4	19
928	The Tumor Microenvironment of Bladder Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1296, 275-290.	0.8	18
929	Therapy Response Imaging in Genitourinary Malignancies. <i>Medical Radiology</i> , 2020, , 139-157.	0.0	0

#	ARTICLE	IF	CITATIONS
931	Applications of Antibodies in Therapy, Diagnosis, and Science. Learning Materials in Biosciences, 2021, , 129-159.	0.2	0
932	Emerging Therapies for Advanced Clear Cell Renal Cell Carcinoma. Journal of Kidney Cancer and VHL, 2020, 7, 17-26.	0.2	7
933	Prognostic and predictive factors to nivolumab in patients with metastatic renal cell carcinoma: a single center study. Anti-Cancer Drugs, 2021, 32, 74-81.	0.7	4
935	C�ncer renal avanzado, perfiles para los nuevos tratamientos. Medicina Clinica Practica, 2022, 5, 100277.	0.2	0
936	Current advances in kidney cancer immunotherapy. Onkourologiya, 2020, 15, 30-38.	0.1	3
937	Current and emerging therapies for first line treatment of metastatic clear cell renal cell carcinoma. , 2021, 7, .		16
938	Is there a preferred first-line therapy for metastatic renal cell carcinoma? A network meta-analysis. Therapeutic Advances in Urology, 2021, 13, 175628722110531.	0.9	11
939	State of the Art for Metastatic Histologies. , 2020, , 211-233.		0
940	Axitinib plus Immuncheckpoint-Inhibitor: evidenz- und expertenbasierte Konsensusempfehlungen f�r die Behandlungsoptimierung und das Management von therapieassoziierten Nebenwirkungen. Karger Kompass Onkologie, 2020, 7, 180-189.	0.0	0
942	Neue Arzneimittel 2019. , 2020, , 43-150.		2
943	Immune checkpoint inhibitor � antiangiogenic drugs combination in treatment-na�ve metastatic clear cell renal cell carcinoma: Why should immunotherapy have all the fun!. International Journal of Molecular and Immuno Oncology, 0, 5, 1-7.	0.0	0
944	Cancer Immunotherapy Confers a Global Benefit. , 2020, , 1-48.		0
945	Immunotherapy in Bladder and Renal Cancers. , 2020, , 451-474.		0
946	Improved prognosis for elderly patients with metastatic renal cell carcinoma in the era of targeted therapy. Molecular and Clinical Oncology, 2020, 12, 557-564.	0.4	2
947	News in the treatment of metastatic renal cancer. Onkologie (Czech Republic), 2020, 14, 26-31.	0.0	0
948	Tumor-Specific and Tumor-Agnostic Molecular Signatures Associated With Response to Immune Checkpoint Inhibitors. JCO Precision Oncology, 2021, 5, 1625-1638.	1.5	10
949	First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma: What Are the Most Appropriate Combination Therapies?. Cancers, 2021, 13, 5548.	1.7	11
950	Persistent Response to a Combination Treatment Featuring a Targeted Agent and an Immune Checkpoint Inhibitor in a Patient With Collecting Duct Renal Carcinoma: A Case Report and Literature Review. Frontiers in Oncology, 2021, 11, 764352.	1.3	4

#	ARTICLE	IF	CITATIONS
951	Cabozantinib beyond progression improves survival in advanced renal cell carcinoma patients: the CABEYOND study (Meet-URO 21). Expert Review of Anticancer Therapy, 2022, 22, 115-121.	1.1	5
953	Nivolumab in metastatic renal cell carcinoma: results from the Turkish Oncology Group Kidney Cancer Consortium database. Future Oncology, 2021, 17, 4861-4869.	1.1	2
954	Stereotactic body radiotherapy in combination with non-frontline PD-1 inhibitors and targeted agents in metastatic renal cell carcinoma. Radiation Oncology, 2021, 16, 211.	1.2	8
955	Combination therapy with immune checkpoint inhibitors in advanced renal cell carcinoma: A meta-analysis of randomized controlled trials. Clinical Immunology, 2021, 232, 108876.	1.4	4
956	Multidisciplinary Management of Advanced Kidney Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 977-981.	2.3	0
959	An Italian, multicenter, real-world, retrospective study of first-line pazopanib in unselected metastatic renal-cell carcinoma patients: the "Pamerit"™ study. Japanese Journal of Clinical Oncology, 2021, 51, 484-491.	0.6	1
960	CCL5-dependent mast cell infiltration into the tumor microenvironment in clear cell renal cell carcinoma patients. Aging, 2020, 12, 21809-21836.	1.4	12
961	Real-accessible novelties in immunotherapy from the perspective of a medical oncologist working in the Czech Republic. Onkologie (Czech Republic), 2020, 14, 199-204.	0.0	0
962	Patients with metastatic renal cell carcinoma treated with cabozantinib in the Czech Republic: analysis of four cancer centers. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2022, 166, 97-104.	0.2	2
963	Combining Immunotherapy with Multikinase Inhibitors: A Cautious New Promise. Indian Journal of Medical and Paediatric Oncology, 2020, 41, 901-905.	0.1	0
964	Round up. Indian Journal of Urology, 2019, 35, 92-93.	0.2	0
965	The Role of Immunotherapy in Urologic Cancers. Missouri Medicine, 2020, 117, 127-132.	0.3	1
966	USP22 promotes proliferation in renal cell carcinoma by stabilizing survivin. Oncology Letters, 2020, 20, 246.	0.8	0
967	Assessment for prognostic value of differentially expressed genes in immune microenvironment of clear cell renal cell carcinoma. American Journal of Translational Research (discontinued), 2020, 12, 5416-5432.	0.0	4
968	Assessment of hazard immune-related genes and tumor immune infiltrations in renal cell carcinoma. American Journal of Translational Research (discontinued), 2020, 12, 7096-7113.	0.0	2
969	What morphology can teach us about renal cell carcinoma clonal evolution. Kidney Cancer Journal: Official Journal of the Kidney Cancer Association, 2020, 18, 68-76.	0.1	5
970	Nierenzellkarzinom. , 2022, , 304-307.		0
971	Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial. Clinical Cancer Research, 2021, 27, 6687-6695.	3.2	25

#	ARTICLE	IF	CITATIONS
972	Neutrophil-to-Lymphocyte Ratio as a Prognostic Biomarker for Patients With Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 746976.	1.3	21
973	Combining CTLA-4 and angiopoietin-2 blockade in patients with advanced melanoma: a phase I trial. , 2021, 9, e003318.		7
974	Cabozantinib plus immunotherapy combinations in metastatic renal cell and urothelial carcinoma. <i>Future Oncology</i> , 2022, 18, 21-33.	1.1	5
975	Hypoxia as a driver of resistance to immunotherapy. <i>Drug Resistance Updates</i> , 2021, 59, 100787.	6.5	94
976	Updates on Immunotherapy and Immune Landscape in Renal Clear Cell Carcinoma. <i>Cancers</i> , 2021, 13, 5856.	1.7	39
977	Impact of Value Frameworks on the Magnitude of Clinical Benefit: Evaluating a Decade of Randomized Trials for Systemic Therapy in Solid Malignancies. <i>Current Oncology</i> , 2021, 28, 4894-4928.	0.9	0
978	Combination of Osimertinib and Pembrolizumab Successfully Overcome Dual Resistances in a Patient with Advanced Adenocarcinoma of the Lung, a Case Report. <i>Current Problems in Cancer Case Reports</i> , 2021, , 100132.	0.1	0
979	Association of Neutrophil-to-Lymphocyte Ratio with Efficacy of First-Line Avelumab plus Axitinib vs. Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase 3 JAVELIN Renal 101 Trial. <i>Clinical Cancer Research</i> , 2022, 28, 738-747.	3.2	11
980	The WIRE study a phase II, multi-arm, multi-centre, non-randomised window-of-opportunity clinical trial platform using a Bayesian adaptive design for proof-of-mechanism of novel treatment strategies in operable renal cell cancer – a study protocol. <i>BMC Cancer</i> , 2021, 21, 1238.	1.1	4
981	Identification of a Novel Stem Cell Subtype for Clear Cell Renal Cell Carcinoma Based on Stem Cell Gene Profiling. <i>Frontiers in Oncology</i> , 2021, 11, 758989.	1.3	2
982	Identification of CCL4 as an Immune-Related Prognostic Biomarker Associated With Tumor Proliferation and the Tumor Microenvironment in Clear Cell Renal Cell Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 694664.	1.3	4
983	Utility of Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and Systemic Immune Inflammation Index as Prognostic, Predictive Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab and Ipilimumab. <i>Journal of Clinical Medicine</i> , 2021, 10, 5325.	1.0	25
984	Risk Stratification and Treatment Algorithm of Metastatic Renal Cell Carcinoma. <i>Journal of Clinical Medicine</i> , 2021, 10, 5339.	1.0	5
985	Combination of HER2-targeted agents with immune checkpoint inhibitors in the treatment of HER2-positive breast cancer. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 385-395.	1.4	5
986	Combination Therapy in Renal Cell Carcinoma: the Best Choice for Every Patient?. <i>Current Oncology Reports</i> , 2021, 23, 147.	1.8	15
987	Treatment Selection in First-line Metastatic Renal Cell Carcinoma – The Contemporary Treatment Paradigm in the Age of Combination Therapy. <i>JAMA Oncology</i> , 2022, 8, 292.	3.4	35
988	From Bench to Bedside: How the Tumor Microenvironment Is Impacting the Future of Immunotherapy for Renal Cell Carcinoma. <i>Cells</i> , 2021, 10, 3231.	1.8	18
989	Clinical experience with CTLA-4 blockade for cancer immunotherapy: From the monospecific monoclonal antibody ipilimumab to probodies and bispecific molecules targeting the tumor microenvironment. <i>Pharmacological Research</i> , 2022, 175, 105997.	3.1	43

#	ARTICLE	IF	CITATIONS
990	Assessment of prognostic factors in previously treated Japanese patients with metastatic renal cell carcinoma who received nivolumab: An observational multi-institute study. <i>Molecular and Clinical Oncology</i> , 2021, 16, 17.	0.4	2
991	Impact of Patient Age on Clinical Efficacy and Toxicity of Checkpoint Inhibitor Therapy. <i>Frontiers in Immunology</i> , 2021, 12, 786046.	2.2	17
992	Randomized phase II trial of avelumab alone or in combination with cetuximab for patients with previously treated, locally advanced, or metastatic squamous cell anal carcinoma: the CARACAS study. <i>Frontiers in Immunology</i> , 2021, 12, 727464.	2.2	5
993	T Cell Bispecific Antibodies: An Antibody-Based Delivery System for Inducing Antitumor Immunity. <i>Pharmaceuticals</i> , 2021, 14, 1172.	1.7	13
994	Inhibition of FGFR Reactivates IFN γ Signaling in Tumor Cells to Enhance the Combined Antitumor Activity of Lenvatinib with Anti-PD-1 Antibodies. <i>Cancer Research</i> , 2022, 82, 292-306.	0.4	58
995	Anti-Angiogenic Agent Combined with Anti-PD-1 Immunotherapy Showed Activity in Patients With Classical Hodgkin Lymphoma Who Have Failed Immunotherapy: A Retrospective Case Report Study. <i>Frontiers in Immunology</i> , 2021, 12, 727464.	2.2	5
996	Stereotactic Radiosurgery Results for Brain Metastasis Patients with Renal Cancer: A Validity Study of Renal Graded Prognostic Assessment and Proposal of a New Grading Index (JLGK2101 Study). <i>Clinical and Translational Radiation Oncology</i> , 2021, 32, 69-75.	0.9	1
997	Molecular Mechanisms of Resistance to Immunotherapy and Antiangiogenic Treatments in Clear Cell Renal Cell Carcinoma. <i>Cancers</i> , 2021, 13, 5981.	1.7	31
998	Immune Checkpoint Inhibitor Therapy for Bone Metastases: Specific Microenvironment and Current Situation. <i>Journal of Immunology Research</i> , 2021, 2021, 1-18.	0.9	21
1000	Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with renal cell carcinoma. <i>ESMO Open</i> , 2021, 6, 100304.	2.0	14
1001	Rational Combination with an Immunotherapy Backbone in Genitourinary Cancers. <i>Urological Science</i> , 2020, 31, 4-7.	0.2	4
1002	Current and Future Aspect of Immunotherapy for Advanced Renal Cell Carcinoma. <i>Urological Science</i> , 2020, 31, 8-14.	0.2	2
1004	Landscape of Immunotherapy in Genitourinary Malignancies. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1342, 143-192.	0.8	2
1005	A Systematic Analysis of Post-Protocol Therapy in First Line Checkpoint Inhibitor Trials. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1006	CD47 reactive protein flare response predicts long-term efficacy to first-line anti-PD-1 based combination therapy in metastatic renal cell carcinoma. <i>Clinical and Translational Immunology</i> , 2021, 10, e1358.	1.7	15
1007	Immune inactivation by CD47 expression predicts clinical outcomes and therapeutic responses in clear cell renal cell carcinoma patients. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 166.e15-166.e25.	0.8	6
1008	HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study. <i>Lancet Oncology</i> , The, 2022, 23, 172-184.	5.1	58
1009	Avelumab in locally advanced or metastatic urothelial carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2022, , .	1.1	1

#	ARTICLE	IF	CITATIONS
1010	Regorafenibâ€“avelumab combination in patients with biliary tract cancer (REGOMUNE): a single-arm, open-label, phase II trial. <i>European Journal of Cancer</i> , 2022, 162, 161-169.	1.3	22
1011	USP22 promotes proliferation in renal cell carcinoma by stabilizing survivin. <i>Oncology Letters</i> , 2020, 20, 1-1.	0.8	4
1012	The efficacy and safety of immune checkpoint inhibitors combined with antiangiogenic drugs in renal cell carcinomas: a systematic review and meta-analysis. <i>Translational Cancer Research</i> , 2020, 9, 6780-6791.	0.4	2
1013	Tumors: <i>Urologic Cancer</i> . , 2021, , 5291-5301.		0
1014	Novel emerging biomarkers to immunotherapy in kidney cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110593.	1.4	12
1015	A New Direction of Tumor Therapyâ€”Immune Checkpoint Inhibitor Combined with Anti Angiogenesis Therapy. <i>Advances in Clinical Medicine</i> , 2021, 11, 5666-5672.	0.0	0
1016	Fortgeschrittenes Nierenzellkarzinom: Neuerungen beim Einsatz zielgerichteter Therapien. , 0, , .		0
1018	Immune checkpoint-targeted antibodies: a room for dose and schedule optimization?. <i>Journal of Hematology and Oncology</i> , 2022, 15, 6.	6.9	17
1019	Peripheral neuropathy and headache in cancer patients treated with immunotherapy and immuno-oncology combinations: the MOUSEION-02 study. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2021, 17, 1455-1466.	1.5	7
1020	Improvement of Medical Treatment in Japanese Patients With Metastatic Renal Cell Carcinoma. <i>Cancer Diagnosis & Prognosis</i> , 2022, 2, 25-30.	0.3	0
1021	High Complete Response Rate in Patients With Metastatic Renal Cell Carcinoma Receiving Autologous Cytokine-Induced Killer Cell Therapy Plus Anti-Programmed Death-1 Agent: A Single-Center Study. <i>Frontiers in Immunology</i> , 2021, 12, 779248.	2.2	3
1022	Outcomes of sorafenib treatment of advanced renal cell carcinoma according to International Metastatic Renal Cell Carcinoma Data Consortium risk criteria: analysis of Japanese real-world data from postmarketing all-patient surveillance of sorafenib. <i>Future Oncology</i> , 2022, , .	1.1	1
1023	Combination of Anti-Angiogenics and Checkpoint Inhibitors for Renal Cell Carcinoma: Is the Whole Greater Than the Sum of Its Parts?. <i>Cancers</i> , 2022, 14, 644.	1.7	11
1025	Methods of screening, monitoring and management of cardiac toxicity induced by chemotherapeuticsâ€œ°. <i>Chinese Chemical Letters</i> , 2022, , .	4.8	3
1026	Adverse Events of Immune Checkpoint Inhibitors Therapy for Urologic Cancer Patients in Clinical Trials: A Collaborative Systematic Review and Meta-analysis. <i>European Urology</i> , 2022, 81, 414-425.	0.9	40
1027	Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 71-90.	2.3	248
1029	Systemic Injection of Oncolytic Vaccinia Virus Suppresses Primary Tumor Growth and Lung Metastasis in Metastatic Renal Cell Carcinoma by Remodeling Tumor Microenvironment. <i>Biomedicines</i> , 2022, 10, 173.	1.4	6
1030	Immunotherapy for Biliary Tract Cancer in the Era of Precision Medicine: Current Knowledge and Future Perspectives. <i>International Journal of Molecular Sciences</i> , 2022, 23, 820.	1.8	15

#	ARTICLE	IF	CITATIONS
1031	Immunotherapy: A new standard in the treatment of metastatic clear cell renal cell carcinoma. <i>World Journal of Clinical Oncology</i> , 2022, 13, 28-38.	0.9	10
1032	Independent Drug Action in Combination Therapy: Implications for Precision Oncology. <i>Cancer Discovery</i> , 2022, 12, 606-624.	7.7	93
1033	The Frontline Immunotherapy-Based Treatment of Advanced Clear Cell Renal Cell Carcinoma: Current Evidence and Clinical Perspective. <i>Biomedicines</i> , 2022, 10, 251.	1.4	13
1034	Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies. , 2022, 10, e003024.		15
1035	IL-1A is associated with postoperative survival and immune contexture in clear cell renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, , .	0.8	3
1036	Predictable Clinical Benefits without Evidence of Synergy in Trials of Combination Therapies with Immune-Checkpoint Inhibitors. <i>Clinical Cancer Research</i> , 2022, 28, 368-377.	3.2	40
1037	Update on the treatment of metastatic renal cell carcinoma. <i>World Journal of Clinical Oncology</i> , 2022, 13, 1-8.	0.9	10
1038	Antiangiogenic drugs: Chemosensitizers for combination cancer therapy. , 2022, , 29-66.		1
1039	A novel FBW7/NFAT1 axis regulates cancer immunity in sunitinib-resistant renal cancer by inducing PD-L1 expression. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 38.	3.5	17
1040	Comparative Efficacy of Combination Therapy of Ipilimumab Plus Nivolumab for Non-clear Cell Renal Cell Carcinoma. <i>Anticancer Research</i> , 2022, 42, 973-979.	0.5	5
1041	Tumors resurrect an embryonic vascular program to escape immunity. <i>Science Immunology</i> , 2022, 7, eabm6388.	5.6	27
1042	The Essentials of Multiomics. <i>Oncologist</i> , 2022, 27, 272-284.	1.9	11
1043	A Randomized Phase II Trial of mFOLFOX6 + Bevacizumab Alone or with AdCEA Vaccine + Avelumab Immunotherapy for Untreated Metastatic Colorectal Cancer. <i>Oncologist</i> , 2022, 27, 198-209.	1.9	18
1044	Phase II Trial of Stereotactic Ablative Radiation for Oligoprogressive Metastatic Kidney Cancer. <i>European Urology Oncology</i> , 2022, 5, 216-224.	2.6	26
1045	General conclusions and future perspectives. , 2022, , 241-260.		0
1046	Antiangiogenic drugs as chemosensitizer in renal cell cancer. , 2022, , 79-84.		0
1047	Afatinib and Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (ALPHA Study): A Phase II Study with Biomarker Analysis. <i>Clinical Cancer Research</i> , 2022, 28, 1560-1571.	3.2	33
1048	A phase III, randomized, open-label study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy in patients with metastaticÂcastration-resistant prostate cancer. <i>Future Oncology</i> , 2022, 18, 1185-1198.	1.1	10

#	ARTICLE	IF	CITATIONS
1049	2021 Updated European Association of Urology Guidelines on the Use of Adjuvant Pembrolizumab for Renal Cell Carcinoma. <i>European Urology</i> , 2022, 81, 134-137.	0.9	29
1050	Recent Advances in First-Line Management of Metastatic Renal Cell Carcinoma. <i>Indian Journal of Medical and Paediatric Oncology</i> , 0, , .	0.1	0
1051	Chronic Use of Proton Pump Inhibitors Is Associated With an Increased Risk of Immune Checkpoint Inhibitor Colitis in Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 260-269.	0.9	8
1052	Management of adverse events associated with cabozantinib plus nivolumab in renal cell carcinoma: A review. <i>Cancer Treatment Reviews</i> , 2022, 103, 102333.	3.4	21
1053	Global management of brain metastasis from renal cell carcinoma. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 171, 103600.	2.0	2
1054	Efficacy and Safety of First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis. <i>European Urology Open Science</i> , 2022, 37, 14-26.	0.2	48
1055	OUP accepted manuscript. <i>Oncologist</i> , 2022, , .	1.9	2
1056	Outcomes following cytoreductive nephrectomy without immediate postoperative systemic therapy for patients with synchronous metastatic renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 166.e1-166.e8.	0.8	5
1057	Disrupting cancer angiogenesis and immune checkpoint networks for improved tumor immunity. <i>Seminars in Cancer Biology</i> , 2022, 86, 981-996.	4.3	15
1058	Soluble PD-L1 as an early marker of progressive disease on nivolumab. , 2022, 10, e003527.		35
1059	Predictors of Survival in Favorable Risk Patients with Metastatic Renal Cell Carcinoma Treated with a Single-Agent First-Line Therapy. <i>Urologia Internationalis</i> , 2022, , 1-5.	0.6	1
1060	Coordinated Pembrolizumab and High Dose IL-2 (5-in-a-Row Schedule) for Therapy of Metastatic Clear Cell Renal Cancer. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 252-259.	0.9	4
1061	Risk of toxicity with immunotherapyâ€“tyrosine kinase inhibitors for metastatic renal cell carcinoma: a meta-analysis of randomized controlled trials. <i>Future Oncology</i> , 2022, 18, 625-634.	1.1	4
1062	Stereotactic Radiotherapy and Short-course Pembrolizumab for Oligometastatic Renal Cell Carcinomaâ€“The RAPPORT Trial. <i>European Urology</i> , 2022, 81, 364-372.	0.9	70
1063	Immune Checkpoint Inhibitors in 10 Years: Contribution of Basic Research and Clinical Application in Cancer Immunotherapy. <i>Immune Network</i> , 2022, 22, e2.	1.6	53
1065	Nierenzellkarzinom. , 2022, , 130-134.		0
1066	Monoclonal Antibodies to CTLA-4 with Focus on Ipilimumab. <i>Experientia Supplementum (2012)</i> , 2022, 113, 295-350.	0.5	3
1067	Comprehensive Immune Landscape and Molecular Characteristics of Clinical Responses to Chemotherapy, Antiangiogenic Agents and PD-1 Inhibitors in Advanced Nasopharyngeal Cancer. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0

#	ARTICLE	IF	CITATIONS
1068	Overview of clinical management for older patients with renal cell carcinoma. Japanese Journal of Clinical Oncology, 2022, 52, 665-681.	0.6	2
1070	Cabozantinib in Patients with Advanced Renal Cell Carcinoma Primary Refractory to First-line Immunocombinations or Tyrosine Kinase Inhibitors. European Urology Focus, 2022, 8, 1696-1702.	1.6	17
1071	First-line Immune Checkpoint Inhibitor Combinations in Metastatic Renal Cell Carcinoma: Where Are We Going, Where Have We Been?. Drugs, 2022, 82, 439-453.	4.9	3
1072	The Research Progress of Antiangiogenic Therapy, Immune Therapy and Tumor Microenvironment. Frontiers in Immunology, 2022, 13, 802846.	2.2	44
1073	Comprehensive Characterization of Metabolism-Associated Subtypes of Renal Cell Carcinoma to Aid Clinical Therapy. Oxidative Medicine and Cellular Longevity, 2022, 2022, 1-27.	1.9	3
1074	Model-informed drug development supporting the approval of the avelumab flat-dose regimen in patients with advanced renal cell carcinoma. CPT: Pharmacometrics and Systems Pharmacology, 2022, 11, 458-468.	1.3	5
1075	Nivolumab VERSUS Cabozantinib as Second-Line Therapy in Patients With Advanced Renal Cell Carcinoma: A Real-World Comparison. Clinical Genitourinary Cancer, 2022, 20, 285-295.	0.9	5
1076	Cabozantinib plus Nivolumab: A Review in Advanced Renal Cell Carcinoma. Targeted Oncology, 2022, 17, 193-201.	1.7	2
1077	REchallenge of NIVolumab (RENIVO) or Nivolumab-Ipilimumab in Metastatic Renal Cell Carcinoma: An Ambispective Multicenter Study. Journal of Oncology, 2022, 2022, 1-12.	0.6	7
1078	Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial. Nature Medicine, 2022, 28, 704-712.	15.2	181
1079	Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer. JAMA Network Open, 2022, 5, e2149040.	2.8	48
1080	Cancer immunotherapy by immune checkpoint blockade and its advanced application using bio-nanomaterials. Seminars in Cancer Biology, 2022, 86, 909-922.	4.3	26
1081	Utilizing restricted mean duration of response for efficacy evaluation of cancer treatments. Pharmaceutical Statistics, 2022, 21, 865-878.	0.7	6
1082	Revolutionization in Cancer Therapeutics via Targeting Major Immune Checkpoints PD-1, PD-L1 and CTLA-4. Pharmaceuticals, 2022, 15, 335.	1.7	35
1083	Kidney Cancer Research Highlights from ASCO GU 2022 Meeting. Kidney Cancer Journal: Official Journal of the Kidney Cancer Association, 2022, 20, 30-32.	0.1	0
1084	Analysis of Ferroptosis-Related LncRNAs Signatures Associated with Tumor Immune Infiltration and Experimental Validation in Clear Cell Renal Cell Carcinoma. International Journal of General Medicine, 2022, Volume 15, 3215-3235.	0.8	12
1085	The roaring 2020s: a new decade of systemic therapy for renal cell carcinoma. Current Opinion in Oncology, 2022, 34, 234-242.	1.1	16
1086	A WIN Consortium phase I study exploring avelumab, palbociclib, and axitinib in advanced non-small cell lung cancer. Cancer Medicine, 2022, 11, 2790-2800.	1.3	7

#	ARTICLE	IF	CITATIONS
1087	Multi-Omics Investigations Revealed Underlying Molecular Mechanisms Associated With Tumor Stiffness and Identified Sunitinib as a Potential Therapy for Reducing Stiffness in Pituitary Adenomas. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 820562.	1.8	1
1088	Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment. <i>Nature Reviews Drug Discovery</i> , 2022, 21, 440-462.	21.5	58
1089	Effect of systemic therapies or best supportive care after disease progression to both nivolumab and cabozantinib in metastatic renal cell carcinoma: The <scp>Meetâ€uro 19BEYOND</scp> study. <i>Cancer Medicine</i> , 2022, 11, 3084-3092.	1.3	4
1090	The Thermal Dose of Photothermal Therapy Generates Differential Immunogenicity in Human Neuroblastoma Cells. <i>Cancers</i> , 2022, 14, 1447.	1.7	6
1091	Molecular biomarkers of prognosis in advanced renal cell carcinoma patients treated with Pazopanib plus interferon alpha (INF-2A) in a phase I/II study by the Spanish Oncology Genitourinary Group. <i>Clinical Genitourinary Cancer</i> , 2022, , .	0.9	0
1092	Evaluating management of progressive disease for control arm patients in trials of first line PD-1 or PD-L1 inhibitor-based treatment for metastatic solid tumours. <i>European Journal of Cancer</i> , 2022, 164, 95-104.	1.3	0
1093	Combining immune checkpoint inhibition plus tyrosine kinase inhibition as first and subsequent treatments for metastatic renal cell carcinoma. <i>Cancer Medicine</i> , 2022, 11, 3106-3114.	1.3	10
1094	Axitinib Trough Concentration and its Influence on the Efficacy and Toxicity of Second-line Renal Cell Carcinoma Treatment. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 390.e1-390.e8.	0.9	3
1095	The Effects of Axitinib plus Tislelizumab in the Treatment of Advanced Renal Cell Carcinoma. <i>Journal of Oncology</i> , 2022, 2022, 1-5.	0.6	0
1096	Safety and Efficacy of Avelumab in Small Bowel Adenocarcinoma. <i>Clinical Colorectal Cancer</i> , 2022, 21, 236-243.	1.0	6
1097	Angiogenesis Inhibitors and Immunomodulation in Renal Cell Cancers: The Past, Present, and Future. <i>Cancers</i> , 2022, 14, 1406.	1.7	13
1098	Reshaping Treatment Paradigms for Advanced Renal Cell Cancer Patients and Improving Patient Management. <i>Current Treatment Options in Oncology</i> , 2022, 23, 609-629.	1.3	1
1099	Camrelizumab Plus Apatinib in Treatment-Naive Patients With Advanced Nonsquamous NSCLC: A Multicenter, Open-Label, Single-Arm, Phase 2 Trial. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100312.	0.6	7
1100	Surgical and focal treatment for metastatic renal cell carcinoma: A literature review. <i>International Journal of Urology</i> , 2022, 29, 494-501.	0.5	8
1101	Avelumab in paediatric patients with refractory or relapsed solid tumours: dose-escalation results from an open-label, single-arm, phase 1/2 trial. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 2485-2495.	2.0	11
1102	Approaches to First-Line Therapy for Metastatic Clear Cell Renal Cell Carcinoma. <i>Current Oncology Reports</i> , 2022, 24, 695-702.	1.8	9
1103	Temporal trends of adverse events and costs of nivolumab plus ipilimumab versus sunitinib in advanced renal cell carcinoma. <i>Future Oncology</i> , 2022, 18, 1219-1234.	1.1	3
1104	Effect of active anticancer therapy on serologic response to SARSâ€CoVâ€2 BNT162b2 vaccine in patients with urothelial and renal cell carcinoma. <i>International Journal of Urology</i> , 2022, , .	0.5	4

#	ARTICLE	IF	CITATIONS
1105	“PROBE”ing the Role of Cytoreductive Nephrectomy in Advanced Renal Cancer. <i>Kidney Cancer</i> , 2022, 6, 3-9.	0.2	7
1106	Complete remission of renal cell carcinoma with lung carcinomatous lymphangiosis after primary therapy with immune checkpoint inhibitors followed by partial nephrectomy for surgical consolidation. <i>IJU Case Reports</i> , 2022, 5, 168-171.	0.1	2
1107	Extended Disease Control with Unconventional Cabozantinib Dose Increase in Metastatic Renal Cell Carcinoma. <i>Kidney Cancer</i> , 2022, 6, 69-79.	0.2	2
1108	Risk factors of proteinuria and potentially protective effect of renin-angiotensin system inhibitors in patients with renal cell carcinoma receiving axitinib. <i>Cancer Chemotherapy and Pharmacology</i> , 2022, 89, 833-838.	1.1	4
1109	A Network Meta-Analysis of the Differences in Effectiveness and Safety between Nivolumab and Targeted Drug Therapy in Metastatic Renal Cell Carcinoma. <i>Journal of Oncology</i> , 2022, 2022, 1-8.	0.6	0
1110	The Efficacy of Adjuvant Targeted Therapy in Patients with Advanced Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. <i>Computational and Mathematical Methods in Medicine</i> , 2022, 2022, 1-9.	0.7	4
1111	Identification of a Twelve Epithelial-Mesenchymal Transition-Related lncRNA Prognostic Signature in Kidney Clear Cell Carcinoma. <i>Disease Markers</i> , 2022, 2022, 1-18.	0.6	6
1112	Prognostic model of upfront cytoreductive nephrectomy in patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors and/or targeted agents. <i>International Urology and Nephrology</i> , 2022, 54, 1225-1232.	0.6	8
1113	Prospective Cardiovascular Surveillance of Immune Checkpoint Inhibitor-Based Combination Therapy in Patients With Advanced Renal Cell Cancer: Data From the Phase III JAVELIN Renal 101 Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 1929-1938.	0.8	33
1114	Successful apatinib treatment for advanced clear cell renal carcinoma as a first-line palliative treatment: A case report. <i>World Journal of Clinical Cases</i> , 2022, 10, 3593-3600.	0.3	1
1115	Renal cell carcinoma presentation highlights from the ESMO Congress 2021. <i>Memo - Magazine of European Medical Oncology</i> , 0, , 1.	0.3	1
1116	Recent Advances in Medical Therapy for Urological Cancers. <i>Frontiers in Oncology</i> , 2022, 12, 746922.	1.3	8
1117	First-line immune checkpoint inhibitors in advanced or metastatic renal cell carcinoma with sarcomatoid features. <i>Cancer Treatment Reviews</i> , 2022, 105, 102374.	3.4	7
1118	Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons. <i>Cell Communication and Signaling</i> , 2022, 20, 44.	2.7	109
1119	Models of Renal Cell Carcinoma Used to Investigate Molecular Mechanisms and Develop New Therapeutics. <i>Frontiers in Oncology</i> , 2022, 12, 871252.	1.3	8
1120	Efficacy and safety of avelumab plus axitinib in elderly patients with advanced renal cell carcinoma: extended follow-up results from JAVELIN Renal 101. <i>ESMO Open</i> , 2022, 7, 100450.	2.0	14
1121	Efficacy of second-line ICIs combined with TKIs among patients with metastatic renal cell carcinoma: a real-world study. <i>Immunotherapy</i> , 2022, 14, 309-320.	1.0	0
1122	Results from the INMUNOSUN-SOGUG trial: a prospective phase II study of sunitinib as a second-line therapy in patients with metastatic renal cell carcinoma after immune checkpoint-based combination therapy. <i>ESMO Open</i> , 2022, 7, 100463.	2.0	5

#	ARTICLE	IF	CITATIONS
1123	Dermatological adverse events associated with immune checkpoint inhibitor-based combinations of anticancer therapies: a systematic review. <i>Immunotherapy</i> , 2022, 14, 489-503.	1.0	1
1124	Setting a new standard for long-term survival in metastatic kidney cancer. <i>Cancer</i> , 2022, 128, 2058-2060.	2.0	0
1125	“The first ones now, will later be last” understanding the importance of historical context when reading ESMO-MCBS scores. <i>ESMO Open</i> , 2022, 7, 100413.	2.0	0
1126	The Chromosomes and the Kidney. <i>Physician Assistant Clinics</i> , 2022, 7, 367-375.	0.1	0
1127	New first-line immunotherapy-based combinations for metastatic renal cell carcinoma: A systematic review and network meta-analysis. <i>Cancer Treatment Reviews</i> , 2022, 106, 102377.	3.4	20
1128	The effect of immune checkpoint inhibitor combination therapies in metastatic renal cell carcinoma patients with and without previous cytoreductive nephrectomy: A systematic review and meta-analysis. <i>International Immunopharmacology</i> , 2022, 108, 108720.	1.7	13
1129	Nephrotoxicity From Molecularly Targeted Chemotherapeutic Agents. <i>Advances in Chronic Kidney Disease</i> , 2021, 28, 415-428.e1.	0.6	4
1130	Renal Cell Cancer and Chronic Kidney Disease. <i>Advances in Chronic Kidney Disease</i> , 2021, 28, 460-468.e1.	0.6	19
1131	Immune Regulatory Processes of the Tumor Microenvironment under Malignant Conditions. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13311.	1.8	54
1132	Immunotherapy and Metastatic Renal Cell Carcinoma: A Review of New Treatment Approaches. <i>Life</i> , 2022, 12, 24.	1.1	12
1133	CD146 as a Prognostic-Related Biomarker in ccRCC Correlating With Immune Infiltrates. <i>Frontiers in Oncology</i> , 2021, 11, 744107.	1.3	11
1134	Phase Ib Study of Atezolizumab Plus Interferon- γ with or without Bevacizumab in Patients with Metastatic Renal Cell Carcinoma and Other Solid Tumors. <i>Current Oncology</i> , 2021, 28, 5466-5479.	0.9	2
1135	Comparative Analysis of Predictive Biomarkers for PD-1/PD-L1 Inhibitors in Cancers: Developments and Challenges. <i>Cancers</i> , 2022, 14, 109.	1.7	21
1136	Cost-Effectiveness of Nivolumab Plus Cabozantinib Versus Sunitinib as a First-Line Treatment for Advanced Renal Cell Carcinoma in the United States. <i>Frontiers in Pharmacology</i> , 2021, 12, 736860.	1.6	4
1138	An immune-related lncRNA risk coefficient model to predict the outcomes in clear cell renal cell carcinoma. <i>Aging</i> , 2021, 13, 26046-26062.	1.4	7
1140	Real-World Data on the Use of Nivolumab Monotherapy in the Treatment of Advanced Renal Cell Carcinoma after Prior Therapy: Interim Results from the Noninterventional NORA Study. <i>European Urology Focus</i> , 2022, 8, 1289-1299.	1.6	4
1141	Concomitant Proton Pump Inhibitors and Outcome of Patients Treated with Nivolumab Alone or Plus Ipilimumab for Advanced Renal Cell Carcinoma. <i>Targeted Oncology</i> , 2022, 17, 61-68.	1.7	61
1142	A real-world pharmacovigilance study of axitinib: data mining of the public version of FDA adverse event reporting system. <i>Expert Opinion on Drug Safety</i> , 2022, 21, 563-572.	1.0	27

#	ARTICLE	IF	CITATIONS
1143	Combination therapy patents: a new front in evergreening. <i>Nature Biotechnology</i> , 2021, 39, 1504-1510.	9.4	8
1144	Case Report: Early ⁶⁸ Ga-PSMA-PET Metabolic Assessment and Response to Systemic Treatment for First-Line Metastatic Clear Cell Renal Cell Carcinoma; About Two Clinical Cases. <i>Frontiers in Oncology</i> , 2021, 11, 782166.	1.3	3
1145	Predictive Biomarkers of Overall Survival in Patients with Metastatic Renal Cell Carcinoma Treated with IFN α ± Bevacizumab: Results from CALGB 90206 (Alliance). <i>Clinical Cancer Research</i> , 2022, 28, 2771-2778.	3.2	8
1146	FGL1 as a Novel Mediator and Biomarker of Malignant Progression in Clear Cell Renal Cell Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 756843.	1.3	8
1147	Aktuelles zur medikamentösen Therapie des rezidierten/metastasierten Nierenzellkarzinoms (mNCC). <i>Onkologische Welt</i> , 2021, 12, 361-367.	0.0	0
1149	Differential effects of cyclo-oxygenase 1 and 2 inhibition on angiogenesis inhibitor-induced hypertension and kidney damage. <i>Clinical Science</i> , 2022, 136, 675-694.	1.8	6
1150	A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy. <i>Science Translational Medicine</i> , 2022, 14, eabm6420.	5.8	29
1151	m6A Methylation Patterns and Tumor Microenvironment Infiltration Characterization in Clear-Cell Renal Cell Carcinoma. <i>Frontiers in Genetics</i> , 2022, 13, 864549.	1.1	5
1152	Identification of BAP1 mutation as a common mutation correlated with tumor mutation burden and immune infiltration in kidney renal clear cell carcinoma. <i>International Journal of Transgender Health</i> , 2022, 15, 470-478.	1.1	3
1153	The Landscape of Immunotherapy Resistance in NSCLC. <i>Frontiers in Oncology</i> , 2022, 12, 817548.	1.3	27
1154	Research Trends and Most Influential Clinical Studies on Anti-PD1/PDL1 Immunotherapy for Cancers: A Bibliometric Analysis. <i>Frontiers in Immunology</i> , 2022, 13, 862084.	2.2	18
1155	Novel immune-related signature based on immune cells for predicting prognosis and immunotherapy response in clear cell renal cell carcinoma. <i>Journal of Clinical Laboratory Analysis</i> , 2022, , e24409.	0.9	1
1156	T Cell-Mediated Targeted Delivery of Anti-PD-L1 Nanobody Overcomes Poor Antibody Penetration and Improves PD-L1 Blocking at the Tumor Site. <i>Cancer Immunology Research</i> , 2022, 10, 713-727.	1.6	4
1157	Front-Line Therapy for Metastatic Renal Cell Carcinoma: A Perspective on the Current Algorithm and Future Directions. <i>Cancers</i> , 2022, 14, 2049.	1.7	7
1158	Immune-Related Adverse Events (irAEs) in Cancer, with Inputs from a Nursing Expert: A Review. <i>Indian Journal of Medical and Paediatric Oncology</i> , 0, 43, .	0.1	0
1185	Opposing Roles of Vascular Endothelial Growth Factor C in Metastatic Dissemination and Resistance to Radio/Chemotherapy: Discussion of Mechanisms and Therapeutic Strategies. <i>Methods in Molecular Biology</i> , 2022, 2475, 1-23.	0.4	2
1186	Surufatinib plus toripalimab in patients with advanced solid tumors: a single-arm, open-label, phase 1 trial. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 779-789.	1.2	10
1187	Changes in Real-World Outcomes in Patients with Metastatic Renal Cell Carcinoma from the Molecular-Targeted Therapy Era to the Immune Checkpoint Inhibitor Era. <i>Targeted Oncology</i> , 2022, 17, 307-319.	1.7	4

#	ARTICLE	IF	CITATIONS
1188	Anti-angiogenesis revisited: reshaping the treatment landscape of advanced non-small cell lung cancer. <i>Archives of Pharmacal Research</i> , 2022, 45, 263-279.	2.7	11
1189	A comparison of cytoreductive and non-cytoreductive management strategies for nephron-sparing approaches to tumours in solitary kidneys. <i>Annals of the Royal College of Surgeons of England</i> , 2022, 104, 548-552.	0.3	0
1190	Hematological prognosticators in metastatic renal cell cancer treated with immune checkpoint inhibitors: a meta-analysis. <i>Immunotherapy</i> , 2022, 14, 709-725.	1.0	10
1191	OIP5 Is a Novel Prognostic Biomarker in Clear Cell Renal Cell Cancer Correlating With Immune Infiltrates. <i>Frontiers in Immunology</i> , 2022, 13, 805552.	2.2	7
1193	The Evolving Role of PD-L1 Inhibition in Non-Small Cell Lung Cancer: A Review of Durvalumab and Avelumab.. , 2022, 5, 31-45.		0
1194	Axitinib in management of renal cell carcinoma: Indian perspective. <i>Oncology Journal of India</i> , 2022, 6, 14.	0.1	2
1195	Immunotherapy in Genitourinary Malignancy: Evolution in Revolution or Revolution in Evolution. <i>Cancer Treatment and Research</i> , 2022, 183, 201-223.	0.2	0
1196	Resource Use in Advanced Renal Cancer with the Payer Institution Perspective: The Case of Training and Research Hospital. <i>SÃ¼leyman Demirel Ãœniversitesi Vizyoner Dergisi</i> , 2022, 13, 520-534.	0.1	1
1197	A Systematic Review of Immune Checkpoint Inhibitors in Non-Clear-Cell Renal Cancer. <i>Kidney Cancer</i> , 2022, 6, 115-127.	0.2	2
1198	Rapidly evolving first-line therapy using checkpoint inhibitors in metastatic renal cell cancer. <i>Future Medicinal Chemistry</i> , 2022, , .	1.1	0
1199	Adjuvant therapy for patients with renal cell carcinoma following surgery: a focus on pembrolizumab. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 565-574.	1.1	1
1200	Neoadjuvant Systemic Therapy in Localized and Locally Advanced Renal Cell Carcinoma. <i>Frontiers in Urology</i> , 2022, 2, .	0.2	1
1201	Validation of a Novel Three-Dimensional (3D Fusion) Gross Sampling Protocol for Clear Cell Renal Cell Carcinoma to Overcome Intratumoral Heterogeneity: The Meet-Uro 18 Study. <i>Journal of Personalized Medicine</i> , 2022, 12, 727.	1.1	3
1202	Phase Ib study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis. <i>Hepatology</i> , 2023, 77, 65-76.	3.6	10
1203	Epigenetic editing and tumorâ€™dependent immunosuppressive signaling in head and neck malignancies (Review). <i>Oncology Letters</i> , 2022, 23, 196.	0.8	4
1204	Developments in personalized therapy for metastatic renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 647-655.	1.1	6
1205	Checkpoint inhibition: the current treatment of renal cell carcinoma. <i>Revista Mexicana De Urologia</i> , 2022, 82, 1-13.	0.0	0
1206	Thyroid Dysfunction from Treatments for Solid Organ Cancers. <i>Endocrinology and Metabolism Clinics of North America</i> , 2022, 51, 265-286.	1.2	3

#	ARTICLE	IF	CITATIONS
1207	Systemic therapy in metastatic renal cell carcinoma (mRCC): an evidence-based recommendation of the German interdisciplinary RCC guidelines group. <i>World Journal of Urology</i> , 2022, 40, 2381-2386.	1.2	3
1208	Complementary roles of surgery and systemic treatment in clear cell renal cell carcinoma. <i>Nature Reviews Urology</i> , 2022, 19, 391-418.	1.9	20
1209	Early reduction in spectral dual-layer detector CT parameters as favorable imaging biomarkers in patients with metastatic renal cell carcinoma. <i>European Radiology</i> , 2022, 32, 7323-7334.	2.3	5
1210	The efficacy of immune checkpoint inhibitors in rare tumors: A systematic review of published clinical trials. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 174, 103700.	2.0	6
1211	The multi-molecular mechanisms of tumor-targeted drug resistance in precision medicine. <i>Biomedicine and Pharmacotherapy</i> , 2022, 150, 113064.	2.5	14
1212	The roles of TGF- β 2 and VEGF pathways in the suppression of antitumor immunity in melanoma and other solid tumors. , 2022, 240, 108211.		21
1214	Incidence of fatigue associated with immune checkpoint inhibitors in patients with cancer: a meta-analysis. <i>ESMO Open</i> , 2022, 7, 100474.	2.0	3
1215	Mechanism and Management of Checkpoint Inhibitor-Related Toxicities in Genitourinary Cancers. <i>Cancers</i> , 2022, 14, 2460.	1.7	2
1216	Development of a Phagocytosis-Dependent Gene Signature to Predict Prognosis and Response to Checkpoint Inhibition in Clear-Cell Renal Cell Carcinoma. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	9
1217	Clear Cell Renal Cell Carcinoma with Immunotherapy Effect Mimicking Xanthogranulomatous Pyelonephritis. <i>International Journal of Surgical Pathology</i> , 2022, , 106689692211018.	0.4	0
1218	Clinically approved combination immunotherapy: Current status, limitations, and future perspective. <i>Current Research in Immunology</i> , 2022, 3, 118-127.	1.2	20
1219	Integration of Palliative and Supportive Care Into the Management of Genitourinary Malignancies. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022, , 341-350.	1.8	2
1220	Immune-Associated Gene Signatures Serve as a Promising Biomarker of Immunotherapeutic Prognosis for Renal Clear Cell Carcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	10
1221	Longitudinal Molecular Profiling of Circulating Tumor Cells in Metastatic Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 3633-3641.	0.8	12
1222	Comprehensive assessments of immuno-oncology drug-based combination therapies as first-line treatment for advanced renal cell carcinoma. <i>International Journal of Urology</i> , 2022, 29, 816-822.	0.5	1
1223	First-line therapy for metastatic renal cell carcinoma. <i>Journal of Clinical Urology</i> , 0, , 205141582210929.	0.1	0
1224	Computed Tomography Image Features under Denoising Algorithm for Benign and Malignant Diagnosis of Renal Parenchymal Tumor. <i>Contrast Media and Molecular Imaging</i> , 2022, 2022, 1-8.	0.4	0
1225	Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non-Small-Cell Lung Cancer Previously Treated With Immunotherapy—Lung-MAP S1800A. <i>Journal of Clinical Oncology</i> , 2022, 40, 2295-2307.	0.8	84

#	ARTICLE	IF	CITATIONS
1226	Pembrolizumab in advanced renal cell carcinoma: a meta-analysis providing level 1a evidence. <i>Current Problems in Cancer</i> , 2022, , 100875.	1.0	2
1227	An Evaluation of Cabozantinib for the Treatment of Renal Cell Carcinoma: Focus on Patient Selection and Perspectives. <i>Therapeutics and Clinical Risk Management</i> , 0, Volume 18, 619-632.	0.9	5
1228	Identification of Ligand-Receptor Pairs Associated With Tumour Characteristics in Clear Cell Renal Cell Carcinoma. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	10
1229	Comprehensive Analysis of Senescence Characteristics Defines a Novel Prognostic Signature to Guide Personalized Treatment for Clear Cell Renal Cell Carcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	13
1230	Renal and urinary bladder cancer. , 2023, , 327-335.		0
1232	Durable benefit and change in TCR clonality with nivolumab in a Lynch syndrome-associated glioma. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211008.	1.4	1
1233	Update on Treatment of Renal Cell Carcinoma. <i>Journal of the Nihon University Medical Association</i> , 2022, 81, 77-81.	0.0	0
1234	Clinical activity of immunotherapy-based combination first-line therapies for metastatic renal cell carcinoma: the right treatment for the right patient. <i>Bulletin Du Cancer</i> , 2022, 109, 2S4-2S18.	0.6	3
1235	Surgical management in metastatic renal cell carcinoma. <i>Bulletin Du Cancer</i> , 2022, 109, 2S59-2S65.	0.6	0
1236	Cost-Effectiveness of Lenvatinib Plus Pembrolizumab or Everolimus as First-Line Treatment of Advanced Renal Cell Carcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
1237	Near-Infrared Photoimmunotherapy (NIR-PIT) in Urologic Cancers. <i>Cancers</i> , 2022, 14, 2996.	1.7	9
1238	Combination Immune Checkpoint Blockade Regimens for Previously Untreated Metastatic Renal Cell Carcinoma: The Winship Cancer Institute of Emory University Experience. <i>Journal of Immunotherapy and Precision Oncology</i> , 2022, , .	0.6	1
1239	Precision Medicine: An Optimal Approach to Patient Care in Renal Cell Carcinoma. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	5
1240	An interdisciplinary consensus on the management of brain metastases in patients with renal cell carcinoma. <i>Ca-A Cancer Journal for Clinicians</i> , 2022, 72, 454-489.	157.7	13
1241	Metastatic Clear-Cell Renal Cell Carcinoma in the Era of Immune Checkpoint Inhibitors: Therapies and Ongoing Trials. <i>Cancers</i> , 2022, 14, 2867.	1.7	10
1242	A Study of Pazopanib Safety and Efficacy in Patients With Advanced Clear Cell Renal Cell Carcinoma and ECOG Performance Status 2 (Pazo2): An Open label, Multicentre, Single Arm, Phase II Trial. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 473-481.	0.9	2
1243	Cancer immunohistogram representing cancer-immunity cycle by immunohistochemistry predicts the efficacy of immune checkpoint inhibitors in urological cancer patients. <i>Scientific Reports</i> , 2022, 12, .	1.6	3
1244	Reply to S. Tan et al. <i>Journal of Clinical Oncology</i> , 0, , .	0.8	0

#	ARTICLE	IF	CITATIONS
1245	Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2022, 40, 2957-2995.	0.8	97
1246	Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma. <i>Nature Medicine</i> , 2022, 28, 1599-1611.	15.2	185
1248	Use of Circular RNAs in Diagnosis, Prognosis and Therapeutics of Renal Cell Carcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	5
1249	Immune checkpoint inhibitor-based therapy for advanced clear cell renal cell carcinoma: A narrative review. <i>International Immunopharmacology</i> , 2022, 110, 108900.	1.7	13
1250	Immunotherapy: an alternative promising therapeutic approach against cancers. <i>Molecular Biology Reports</i> , 2022, 49, 9903-9913.	1.0	17
1251	Charting roadmaps towards novel and safe synergistic immunotherapy combinations. <i>Nature Cancer</i> , 2022, 3, 665-680.	5.7	18
1252	Primary Tumor Shrinkage and the Effect on Metastatic Disease and Outcomes in Patients With Advanced Kidney Cancer With Intermediate or Poor Prognosis Treated With Nivolumab Plus Ipilimumab or Cabozantinib. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 498.e1-498.e9.	0.9	3
1253	RCC Real-World Data: Prognostic Factors and Risk Stratification in the Immunotherapy Era. <i>Cancers</i> , 2022, 14, 3127.	1.7	5
1254	A Targetable Myeloid Inflammatory State Governs Disease Recurrence in Clear-Cell Renal Cell Carcinoma. <i>Cancer Discovery</i> , 2022, 12, 2308-2329.	7.7	7
1255	¹⁸ F FDG PET/CT and Novel Molecular Imaging for Directing Immunotherapy in Cancer. <i>Radiology</i> , 2022, 304, 246-264.	3.6	14
1256	A single-cell map of dynamic chromatin landscapes of immune cells in renal cell carcinoma. <i>Nature Cancer</i> , 2022, 3, 885-898.	5.7	20
1257	Evaluation of Provider Preferences in First-Line Metastatic Renal Cell Carcinoma: Comparison Between Dual Immunotherapy vs. Immunotherapy/Tyrosine Kinase Inhibitors. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 510-514.	0.9	0
1258	Efficacy and Safety of Immunotherapy-Based Combinations as First-Line Therapy for Metastatic Renal Cell Carcinoma in Patients Who Do Not Meet Trial Eligibility Criteria. <i>Targeted Oncology</i> , 2022, 17, 475-482.	1.7	4
1259	Efficacy and Safety of Concomitant Proton Pump Inhibitor and Nivolumab in Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 488-494.	0.9	4
1260	External Validation of a Novel Risk Model in Patients With Favorable Risk Renal Cell Carcinoma Defined by International Metastatic Renal Cell Carcinoma Database Consortium (IMDC): Results From the Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database. <i>Clinical Genitourinary Cancer</i> , 2023, 21, 175-182.	0.9	2
1261	A Cluster of Metabolic-Related Genes Serve as Potential Prognostic Biomarkers for Renal Cell Carcinoma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	5
1262	Does the Time to Start First-Line Treatment Influence the Survival of Favorable-Risk Patients With Metastatic Renal Cell Carcinoma? Results of the MetaSurvâ€UroCCR 79 Study. <i>Clinical Genitourinary Cancer</i> , 2023, 21, 194-202.	0.9	0
1263	Combination therapy regimens in the treatment of metastatic renal cell carcinoma: A review. <i>Journal of Modern Oncology</i> , 2022, 24, 191-198.	0.1	0

#	ARTICLE	IF	CITATIONS
1264	Real-world efficacy and safety of nivolumab plus ipilimumab in untreated metastatic renal cell carcinoma, and the impact of previous nephrectomy on clinical outcome: Japanese multi-institutional retrospective study. <i>International Journal of Clinical Oncology</i> , 2022, 27, 1596-1604.	1.0	11
1265	Case report: treatment of metastatic renal cell carcinoma with nivolumab plus cabozantinib in routine clinical practice. <i>Malignant Tumours</i> , 2022, 12, 45-51.	0.1	0
1266	Health-related Quality of Life Analysis from KEYNOTE-426: Pembrolizumab plus Axitinib Versus Sunitinib for Advanced Renal Cell Carcinoma. <i>European Urology</i> , 2022, 82, 427-439.	0.9	15
1268	Cuproptosis-Associated lncRNA Establishes New Prognostic Profile and Predicts Immunotherapy Response in Clear Cell Renal Cell Carcinoma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	58
1269	Risk of Rash in PD-1 or PD-L1-Related Cancer Clinical Trials: A Systematic Review and Meta-Analysis. <i>Journal of Oncology</i> , 2022, 2022, 1-27.	0.6	5
1270	Case Report: A Durable Response to Camrelizumab and Apatinib Combination Therapy in a Heavily Treated Small Cell Carcinoma of the Ovary, Hypercalcemic Type. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
1271	Trends in Incidence and Mortality of Kidney Cancer in a Northern Italian Province: An Update to 2020. <i>Biology</i> , 2022, 11, 1048.	1.3	1
1272	A Profile of Avelumab Plus Axitinib in the Treatment of Renal Cell Carcinoma. <i>Therapeutics and Clinical Risk Management</i> , 0, Volume 18, 683-698.	0.9	2
1273	Therapeutic role of deferred cytoreductive nephrectomy in patients with metastatic renal cell carcinoma treated with nivolumab plus ipilimumab. <i>Japanese Journal of Clinical Oncology</i> , 0, , .	0.6	1
1274	GRAMD1A Is a Biomarker of Kidney Renal Clear Cell Carcinoma and Is Associated with Immune Infiltration in the Tumour Microenvironment. <i>Disease Markers</i> , 2022, 2022, 1-25.	0.6	2
1275	Facts and Hopes for Immunotherapy in Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2022, 28, 5013-5020.	3.2	8
1276	Complete response to an anti-programmed cell death 1 antibody following a combination therapy of an anti-programmed cell death ligand 1 antibody and a tyrosine kinase inhibitor for metastatic renal cell carcinoma. <i>Asian Journal of Urology</i> , 2023, 10, 103-105.	0.5	1
1277	Safety, recommended dose, efficacy and immune correlates for nintedanib in combination with pembrolizumab in patients with advanced cancers. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, .	3.5	15
1278	Impact of modified Glasgow prognostic score on predicting prognosis and modification of risk model for patients with metastatic renal cell carcinoma treated with first line tyrosine kinase inhibitor. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 455.e11-455.e18.	0.8	2
1279	The Multi-Kinase Inhibitor Lucitanib Enhances the Antitumor Activity of Coinhibitory and Costimulatory Immune Pathway Modulators in Syngeneic Models. <i>Journal of Immunotherapy</i> , 0, Publish Ahead of Print, .	1.2	3
1280	The value measurement of emerging therapeutics in renal cell carcinoma: ASCO value framework and ESMO-MCBS. <i>BMC Health Services Research</i> , 2022, 22, .	0.9	3
1281	Dose Individualization of Oral Multi-Kinase Inhibitors for the Implementation of Therapeutic Drug Monitoring. <i>Biological and Pharmaceutical Bulletin</i> , 2022, 45, 814-823.	0.6	2
1282	Statin use improves the efficacy of nivolumab in patients with advanced renal cell carcinoma. <i>European Journal of Cancer</i> , 2022, 172, 191-198.	1.3	8

#	ARTICLE	IF	CITATIONS
1283	Normalization of tumor vasculature: A potential strategy to increase the efficiency of immune checkpoint blockades in cancers. <i>International Immunopharmacology</i> , 2022, 110, 108968.	1.7	2
1284	Immune Checkpoint Inhibitor Rechallenge After Prior Immune Toxicity. <i>Current Treatment Options in Oncology</i> , 2022, 23, 1153-1168.	1.3	7
1285	Two case reports of immune checkpoint therapy on chromophobe renal cell carcinoma with sarcomatoid differentiation. <i>International Cancer Conference Journal</i> , 0, , .	0.2	1
1286	Blockade of CD47 enhances the antitumor effect of macrophages in renal cell carcinoma through trogocytosis. <i>Scientific Reports</i> , 2022, 12, .	1.6	1
1287	Recent advances in the molecular basis of chemotherapy resistance and potential application of epigenetic therapeutics in chemorefractory renal cell carcinoma. <i>WIREs Mechanisms of Disease</i> , 2022, 14, .	1.5	1
1288	Knowledge mapping and research hotspots of immunotherapy in renal cell carcinoma: A text-mining study from 2002 to 2021. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	15
1289	Distinct Predictive Immunogenomic Profiles of Response to Immune Checkpoint Inhibitors and IL2: A Real-world Evidence Study of Patients with Advanced Renal Cancer. <i>Cancer Research Communications</i> , 2022, 2, 894-903.	0.7	0
1290	Current insight into the regulation of PD-L1 in cancer. <i>Experimental Hematology and Oncology</i> , 2022, 11, .	2.0	23
1291	Next Wave of Targets in the Treatment of Advanced Renal Cell Carcinoma. <i>Current Oncology</i> , 2022, 29, 5426-5441.	0.9	5
1292	Real world data on IO-based therapy for metastatic renal cell carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 3249-3258.	1.2	7
1293	PBAF loss leads to DNA damage-induced inflammatory signaling through defective G2/M checkpoint maintenance. <i>Genes and Development</i> , 2022, 36, 790-806.	2.7	4
1294	Therapeutic targeting of VEGF and/or TGF- β 2 to enhance anti-PD-(L)1 therapy: The evidence from clinical trials. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
1295	Clinical outcome following checkpoint therapy in renal cell carcinoma is associated with a burst of activated CD8 T cells in blood. , 2022, 10, e004803.		15
1296	PANK1 associates with cancer metabolism and immune infiltration in clear cell renal cell carcinoma: a retrospective prognostic study based on the TCGA database. <i>Translational Cancer Research</i> , 2022, 11, 2321-2337.	0.4	1
1297	Role of metastasectomy in the management of renal cell carcinoma. <i>Frontiers in Surgery</i> , 0, 9, .	0.6	6
1298	Weight and skeletal muscle loss with cabozantinib in metastatic renal cell carcinoma. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 0, , .	2.9	4
1299	Efficacy of avelumab plus axitinib for advanced renal cell carcinoma as late-line therapy: A case report. <i>Urology Case Reports</i> , 2022, , 102198.	0.1	1
1300	Efficacy and Safety of Apatinib for the Treatment of Advanced or Recurrent Cervical Cancer: A Single-Arm Meta-Analysis Among Chinese Patients. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	1

#	ARTICLE	IF	CITATIONS
1301	Recent Advances and Challenges in Cancer Immunotherapy. <i>Cancers</i> , 2022, 14, 3972.	1.7	26
1302	First-line avelumab for patients with PD-L1-positive metastatic or locally advanced urothelial cancer who are unfit for cisplatin. <i>Annals of Oncology</i> , 2022, 33, 1179-1185.	0.6	4
1303	Immune checkpoint inhibitors: the mechanisms, limitations, and improvements. , 0, 8, 14-22.		0
1304	Development of a SETD2-related immune prognostic signature in clear cell renal cell carcinoma. <i>Medicine (United States)</i> , 2022, 101, e29561.	0.4	0
1305	Is Cytoreductive Nephrectomy Still Beneficial for Patients With Metastatic Renal Cell Carcinoma in the Contemporary Immunotherapy Era?. <i>The Korean Journal of Urological Oncology</i> , 2022, 20, 139-150.	0.1	0
1306	Immune-based combination therapy to convert immunologically cold tumors into hot tumors: an update and new insights. <i>Acta Pharmacologica Sinica</i> , 2023, 44, 288-307.	2.8	14
1307	Molecular Mechanisms and Future Implications of VEGF/VEGFR in Cancer Therapy. <i>Clinical Cancer Research</i> , 2023, 29, 30-39.	3.2	53
1308	Synergistic effect of combining sunitinib with a peptide-based vaccine in cancer treatment after microenvironment remodeling. <i>Oncolimmunology</i> , 2022, 11, .	2.1	1
1309	IL-8 and its role as a potential biomarker of resistance to anti-angiogenic agents and immune checkpoint inhibitors in metastatic renal cell carcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	5
1310	Concomitant Use of Statins, Metformin, or Proton Pump Inhibitors in Patients with Advanced Renal Cell Carcinoma Treated with First-Line Combination Therapies. <i>Targeted Oncology</i> , 0, , .	1.7	4
1311	Improving survival in metastatic renal cell carcinoma (mRCC) patients: do elderly patients benefit from expanded targeted therapeutic options?. <i>World Journal of Urology</i> , 2022, 40, 2489-2497.	1.2	3
1312	The expanding role for small molecules in immuno-oncology. <i>Nature Reviews Drug Discovery</i> , 2022, 21, 821-840.	21.5	50
1314	Impact of Body Mass Index on Outcomes in an Asian population of Advanced Renal Cell Carcinoma and Urothelial Carcinoma Treated With Immune Checkpoint Inhibitors. <i>Clinical Genitourinary Cancer</i> , 2023, 21, 136-145.	0.9	2
1315	2021 Consensus Statements on the Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma From the Korean Renal Cancer Study Group (KRCS). <i>The Korean Journal of Urological Oncology</i> , 2022, 20, 151-162.	0.1	1
1316	Stereotactic Ablative Radiation for Systemic Therapy-naïve Oligometastatic Kidney Cancer. <i>European Urology Oncology</i> , 2022, 5, 695-703.	2.6	17
1317	Lenvatinib for effectively treating antiangiogenic drug-resistant nasopharyngeal carcinoma. <i>Cell Death and Disease</i> , 2022, 13, .	2.7	6
1318	Real-world effectiveness of nivolumab plus ipilimumab and second-line therapy in Japanese untreated patients with metastatic renal cell carcinoma: 2-year analysis from a multicenter retrospective clinical study (J-cardinal study). <i>Japanese Journal of Clinical Oncology</i> , 0, , .	0.6	1
1319	Improved Survival of Real-world Japanese Patients With Advanced Renal Cell Carcinoma Treated With Immuno-oncology Combination Therapy. <i>Anticancer Research</i> , 2022, 42, 4573-4580.	0.5	2

#	ARTICLE	IF	CITATIONS
1320	Targeting KRAS: Crossroads of Signaling and Immune Inhibition. <i>Journal of Immunotherapy and Precision Oncology</i> , 2022, 5, 68-78.	0.6	6
1321	IL1R2 promotes tumor progression via JAK2/STAT3 pathway in human clear cell renal cell carcinoma. <i>Pathology Research and Practice</i> , 2022, 238, 154069.	1.0	5
1322	Sarcomatoid-associated gene risk index for clear cell renal cell carcinoma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	3
1323	Dissociated response among multiple metastatic lesions in the patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors. <i>Japanese Journal of Clinical Oncology</i> , 0, , .	0.6	0
1324	Avelumab plus axitinib in unresectable or metastatic type B3 thymomas and thymic carcinomas (CAVEATT): a single-arm, multicentre, phase 2 trial. <i>Lancet Oncology</i> , The, 2022, 23, 1287-1296.	5.1	18
1325	Association of C-reactive protein with efficacy of avelumab plus axitinib in advanced renal cell carcinoma: long-term follow-up results from JAVELIN Renal 101. <i>ESMO Open</i> , 2022, 7, 100564.	2.0	4
1326	Development and validation of a bioanalytical method for the quantification of axitinib from plasma and capillary blood using volumetric absorptive microsampling (VAMS) and on-line solid phase extraction (SPE) LC-MS. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2022, 221, 115033.	1.4	5
1327	Inducing vascular normalization: A promising strategy for immunotherapy. <i>International Immunopharmacology</i> , 2022, 112, 109167.	1.7	2
1328	Selenium substituted axitinib reduces axitinib side effects and maintains its anti-renal tumor activity. <i>RSC Advances</i> , 2022, 12, 21821-21826.	1.7	3
1329	Coexpression of lymphocyte-activation gene 3 and programmed death ligand-1 in tumor infiltrating immune cells predicts worse outcome in renal cell carcinoma. <i>International Journal of Immunopathology and Pharmacology</i> , 2022, 36, 039463202211255.	1.0	6
1330	Role of axitinib and other tyrosine kinase inhibitors in the management of metastatic renal cell carcinoma. <i>Journal of Current Oncology</i> , 2022, 5, 35.	0.2	0
1331	Current and future perspectives on CAR-T cell therapy for renal cell carcinoma: A comprehensive review. <i>Investigative and Clinical Urology</i> , 2022, 63, 486.	1.0	7
1332	Available Immunotherapy Drugs in Oncology. <i>Current Clinical Pathology</i> , 2022, , 5-23.	0.0	0
1333	The role of gut microbiome in immune modulation in metastatic renal cell carcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211227.	1.4	7
1334	Clinical characteristics and outcomes of tyrosine kinase inhibitor-related lower GI adverse effects. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 3965-3976.	1.2	2
1335	On the Immunotherapy for Tumors. <i>Science Insights</i> , 2022, 41, 611-617.	0.1	0
1336	Economic evaluation of first-line nivolumab plus cabozantinib for advanced renal cell carcinoma in China. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	2
1337	A risk signature based on necroptotic-process-related genes predicts prognosis and immune therapy response in kidney cell carcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1

#	ARTICLE	IF	CITATIONS
1338	Overcoming the cardiac toxicities of cancer therapy immune checkpoint inhibitors. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	5
1339	Expression of nectin-4 in papillary renal cell carcinoma. <i>Discover Oncology</i> , 2022, 13, .	0.8	2
1340	A radiogenomics biomarker based on immunological heterogeneity for non-invasive prognosis of renal clear cell carcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	9
1341	Arborinine from <i>Glycosmis parva</i> leaf extract inhibits clear-cell renal cell carcinoma by inhibiting KDM1A/UBE2O signaling. <i>Food and Nutrition Research</i> , 0, 66, .	1.2	3
1342	Immunotherapy in advanced kidney cancer: an alternative meta-analytic method using reconstructed survival data in case of proportional hazard assumption violation. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
1343	Enhancing therapeutic anti-cancer responses by combining immune checkpoint and tyrosine kinase inhibition. <i>Molecular Cancer</i> , 2022, 21, .	7.9	5
1344	The Predictive Value of Three Variables in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-Based Combination Therapies in Randomized Clinical Trials: A Systematic Review and Meta-Analysis. <i>Journal of Oncology</i> , 2022, 2022, 1-12.	0.6	1
1345	Prognostic value of immune phenotype and PD-L1 status in recurrent or metastatic renal cell carcinoma: an exploratory analysis of the ARCHERY study. <i>Pathology</i> , 2022, , .	0.3	0
1346	Maximizing the value of phase III trials in immuno-oncology: A checklist from the Society for Immunotherapy of Cancer (SITC)., 2022, 10, e005413.		6
1347	Lenvatinib plus pembrolizumab combination therapy for adult patients with advanced renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 1049-1059.	1.1	5
1348	Extensive plasma proteomic profiling revealed receptor activator of nuclear factor kappa- β ligand (RANKL) as emerging biomarker of nivolumab clinical benefit in patients with metastatic renal cell carcinoma. , 2022, 10, e005136.		7
1349	A novel molecular signature identifies mixed subtypes in renal cell carcinoma with poor prognosis and independent response to immunotherapy. <i>Genome Medicine</i> , 2022, 14, .	3.6	11
1350	ImmunoPET Imaging with ⁸⁹ Zr-Labeled Atezolizumab Enables <i>In Vivo</i> Evaluation of PD-L1 in Tumorgraft Models of Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2022, 28, 4907-4916.	3.2	7
1351	Management of Immune-Related Adverse Events from Immune-Checkpoint Inhibitors in Advanced or Metastatic Renal Cell Carcinoma. <i>Cancers</i> , 2022, 14, 4369.	1.7	4
1352	Targeted Nanobubbles of PD-L1 mAb Combined with Doxorubicin as a Synergistic Tumor Repressor in Hepatocarcinoma. <i>International Journal of Nanomedicine</i> , 0, Volume 17, 3989-4008.	3.3	7
1353	Effectiveness and Safety of Molecular-Targeted Therapy after Nivolumab Plus Ipilimumab for Advanced or Metastatic Renal Cell Carcinoma: A Multicenter, Retrospective Cohort Study. <i>Cancers</i> , 2022, 14, 4579.	1.7	1
1354	Incidence risk of peripheral edema in cancer patients treated with PD-1/PD-L1 inhibitors: A PRISMA guideline systematic review and meta-analysis. <i>Medicine (United States)</i> , 2022, 101, e30151.	0.4	0
1355	Determining Front-Line Therapeutic Strategy for Metastatic Clear Cell Renal Cell Carcinoma. <i>Cancers</i> , 2022, 14, 4607.	1.7	2

#	ARTICLE	IF	CITATIONS
1356	Systemic therapies for metastatic renal cell carcinoma in the second-line setting: A systematic review and network meta-analysis. <i>Medicine (United States)</i> , 2022, 101, e30333.	0.4	3
1357	Personalizing immunotherapy for renal cell carcinoma: how far have we come?. <i>Expert Opinion on Biological Therapy</i> , 0, , 1-5.	1.4	2
1358	The Emerging Role of Radiation Therapy in Renal Cell Carcinoma. <i>Cancers</i> , 2022, 14, 4693.	1.7	10
1359	Crosstalk of necroptosis and pyroptosis defines tumor microenvironment characterization and predicts prognosis in clear cell renal carcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
1360	Response to BRAF-targeted Therapy Is Enhanced by Cotargeting VEGFRs or WNT/ β -Catenin Signaling in BRAF-mutant Colorectal Cancer Models. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 1777-1787.	1.9	3
1361	Clinical impact of early response to first-line $\text{VEGFR}^{\text{TKI}}$ in patients with metastatic renal cell carcinoma on survival: A multi-institutional retrospective study. <i>Cancer Medicine</i> , 0, , .	1.3	1
1362	Risk of developing hypothyroidism with the use of tyrosine kinase inhibitors and immune checkpoint inhibitors. <i>Cancer Epidemiology</i> , 2022, 81, 102265.	0.8	2
1363	Cancer Immunodiagnosis in Upper Gastrointestinal Cancers. , 2022, , 1-33.		0
1364	Chemotherapeutic Protocols for the Treatment of Genitourinary Cancer. , 2022, , 201-231.		0
1366	Network $\text{Meta}^{\text{Interpolation}}$: Effect modification adjustment in network meta-analysis using subgroup analyses. <i>Research Synthesis Methods</i> , 0, , .	4.2	0
1367	Less is More? First Impressions From COSMIC-313. <i>Cancer Investigation</i> , 2023, 41, 101-106.	0.6	4
1368	A predictive signature based on enhancer RNA associates with immune infiltration and aids treatment decision in clear cell renal cell carcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
1370	Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021. <i>Journal of Hematology and Oncology</i> , 2022, 15, .	6.9	59
1372	Outcomes of High-Dose Stereotactic Ablative Radiotherapy to All/Multiple Sites for Oligometastatic Renal Cell Cancer Patients. <i>Current Oncology</i> , 2022, 29, 7832-7841.	0.9	4
1373	Small molecule inhibitors targeting the cancers. <i>MedComm</i> , 2022, 3, .	3.1	25
1374	Recurrent multiple liver metastases of clear cell renal cell carcinoma with a significant response to sunitinib after nivolumab treatment. <i>IJU Case Reports</i> , 0, , .	0.1	1
1375	IO-IO vs IO-TKI efficacy in metastatic kidney cancer patients: A structured systematic review over time. <i>Seminars in Oncology</i> , 2022, 49, 394-399.	0.8	2
1376	Location matters: LAG3 levels are lower in renal cell carcinoma metastatic sites compared to primary tumors, and expression at metastatic sites only may have prognostic importance. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	8

#	ARTICLE	IF	CITATIONS
1377	Upfront Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors or Targeted Therapy: An Observational Study from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>European Urology</i> , 2023, 83, 145-151.	0.9	44
1378	Emerging Targets in Clear Cell Renal Cell Carcinoma. <i>Cancers</i> , 2022, 14, 4843.	1.7	10
1379	Potential of VEGFR2 expression as a predictive marker of PD-1 blockade in patients with advanced NSCLC. <i>Oncology Reports</i> , 2022, 48, .	1.2	4
1380	Immunoregulatory signal networks and tumor immune evasion mechanisms: insights into therapeutic targets and agents in clinical development. <i>Biochemical Journal</i> , 2022, 479, 2219-2260.	1.7	6
1381	Phase I/II study of multi-peptide cancer vaccine IMA901 after single-dose cyclophosphamide in Japanese patients with advanced renal cell cancer with long-term follow up. <i>International Journal of Urology</i> , 0, , .	0.5	1
1382	Longitudinal bioluminescence imaging to monitor breast tumor growth and treatment response using the chick chorioallantoic membrane model. <i>Scientific Reports</i> , 2022, 12, .	1.6	4
1385	Efficacy and safety of vorolanib plus everolimus in metastatic renal cell carcinoma: A three-arm, randomised, double-blind, multicentre phase III study (CONCEPT). <i>European Journal of Cancer</i> , 2023, 178, 205-215.	1.3	4
1386	Epigenetics in advanced renal cell carcinoma: Potential new targets. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 180, 103857.	2.0	2
1387	Subgroup analyses in randomized phase III trials of systemic treatments in patients with advanced solid tumours: a systematic review of trials published between 2017 and 2020. <i>ESMO Open</i> , 2022, 7, 100593.	2.0	2
1388	A Review of Immune Checkpoint Blockade for the General Surgeon. <i>Journal of Surgical Research</i> , 2023, 281, 289-298.	0.8	3
1389	Avelumab plus axitinib combination in treating metastatic renal cell carcinoma. <i>Onkologie (Czech)</i> 10 Tf 50	0.0	0
1390	Primary renal neuroendocrine neoplasms: A systematic literature review, report of four local cases, and original survival analysis of 63 patients from a national registry 2012-2018. <i>Journal of Neuroendocrinology</i> , 2022, 34, .	1.2	2
1391	Cabozantinib sensitizes microsatellite stable colorectal cancer to immune checkpoint blockade by immune modulation in human immune system mouse models. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	7
1392	LTB4R Promotes the Occurrence and Progression of Clear Cell Renal Cell Carcinoma (ccRCC) by Regulating the AKT/mTOR Signaling Pathway. <i>Cells</i> , 2022, 11, 3606.	1.8	3
1393	Manipulation of the crosstalk between tumor angiogenesis and immunosuppression in the tumor microenvironment: Insight into the combination therapy of anti-angiogenesis and immune checkpoint blockade. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	9
1394	Immune Checkpoint Inhibitor (ICI) Genes and Aging in Clear Cell Renal Cell Carcinoma (ccRCC): Clinical and Genomic Study. <i>Cells</i> , 2022, 11, 3641.	1.8	2
1395	Contemporary Drug Therapy for Renal Cell Carcinoma—Evidence Accumulation and Histological Implications in Treatment Strategy. <i>Biomedicines</i> , 2022, 10, 2840.	1.4	5
1397	Progression-free Survival After Second Line of Therapy for Metastatic Clear Cell Renal Cell Carcinoma in Patients Treated with First-line Immunotherapy Combinations. <i>European Urology</i> , 2023, 83, 195-199.	0.9	5

#	ARTICLE	IF	CITATIONS
1398	Adjuvant therapy options in renal cell carcinoma “targeting the metastatic cascade. Nature Reviews Urology, 2023, 20, 179-193.	1.9	4
1399	A Seven-Autophagy-Related Long Non-Coding RNA Signature Can Accurately Predict the Prognosis of Patients with Renal Cell Carcinoma. International Journal of General Medicine, 0, Volume 15, 8143-8157.	0.8	0
1400	French AFU Cancer Committee Guidelines - Update 2022-2024: management of kidney cancer. Progres En Urologie, 2022, 32, 1195-1274.	0.3	11
1401	Challenges in neoantigen-directed therapeutics. Cancer Cell, 2023, 41, 15-40.	7.7	27
1402	Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors. JAMA Oncology, 2023, 9, 40.	3.4	22
1403	Serum C-reactive Protein Level Predicts Overall Survival for Clear Cell and Non-Clear Cell Renal Cell Carcinoma Treated with Ipilimumab plus Nivolumab. Cancers, 2022, 14, 5659.	1.7	4
1404	Avelumab Plus Talazoparib in Patients With <i>BRCA1/2</i> - or <i>ATM</i> -Altered Advanced Solid Tumors. JAMA Oncology, 2023, 9, 29.	3.4	21
1405	Dry and wet experiments reveal the significant role of FUT11 in clear cell renal cell carcinoma. International Immunopharmacology, 2022, 113, 109447.	1.7	2
1406	Cell-Surface Receptors: EGFR- and VEGFR-Targeted Agents. , 2022, , 153-172.		1
1407	Therapeutic sequencing in advanced renal cell carcinoma: How to choose considering clinical and biological factors. Critical Reviews in Oncology/Hematology, 2023, 181, 103881.	2.0	3
1408	Can Molecular Classifications Help Tailor First-line Treatment of Metastatic Renal Cell Carcinoma? A Systematic Review of Available Models. European Urology Open Science, 2023, 47, 12-19.	0.2	1
1409	Improved overall survival of metastatic renal cell carcinoma patients in the era of modern tyrosine kinase inhibitors and immune checkpoint inhibitors: results from a real-life, population-based Austrian study comprising three decades of follow-up. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592211340.	1.4	1
1410	The Tumor Microenvironment in Pancreatic Cancer and Challenges to Immunotherapy. , 2022, , 381-401.		0
1411	Guiding treatment selection with immunotherapy compared to targeted therapy agents in patients with metastatic kidney cancer. Expert Review of Precision Medicine and Drug Development, 2022, 7, 131-149.	0.4	3
1412	Immune landscape and immunotherapy for penile cancer. Frontiers in Immunology, 0, 13, .	2.2	5
1413	Design and reporting of phase III oncology trials with prospective biomarker validation. Journal of the National Cancer Institute, 0, , .	3.0	1
1414	First-Line Lenvatinib Plus Pembrolizumab or Everolimus versus Sunitinib for Advanced Renal Cell Carcinoma: A United States-Based Cost-Effectiveness Analysis. Clinical Genitourinary Cancer, 2023, 21, 417.e1-417.e10.	0.9	1
1415	Incidence rate and treatment strategy of immune checkpoint inhibitor mediated hepatotoxicity: A systematic review. , 2023, 1, 46-55.		1

#	ARTICLE	IF	CITATIONS
1416	The roles of metabolic profiles and intracellular signaling pathways of tumor microenvironment cells in angiogenesis of solid tumors. <i>Cell Communication and Signaling</i> , 2022, 20, .	2.7	18
1417	Immune combinations and complete response: a new hope for metastatic renal cell carcinoma. <i>Reports of Practical Oncology and Radiotherapy</i> , 0, , .	0.3	0
1418	Renal Cell Carcinoma as a Metabolic Disease: An Update on Main Pathways, Potential Biomarkers, and Therapeutic Targets. <i>International Journal of Molecular Sciences</i> , 2022, 23, 14360.	1.8	43
1419	Therapeutic Antibodies in Cancer Treatment in the UK. <i>International Journal of Molecular Sciences</i> , 2022, 23, 14589.	1.8	1
1420	Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma. <i>Nature Reviews Urology</i> , 2023, 20, 133-157.	1.9	46
1421	Tumor-infiltrating immune cell status predicts successful response to immune checkpoint inhibitors in renal cell carcinoma. <i>Scientific Reports</i> , 2022, 12, .	1.6	1
1422	Takotsubo syndrome in a patient with metastatic renal cell carcinoma treated with pembrolizumab plus axitinib. <i>Immunotherapy</i> , 2022, 14, 1297-1305.	1.0	5
1423	A multicenter phase 2 single arm study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pre-treated with one immune-checkpoint inhibitor: The BREAKPOINT trial (Meet-Uro trial 03). <i>Tumori</i> , 2023, 109, 129-137.	0.6	16
1424	The role of Angiogenesis and remodeling (AR) associated signature for predicting prognosis and clinical outcome of immunotherapy in pan-cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
1426	Proinflammatory activity of VEGF-targeted treatment through reversal of tumor endothelial cell anergy. <i>Angiogenesis</i> , 2023, 26, 279-293.	3.7	12
1427	Unfavorable immunotherapy plus tyrosine kinase inhibition outcome of metastatic renal cell carcinoma after radical nephrectomy with increased ADAM9 expression. <i>Immunogenetics</i> , 0, , .	1.2	1
1428	Feasibility of robotic-assisted partial nephrectomy for complete remission of metastatic renal cell carcinoma after long exposure to immune checkpoint inhibitors (UroCCR-106). <i>Journal of Surgical Case Reports</i> , 2022, 2022, .	0.2	1
1429	A Comparison of Alternative Network Meta-Analysis Methods in the Presence of Nonproportional Hazards: A Case Study in First-Line Advanced or Metastatic Renal Cell Carcinoma. <i>Value in Health</i> , 2023, 26, 465-476.	0.1	3
1430	Therapeutic Management of Metastatic Clear Cell Renal Cell Carcinoma: A Revolution in Every Decade. <i>Cancers</i> , 2022, 14, 6230.	1.7	3
1431	Active use of electronic patient-reported outcome in kidney cancer and effect on self-reported physical function: PRORECECA study protocol. <i>Acta OncolÅ³gica</i> , 2022, 61, 1473-1476.	0.8	1
1432	Long-term Clinical Outcomes of a Spanish Cohort of Metastatic Renal Cell Carcinoma Patients with a Complete Response to Sunitinib. <i>Clinical Genitourinary Cancer</i> , 2023, 21, e166-e174.	0.9	0
1433	Immune Checkpoint Inhibitor Therapy inÂOncology. <i>JACC: CardioOncology</i> , 2022, 4, 579-597.	1.7	25
1434	Clinical potential of PD-1/PD-L1 blockade therapy for renal cell carcinoma (RCC): a rapidly evolving strategy. <i>Cancer Cell International</i> , 2022, 22, .	1.8	3

#	ARTICLE	IF	CITATIONS
1435	APOBEC3G expression correlates with unfavorable prognosis and immune infiltration in kidney renal clear cell carcinoma. <i>Heliyon</i> , 2022, 8, e12191.	1.4	5
1436	Rational combinations of targeted cancer therapies: background, advances and challenges. <i>Nature Reviews Drug Discovery</i> , 2023, 22, 213-234.	21.5	69
1437	Clinical outcomes of nivolumab plus ipilimumab in patients with metastatic non-clear cell renal cell carcinoma: Real-world data from a Japanese multicenter retrospective study. <i>International Journal of Urology</i> , 2023, 30, 714-721.	0.5	3
1438	Optimizing targeted drug selection in combination therapy for patients with advanced or metastatic renal cell carcinoma: A systematic review and network meta-analysis of safety. <i>Cancer Medicine</i> , 0, , .	1.3	0
1439	Efficacy and Safety of Cabozantinib in Patients with Advanced or Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Cohort Study. <i>Biomedicines</i> , 2022, 10, 3172.	1.4	2
1440	The prospect of tumor microenvironment-modulating therapeutical strategies. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	7
1441	Current and novel therapeutic strategies for optimizing immunotherapy outcomes in advanced non-small cell lung cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
1442	Optimization of first-line systemic therapy in patients with advanced clear cell renal cell carcinoma. <i>International Journal of Urology</i> , 2023, 30, 705-713.	0.5	1
1443	Expert Insights on Current Treatments for Hepatocellular Carcinoma: Clinical and Molecular Approaches and Bottlenecks to Progress. <i>Journal of Hepatocellular Carcinoma</i> , 0, Volume 9, 1247-1261.	1.8	7
1444	Repurposing of Commercially Existing Molecular Target Therapies to Boost the Clinical Efficacy of Immune Checkpoint Blockade. <i>Cancers</i> , 2022, 14, 6150.	1.7	3
1445	Lenvatinib plus pembrolizumab versus sunitinib for advanced renal cell carcinoma: Japanese patients from the CLEAR study. <i>Cancer Medicine</i> , 2023, 12, 6902-6912.	1.3	3
1446	Case report: Pembrolizumab plus Axitinib related hypothyroid myopathy in two kidney cancer patients. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
1447	Complexity in radiological morphology predicts worse prognosis and is associated with an increase in proteasome component levels in clear cell renal cell carcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
1448	Comparison of the Impact of Immune-Related Adverse Events Due to Immune Checkpoint Inhibitor Dual Combination Therapy and Immune Checkpoint Inhibitor Plus Tyrosine Kinase Inhibitor Combination Therapy in Patients with Advanced Renal Cell Carcinoma. <i>Targeted Oncology</i> , 0, , .	1.7	1
1449	The cuproptosis related genes signature predicts the prognosis and correlates with the immune status of clear cell renal cell carcinoma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	0
1451	Understanding and Targeting the Epigenetic Regulation to Overcome EGFR-TKIs Resistance in Human Cancer. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2023, 18, 506-516.	0.8	5
1452	CD70-Targeted Micelles Enhance HIF2 α siRNA Delivery and Inhibit Oncogenic Functions in Patient-Derived Clear Cell Renal Carcinoma Cells. <i>Molecules</i> , 2022, 27, 8457.	1.7	4
1453	Phase 1b/2 trial of fruquintinib plus sintilimab in treating advanced solid tumours: The dose-escalation and metastatic colorectal cancer cohort in the dose-expansion phases. <i>European Journal of Cancer</i> , 2023, 181, 26-37.	1.3	6

#	ARTICLE	IF	CITATIONS
1454	Radiopharmaceuticals heat anti-tumor immunity. <i>Theranostics</i> , 2023, 13, 767-786.	4.6	4
1455	The regulatory approvals of immune checkpoint inhibitors in China and the United States: A cross-national comparison study. <i>International Journal of Cancer</i> , 2023, 152, 2351-2361.	2.3	3
1456	Navigating the Current Landscape of Non-Clear Cell Renal Cell Carcinoma: A Review of the Literature. <i>Current Oncology</i> , 2023, 30, 923-937.	0.9	5
1458	Mechanisms of Resistance to Immunotherapies in Cancer. , 2023, , 1-30.		0
1459	Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors in the Treatment of Advanced Renal Cancer. <i>Cancers</i> , 2023, 15, 313.	1.7	3
1460	Cost-Effectiveness Analysis of Six Immunotherapy-Based Regimens and Sunitinib in Metastatic Renal Cell Carcinoma: A Public Payer Perspective. <i>JCO Oncology Practice</i> , 0, , .	1.4	0
1461	The Role of Immunotherapy in Renal Cell Carcinoma. , 2023, , 1-31.		0
1462	Increasing cure rates of solid tumors by immune checkpoint inhibitors. <i>Experimental Hematology and Oncology</i> , 2023, 12, .	2.0	17
1463	Bone Metabolism Effects of Medical Therapy in Advanced Renal Cell Carcinoma. <i>Cancers</i> , 2023, 15, 529.	1.7	3
1464	Outcomes With Combination Pembrolizumab and Axitinib in Second and Further Line Treatment of Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2023, 21, 221-229.	0.9	2
1465	Adjuvant Therapy in Renal Cell Carcinoma: Are We Ready for Prime Time?. <i>Kidney Cancer</i> , 2023, 7, 1-11.	0.2	2
1466	Conserved angio-immune subtypes of the tumor microenvironment predict response to immune checkpoint blockade therapy. <i>Cell Reports Medicine</i> , 2023, 4, 100896.	3.3	6
1467	Combining Sunitinib and Bevacizumab for the Management of Advanced Renal Cell Carcinoma: A Phase I/II Trial. <i>Oncologist</i> , 2023, 28, e254-e262.	1.9	3
1468	Exosome-Based Smart Drug Delivery Tool for Cancer Theranostics. <i>ACS Biomaterials Science and Engineering</i> , 2023, 9, 577-594.	2.6	57
1469	Proteomics Characterization of Clear Cell Renal Cell Carcinoma. <i>Journal of Clinical Medicine</i> , 2023, 12, 384.	1.0	1
1470	Advances in pharmacokinetics and pharmacodynamics of PD-1/PD-L1 inhibitors. <i>International Immunopharmacology</i> , 2023, 115, 109638.	1.7	3
1471	Cytoreductive nephrectomy for synchronous metastatic renal cell carcinoma. Is there enough evidence?. <i>Archivio Italiano Di Urologia Andrologia</i> , 2022, 94, 476-485.	0.4	1
1472	A comparative study on nivolumab and axitinib as secondary treatment in patients with metastatic renal cell carcinoma: A multi-institutional retrospective study in Japan. <i>International Journal of Urology</i> , 2023, 30, 723-729.	0.5	2

#	ARTICLE	IF	CITATIONS
1473	Immunotherapy for Urological Tumors on YouTube™: An Information-Quality Analysis. <i>Vaccines</i> , 2023, 11, 92.	2.1	4
1474	Theranostic Applications of Glycosaminoglycans in Metastatic Renal Cell Carcinoma. <i>Cancers</i> , 2023, 15, 266.	1.7	4
1475	Avelumab Plus Axitinib as First-Line Therapy for Advanced Renal Cell Carcinoma: Long-Term Results from the JAVELIN Renal 100 Phase Ib Trial. <i>Oncologist</i> , 2023, 28, 333-340.	1.9	1
1476	A Retrospective Study of Metastatic Renal Cell Carcinoma Patients With Brain Metastases. <i>Cureus</i> , 2023, , .	0.2	0
1477	Nivolumab plus cabozantinib for advanced renal cell carcinoma. <i>Future Oncology</i> , 0, , .	1.1	0
1478	Clear Cell Renal Cell Carcinoma: From Biology to Treatment. <i>Cancers</i> , 2023, 15, 665.	1.7	11
1479	Tumor immunology. , 2023, , 245-452.		0
1480	Adjuvant Therapy for High-Risk Localized Renal Cell Carcinoma: Current Landscape and Future Direction. <i>OncoTargets and Therapy</i> , 0, Volume 16, 49-64.	1.0	1
1481	Hypertransaminasemia in cancer patients receiving immunotherapy and immune-based combinations: the MOUSEION-05 study. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 1381-1394.	2.0	3
1482	Immunotherapy in colorectal cancer: a beacon of hope. <i>ANZ Journal of Surgery</i> , 2023, 93, 15-16.	0.3	1
1483	Survival by Depth of Response and Efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with Lenvatinib Plus Pembrolizumab Versus Sunitinib in Advanced Renal Cell Carcinoma: Analysis of the Phase 3 Randomized CLEAR Study. <i>European Urology Oncology</i> , 2023, 6, 437-446.	2.6	4
1484	Case report: Abolishing primary resistance to PD-1 blockade by short-term treatment of lenvatinib in a patient with advanced metastatic renal cell carcinoma. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	1
1485	PD-L1: expression regulation. <i>Blood Science</i> , 2023, 5, 77-91.	0.4	5
1486	Expression of PD-L1 in renal cancer, prognostic features and clinical utility of its routine staining. <i>Actas Urológicas Españolas (English Edition)</i> , 2023, 47, 271-278.	0.2	0
1487	Camrelizumab Plus Apatinib in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma: An Open-Label, Single-Arm, Phase II Study. <i>Journal of Clinical Oncology</i> , 2023, 41, 2571-2582.	0.8	17
1488	ROS Scavenging Nanozyme Modulates Immunosuppression for Sensitized Cancer Immunotherapy. <i>Advanced Healthcare Materials</i> , 2023, 12, .	3.9	3
1489	Impact of Therapy Management on Axitinib-Related Adverse Events in Patients With Advanced Renal Cell Carcinoma Receiving First-Line Axitinib+Checkpoint Inhibitor. <i>Clinical Genitourinary Cancer</i> , 2023, 21, e343-e351.	0.9	1
1490	Improvement strategy for immune checkpoint blockade: A focus on the combination with immunogenic cell death inducers. <i>Cancer Letters</i> , 2023, 562, 216167.	3.2	5

#	ARTICLE	IF	CITATIONS
1491	Evolving Treatment Options for Metastatic Renal Cell Carcinoma (mRCC). <i>Uro</i> , 2023, 3, 117-131.	0.3	2
1492	Favorable Immunotherapy Plus Tyrosine Kinase Inhibition Outcome of Renal Cell Carcinoma Patients with Low CDK5 Expression. <i>Cancer Research and Treatment</i> , 0, , .	1.3	0
1493	Multicentre real-world data of ramucirumab plus docetaxel after combined platinum-based chemotherapy with programmed death-1 blockade in advanced non-small cell lung cancer: NEJ051 (REACTIVE study). <i>European Journal of Cancer</i> , 2023, 184, 62-72.	1.3	9
1494	Adaptive Immunity in Genitourinary Cancers. <i>European Urology Oncology</i> , 2023, 6, 263-272.	2.6	3
1495	Two is company, is three a crowd? Triplet therapy, novel molecular targets, and updates on the management of advanced renal cell carcinoma. <i>Current Opinion in Oncology</i> , 2023, 35, 206-217.	1.1	1
1496	Metastasis in renal cell carcinoma: Biology and treatment. <i>Advances in Cancer Biology Metastasis</i> , 2023, 7, 100094.	1.1	0
1497	Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma. <i>Management of Urology</i> , 2022, , 237-245.	0.0	0
1498	Hypertransaminasemia in metastatic renal cell carcinoma patients receiving immune-based combinations: a meta-analysis. <i>Immunotherapy</i> , 2023, 15, 117-126.	1.0	2
1499	Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell Carcinoma. <i>European Urology</i> , 2023, 84, 109-116.	0.9	15
1500	Immune Checkpoint Inhibitors in Urological Cancers. , 2023, , 1-25.		0
1501	Life-threatening hemoptysis in patients with metastatic kidney cancer. <i>Clinical Genitourinary Cancer</i> , 2023, 21, 497-506.	0.9	0
1502	HÄmatologische Neoplasien und solide Tumore. , 2022, , 85-151.		0
1503	The Efficacy and Safety of Immune Checkpoint Inhibitor and Tyrosine Kinase Inhibitor Combination Therapy for Advanced or Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Real-World Cohort Study. <i>Cancers</i> , 2023, 15, 947.	1.7	3
1504	The role of immunotherapy in non-clear cell renal cell carcinoma. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	5
1506	Real-world Treatment Patterns and Clinical Outcomes for Metastatic Renal Cell Carcinoma in the Current Treatment Era. <i>European Urology Open Science</i> , 2023, 49, 110-118.	0.2	12
1507	Antibody-Based Therapeutics for the Treatment of Renal Cell Carcinoma: Challenges and Opportunities. <i>Oncologist</i> , 2023, 28, 297-308.	1.9	1
1508	Differential treatment responses to immune checkpoint inhibitor (ICI) therapy in a case of multiple primary malignancies: the programmed death ligand-1 (PD-L1) negative ureteral and lung metastasis from a clear cell renal cell carcinoma appearing after robotic-assisted partial nephrectomy progressed after ICI therapy, while synchronous PD-L1-positive primary lung squamous cell carcinoma responded very well to ICI therapy: a case report. <i>World Journal of Surgical Oncology</i> , 2023, 21, .	0.8	0
1509	Combinations of Anti-Angiogenic Agents and Immune Checkpoint Inhibitors in Renal Cell Carcinoma: Best Option?. <i>Cancers</i> , 2023, 15, 1048.	1.7	1

#	ARTICLE	IF	CITATIONS
1510	LITESPARK-011: belzutifan plus lenvatinib vs cabozantinib in advanced renal cell carcinoma after anti-PD-1/PD-L1 therapy. <i>Future Oncology</i> , 2023, 19, 113-121.	1.1	7
1511	Baseline and Dynamic Changes in Hemoglobin Levels Predict Treatment Response and Prognosis in Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Study. <i>Clinical Genitourinary Cancer</i> , 2023, 21, e242-e251.	0.9	2
1512	The emerging landscape of neo/adjuvant immunotherapy in renal cell carcinoma. <i>Human Vaccines and Immunotherapeutics</i> , 2023, 19, .	1.4	4
1513	Comprehensive Genomic Profiling of <i>NF2</i> -Mutated Kidney Tumors Reveals Potential Targets for Therapy. <i>Oncologist</i> , 0, , .	1.9	3
1514	Cost Effectiveness of Treatment Sequences in Advanced Renal Cell Carcinoma. <i>European Urology Oncology</i> , 2023, , .	2.6	3
1515	Development and validation of a nomogram to evaluate the therapeutic effects of second-line axitinib in patients with metastatic renal cell carcinoma. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0
1516	Downstream Targets of VHL/HIF-1 α Signaling in Renal Clear Cell Carcinoma Progression: Mechanisms and Therapeutic Relevance. <i>Cancers</i> , 2023, 15, 1316.	1.7	11
1517	Fibroblast growth factor receptor type 4 as a potential therapeutic target in clear cell renal cell carcinoma. <i>BMC Cancer</i> , 2023, 23, .	1.1	1
1518	Stereotactic body radiation therapy to the kidney for metastatic renal cell carcinoma: A narrative review of an emerging concept. <i>Cancer Treatment and Research Communications</i> , 2023, 35, 100692.	0.7	2
1519	The Changing Landscape of Immunotherapy for Advanced Renal Cancer. <i>Urologic Clinics of North America</i> , 2023, 50, 335-349.	0.8	2
1520	New Phenylspirodrimanes from the Sponge-Associated Fungus <i>Stachybotrys chartarum</i> MUT 3308. <i>Marine Drugs</i> , 2023, 21, 135.	2.2	2
1521	Avelumab in Men With Metastatic Castration-Resistant Prostate Cancer, Enriched for Patients Treated Previously With a Therapeutic Cancer Vaccine. <i>Journal of Immunotherapy</i> , 2023, 46, 145-151.	1.2	1
1522	An angiogenesis-related three-long non-coding ribonucleic acid signature predicts the immune landscape and prognosis in hepatocellular carcinoma. <i>Heliyon</i> , 2023, 9, e13989.	1.4	5
1523	Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study. <i>Lancet Oncology</i> , The, 2023, 24, 228-238.	5.1	35
1524	Characterization and Management of Adverse Reactions From the CLEAR Study in Advanced Renal Cell Carcinoma Treated With Lenvatinib Plus Pembrolizumab. <i>Oncologist</i> , 2023, 28, 501-509.	1.9	3
1525	The role of VEGF in cancer-induced angiogenesis and research progress of drugs targeting VEGF. <i>European Journal of Pharmacology</i> , 2023, 949, 175586.	1.7	27
1526	Current Advances in Immune Checkpoint Therapy. , 0, , .		0
1527	Phase II Clinical Trial of Axitinib and Avelumab in Patients With Recurrent/Metastatic Adenoid Cystic Carcinoma. <i>Journal of Clinical Oncology</i> , 2023, 41, 2843-2851.	0.8	10

#	ARTICLE	IF	CITATIONS
1528	Navigating and adapting care integrating immunotherapy, antiangiogenic therapy, and combinations in patients with advanced renal cell carcinoma. , 2023, 11, e006361.		1
1529	Strategies targeting PD-L1 expression and associated opportunities for cancer combination therapy. Theranostics, 2023, 13, 1520-1544.	4.6	19
1530	Patientsâ€™ Perceptions Regarding the Relevance of Items Contained in the Functional Assessment of Cancer Therapy Kidney Symptom Index-19. Oncologist, 2023, 28, 494-500.	1.9	2
1531	Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with targeted therapies. , 2023, 11, e005923.		4
1532	Patient-reported outcomes in metastatic renal cell carcinoma trials using combinations versus sunitinib as first-line treatment. Nature Reviews Urology, 2023, 20, 420-433.	1.9	4
1533	A case of metastatic renal cell carcinoma successfully treated with deferred cytoreductive nephrectomy following lenvatinib plus pembrolizumab combination therapy. IJU Case Reports, 0, , .	0.1	0
1534	Clinico-Pathological Features Influencing the Prognostic Role of Body Mass Index in Patients With Advanced Renal Cell Carcinoma Treated by Immuno-Oncology Combinations (ARON-1). Clinical Genitourinary Cancer, 2023, 21, e309-e319.e1.	0.9	4
1535	Comparison of Outcomes Between Therapeutic Combinations Based on Immune Checkpoint Inhibitors or Tyrosine Kinase Inhibitor Monotherapy for First-Line Therapy of Patients with Advanced Renal Cell Carcinoma Outside of Clinical Trials: A Real-World Retrospective Multi-Institutional Study. Targeted Oncology, 2023, 18, 209-220.	1.7	4
1536	Aging microenvironment and antitumor immunity for geriatric oncology: the landscape and future implications. Journal of Hematology and Oncology, 2023, 16, .	6.9	5
1537	Treatment strategies for clear cell renal cell carcinoma: Past, present and future. Frontiers in Oncology, 0, 13, .	1.3	6
1538	Integrative analysis of transcriptomic landscape and urinary signature reveals prognostic biomarkers for clear cell renal cell carcinoma. Frontiers in Oncology, 0, 13, .	1.3	1
1539	Integrated bioinformatic analysis and cell line experiments reveal the significant role of the novel immune checkpoint TIGIT in kidney renal clear cell carcinoma. Frontiers in Oncology, 0, 13, .	1.3	1
1540	Prognostic impact of CD73/adenosine 2A receptor (A2AR) in renal cell carcinoma and immune microenvironmental status with sarcomatoid changes and rhabdoid features. Pathology Research and Practice, 2023, 244, 154423.	1.0	1
1541	Immunogenicity in renal cell carcinoma: shifting focus to alternative sources of tumour-specific antigens. Nature Reviews Nephrology, 2023, 19, 440-450.	4.1	4
1542	Exploring a ferroptosis and oxidative stress-based prognostic model for clear cell renal cell carcinoma. Frontiers in Oncology, 0, 13, .	1.3	1
1543	Impact of sex on prognosis in patients with advanced renal cell carcinoma treated with immune checkpoint inhibitors. Japanese Journal of Clinical Oncology, 0, , .	0.6	0
1544	Immune Checkpoint Inhibitors in Renal Cell Carcinoma: Molecular Basis and Rationale for Their Use in Clinical Practice. Biomedicines, 2023, 11, 1071.	1.4	27
1545	<sc>HMOX1</sc> pathway signature predicts clinical benefit from immunotherapy plus tyrosine kinase inhibitor therapy in advanced renal cell carcinoma. Cancer Medicine, 2023, 12, 10512-10525.	1.3	3

#	ARTICLE	IF	CITATIONS
1546	Cancer immunotherapy with immune checkpoint inhibitors (ICIs): potential, mechanisms of resistance, and strategies for reinvigorating T cell responsiveness when resistance is acquired. <i>Cancer Cell International</i> , 2023, 23, .	1.8	24
1547	Pembrolizumab plus lenvatinib for radically unresectable or metastatic renal cell carcinoma in the Japanese population. <i>Expert Review of Anticancer Therapy</i> , 2023, 23, 461-469.	1.1	1
1548	High levels of baseline serum IL-10 are associated with reduced clinical benefit from first-line immune checkpoint inhibitor therapy in advanced renal cell carcinoma. <i>Journal of Cancer</i> , 2023, 14, 935-942.	1.2	1
1549	Vascular mimicry induced by m6A mediated IGFL2-AS1/AR axis contributes to pazopanib resistance in clear cell renal cell carcinoma. <i>Cell Death Discovery</i> , 2023, 9, .	2.0	4
1550	BAP1-related signature predicts benefits from immunotherapy over VEGFR/mTOR inhibitors in ccRCC: a retrospective analysis of JAVELIN Renal 101 and checkmate-009/010/025 trials. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 2557-2572.	2.0	2
1551	Pathological angiogenesis: mechanisms and therapeutic strategies. <i>Angiogenesis</i> , 2023, 26, 313-347.	3.7	50
1552	Update on combined immunotherapy for the treatment of advanced renal cell carcinoma. <i>Human Vaccines and Immunotherapeutics</i> , 2023, 19, .	1.4	4
1553	Risk Factors for Immune Checkpoint Inhibitorâ€“Mediated Cardiovascular Toxicities. <i>Current Oncology Reports</i> , 2023, 25, 753-763.	1.8	3
1554	Targeted therapy. , 2023, , 205-411.		0
1567	Immunotherapy and Cancer: The Pharmacistsâ€™ Perspective. , 2023, , 1-34.		0
1577	The clinical application of immuno-therapeutics. , 2024, , 237-288.e7.		0
1591	Immune Checkpoint Inhibitors and Anti-Angiogenic Therapy for Cancer. , 2023, , 1-21.		0
1596	Understanding tumour endothelial cell heterogeneity and function from single-cell omics. <i>Nature Reviews Cancer</i> , 2023, 23, 544-564.	12.8	14
1600	Interleukin-1-mediated immune suppression and resistance to immunotherapy in cancer. , 2023, , 87-98.		0
1611	Predictive genomic biomarkers of therapeutic effects in renal cell carcinoma. <i>Cellular Oncology (Dordrecht)</i> , 0, , .	2.1	0
1620	Understanding and integrating cytoreductive nephrectomy with immune checkpoint inhibitors in the management of metastatic RCC. <i>Nature Reviews Urology</i> , 2023, 20, 654-668.	1.9	2
1625	A Podcast Discussion on the Current Treatment Landscape for Renal Cell Carcinoma. <i>Advances in Therapy</i> , 0, , .	1.3	0
1628	The contribution of automated cytometry in immuno-oncology. <i>Methods in Cell Biology</i> , 2023, , .	0.5	0

#	ARTICLE	IF	CITATIONS
1632	Akkermansia muciniphila: a potential booster to improve the effectiveness of cancer immunotherapy. Journal of Cancer Research and Clinical Oncology, 2023, 149, 13477-13494.	1.2	2
1633	Medikamentöse Therapie des metastasierten Nierenzellkarzinoms. Springer Reference Medizin, 2023, , 551-559.	0.0	0
1661	Checkpoint inhibitors and anti-angiogenic agents: a winning combination. British Journal of Cancer, 0, , .	2.9	2
1672	Perspective Chapter: An Update on Renal Cell Carcinoma. , 0, , .		0
1686	Management of Metastatic Renal Cell Carcinoma. , 2023, , 41-52.		0
1699	Molecular insight into renal cancer and latest therapeutic approaches to tackle it: an updated review. , 2023, 40, .		0
1711	Novel Targets in Development for Advanced Renal Cell Carcinoma. , 2023, , 309-342.		0
1712	Management of Renal Cell Carcinoma with IVC Thrombus, Nodal Involvement, and T4 Disease. , 2023, , 143-181.		0
1713	Approach to Special Populations with Advanced Renal Cell Carcinoma. , 2023, , 377-397.		0
1714	Subsequent Line Systemic Treatment Options for Advanced Renal Cell Carcinoma. , 2023, , 293-308.		0
1715	Predictive Biomarkers in Advanced Renal Cell Carcinoma. , 2023, , 251-268.		0
1716	Prognostic Factors in Advanced Renal Cell Carcinoma. , 2023, , 233-250.		0
1717	Neoadjuvant Therapy in Locally Advanced Renal Cell Carcinoma. , 2023, , 195-229.		0
1718	Role of Primary and Metastasis-Directed Stereotactic Radiation Therapy for Advanced Renal Cell Carcinoma. , 2023, , 343-357.		0
1719	First-Line Systemic Treatment Options for Advanced Renal Cell Carcinoma. , 2023, , 269-292.		0
1744	Machine Learning Modeling Predicting Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) Inhibitors Structure-Activity Relationships Using Quantum DFT Descriptors. , 2023, , .		0
1746	Current status and future perspective of immunotherapy for renal cell carcinoma. International Journal of Clinical Oncology, 0, , .	1.0	0
1778	Updated systematic review and network meta-analysis of first-line treatments for metastatic renal cell carcinoma with extended follow-up data. Cancer Immunology, Immunotherapy, 2024, 73, .	2.0	0

#	ARTICLE	IF	CITATIONS
1797	HÄmatologische Neoplasien und solide Tumore. , 2023, , 99-174.		0
1823	Cancer Stem Cells: Current Challenges and Future Perspectives. Methods in Molecular Biology, 2024, , 1-18.	0.4	0